NOTE\n2 \u2014 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
\n\n\u00a0
\n\nBasis\nof Presentation
\n\n\u00a0
\n\nThe\naccompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States\nof America (\u201cGAAP\u201d).
\n\n\u00a0
\n\nCertain\nreclassifications have been made to prior periods\u2019 data to conform to the current period presentation. These reclassifications\nhad no effect on reported income (losses) or cash flows.
\n\n\u00a0
\n\nPrinciples\nof Consolidation
\n\n\u00a0
\n\nThe\naccompanying consolidated financial statements include the accounts of MariMed Inc. and the following majority-owned subsidiaries\nat December 31, 2021:
\n\n\u00a0SCHEDULE OF MAJORITY OWNED SUBSIDIARIES
\n\n| Subsidiary: | \u00a0 | \nPercentage Owned | \u00a0 | |
| MariMed Advisors Inc. | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| Mia Development LLC | \u00a0 | \n\u00a0 | 89.5% | \u00a0 |
| Mari Holdings IL LLC | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| Mari Holdings MD LLC | \u00a0 | \n\u00a0 | 97.4% | \u00a0 |
| Mari Holdings NJ LLC | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| Mari Holdings NV LLC | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| Mari Holdings Metropolis LLC | \u00a0 | \n\u00a0 | 70.0% | \u00a0 |
| Mari Holdings Mt. Vernon LLC | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| Mari Mfg LLC | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| Hartwell Realty Holdings LLC | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| iRollie LLC | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| ARL Healthcare Inc. | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| KPG of Anna LLC | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| KPG of Harrisburg LLC | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| MariMed OH LLC | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| MariMed Hemp Inc. | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| MediTaurus LLC | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
\u00a0
\n\nIntercompany\naccounts and transactions have been eliminated.
\n\n\u00a0
\n\nUse\nof Estimates
\n\n\u00a0
\n\nThe\npreparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported\namounts within the financial statements and disclosures thereof. Actual results could differ from these estimates or assumptions.
\n\n\u00a0
\n\nCash\nEquivalents
\n\n\u00a0
\n\nThe\nCompany considers all highly liquid investments with a maturity date of three months or less to be cash equivalents. The fair values\nof these investments approximate their carrying values.
\n\n\u00a0
\n\n\n\n
At December 31, 2021 and 2020, cash of approximately\n$5,101,000 and $101,000, respectively, was held in escrow. The 2021 balance was primarily comprised of a $5,000,000 escrow deposit in\nconnection with the acquisition of Kind Therapeutics USA Inc. as further discussed in Note 3 \u2013 Acquisitions.
\n\n\n
\u00a0
\n\nThe\nCompany\u2019s cash and cash equivalents are maintained with recognized financial institutions located in the United States. In the\nnormal course of business, the Company may carry balances with certain financial institutions that exceed federally insured limits. The\nCompany has not experienced losses on balances in excess of such limits and management believes the Company is not exposed to significant\nrisks in that regard.
\n\n\n\n\u00a0
\n\nAccounts\nReceivable
\n\n\u00a0
\n\nAccounts\nreceivable consist of trade receivables and are carried at their estimated collectible amounts.
\n\n\u00a0
\n\nThe\nCompany provides credit to its clients in the form of payment terms. The Company limits its credit risk by performing credit evaluations\nof its clients and maintaining a reserve, if deemed necessary, for potential credit losses. Such evaluations include the review of a\nclient\u2019s outstanding balances with consideration towards such client\u2019s historical collection experience, as well as prevailing\neconomic and market conditions and other factors. Based on such evaluations, the Company maintained a reserve of approximately $41.4\nmillion and $40.0\nmillion at December 31, 2021 and 2020, respectively.\nFor further discussion on receivable reserves, please refer to Note 18 \u2013 Bad Debts and the Bankruptcy Claim section\nof Note 21 \u2013 Commitments and Contingencies.
\n\n\u00a0
\n\n\n\n\n\u00a0
\n\nInventory
\n\n\u00a0
\n\nInventory\nis carried at the lower of cost or net realizable value, with the cost being determined on a first-in, first-out (FIFO) basis. The Company\nallocates a certain percentage of overhead cost to its manufactured inventory; such allocation is based on square footage and other industry-standard\ncriteria. The Company reviews physical inventory for obsolescence and/or excess and will record a reserve if necessary. As of the date\nof this report, no reserve was deemed necessary.
\n\n\u00a0
\n\nInvestments
\n\n\u00a0
\n\nInvestments\nare comprised of equity holding of public and private companies. These investments are recorded at fair value on the Company\u2019s\nconsolidated balance sheet, with changes to fair value included in income. Investments are evaluated for permanent impairment and are\nwritten down if such impairments are deemed to have occurred.
\n\n\u00a0
\n\nRevenue\nRecognition
\n\n\u00a0
\n\nThe\nCompany recognizes revenue in accordance with the Financial Accounting Standards Board\u2019s Accounting Standards Codification (\u201cASC\u201d)\n606, Revenue from Contract with Customers, as amended by subsequently issued Accounting Standards Updates. This revenue standard\nrequires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration\nthat it expects to be entitled to in exchange for those goods or services. The recognition of revenue is determined by performing the\nfollowing consecutive steps:
\n\n\u00a0
\n\n| \u00a0 | \n\u25cf | \nIdentify\n the contract(s) with a customer; |
| \u00a0 | \n\u25cf | \nIdentify\n the performance obligations in the contract(s); |
| \u00a0 | \n\u25cf | \nDetermine\n the transaction price; |
| \u00a0 | \n\u25cf | \nAllocate\n the transaction price to the performance obligations in the contract(s); and |
| \u00a0 | \n\u25cf | \nRecognize\n revenue as the performance obligation is satisfied. |
\u00a0
\n\nAdditionally,\nwhen another party is involved in providing goods or services to the Company\u2019s clients, a determination is made as to who\u2014the\nCompany or the other party\u2014is acting in the capacity as the principal in the sale transaction, and who is merely the agent arranging\nfor goods or services to be provided by the other party.
\n\n\u00a0
\n\nThe\nCompany is typically considered the principal if it controls the specified good or service before such good or service is transferred\nto its client. The Company may also be deemed to be the principal even if it engages another party (an agent) to satisfy some of the\nperformance obligations on its behalf, provided the Company (i) takes on certain responsibilities, obligations, and risks, (ii) possesses\ncertain abilities and discretion, or (iii) other relevant indicators of the sale. If deemed an agent, the Company would not recognize\nrevenue for the performance obligations it does not satisfy.
\n\n\u00a0
\n\nThe\nCompany\u2019s main sources of revenue are comprised of the following:
\n\n\u00a0
\n\n| \u00a0 | \n\u25cf | \nProduct\n Sales \u2013 direct sales of cannabis and cannabis-infused products by the Company\u2019s retail dispensaries and wholesale operations\n in Massachusetts and Illinois, and sales of hemp and hemp-infused products. This revenue is recognized when products are delivered or at retail points-of-sale. |
| \u00a0 | \n\u00a0 | \n\u00a0 |
| \u00a0 | \n\u25cf | \nReal\n Estate \u2013 rental income and additional rental fees generated from leasing of the Company\u2019s state-of-the-art, regulatory-compliant\n cannabis facilities to its cannabis-licensed clients. Rental income is generally a fixed amount per month that escalates over the\n respective lease terms, while additional rental fees are based on a percentage of tenant revenues that exceed specified amounts. |
| \u00a0 | \n\u00a0 | \n\u00a0 |
| \u00a0 | \n\u25cf | \nManagement\n \u2013 fees for providing the Company\u2019s cannabis clients with comprehensive oversight of their cannabis cultivation, production,\n and dispensary operations. These fees are based on a percentage of such clients\u2019 revenue and are recognized after services\n have been performed. |
| \u00a0 | \n\u00a0 | \n\u00a0 |
| \u00a0 | \n\u25cf | \nSupply\n Procurement \u2013 the Company maintains volume discounts with top national vendors of cultivation and production resources, supplies,\n and equipment, which the Company acquires and resells to its clients or third parties within the cannabis industry. The Company recognizes\n this revenue after the delivery and acceptance of goods by the purchaser. |
| \u00a0 | \n\u00a0 | \n\u00a0 |
| \u00a0 | \n\u25cf | \nLicensing\n \u2013 royalties from the licensed distribution of the Company\u2019s branded products including Kalm Fusion and Betty\u2019s\n Eddies, and from sublicensing of contracted brands including Healer and Tikun Olam, to regulated dispensaries throughout the\n United States and Puerto Rico. The recognition of this revenue occurs when the products are delivered. |
\u00a0
\n\n\n\n\n\u00a0
\n\nResearch\nand Development Costs
\n\n\u00a0
\n\nResearch\nand development costs are charged to operations as incurred.
\n\n\u00a0
\n\nProperty\nand Equipment
\n\n\u00a0
\n\nProperty\nand equipment are stated at cost less accumulated depreciation, with depreciation recognized on a straight-line basis over the shorter\nof the estimated useful life of the asset or the lease term, if applicable. When assets are retired or disposed, the cost and accumulated\ndepreciation are removed from the accounts, and any resulting gains or losses are included in income. Repairs and maintenance are charged\nto expense in the period incurred.
\n\n\u00a0
\n\nThe\nestimated useful lives of property and equipment are generally as follows: buildings and building improvements, forty years; tenant improvements,\nthe remaining duration of the related lease; furniture and fixtures, seven to ten years; machinery and equipment, ten years. Land is\nnot depreciated.
\n\n\u00a0
\n\nThe\nCompany\u2019s property and equipment are individually reviewed for impairment whenever events or changes in circumstances indicate\nthat the carrying amount of an asset may not be recoverable from the undiscounted future cash flows of such asset over the anticipated\nholding period. An impairment loss is measured by the excess of the asset\u2019s carrying amount over its estimated fair value.
\n\n\u00a0
\n\nImpairment\nanalyses are based on management\u2019s current plans, asset holding periods, and currently available market information. If these criteria\nchange, the Company\u2019s evaluation of impairment losses may be different and could have a material impact to the consolidated financial\nstatements.
\n\n\u00a0
\n\nFor\nthe years ended December 31, 2021 and 2020, based on the results of management\u2019s impairment analyses, there were no impairment\nlosses.
\n\n\u00a0
\n\nLeases
\n\n\u00a0
\n\nThe\nconsolidated financial statements reflect the Company\u2019s adoption of ASC 842, Leases, as amended by subsequent accounting\nstandards updates. Under ASC 842, arrangements that are determined to be leases with a term greater than one year are accounted\nfor by the recognition of right-of-use assets, that represent the Company\u2019s right to use an underlying asset for the lease term,\nand lease liabilities, that represent the Company\u2019s obligation to make lease payments arising from the lease. Non-lease components\nwithin lease agreements are accounted for separately.
\n\n\u00a0
\n\nRight-of-use\nassets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term, utilizing\nthe Company\u2019s incremental borrowing rate. The Company\u2019s lease terms may include options to extend or terminate the lease\nwhen it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line\nbasis over the lease term.
\n\n\u00a0
\n\nImpairment\nof Long-Lived Assets
\n\n\u00a0
\n\nThe\nCompany evaluates the recoverability of its fixed assets and other assets in accordance with ASC 360-10-15, Impairment or Disposal\nof Long-Lived Assets. Impairment of long-lived assets is recognized when the net book value of such assets exceeds their expected\ncash flows, in which case the assets are written down to fair value, which is determined based on discounted future cash flows or appraised\nvalues.
\n\n\u00a0
\n\nFair\nValue of Financial Instruments
\n\n\u00a0
\n\nThe\nCompany follows the provisions of ASC 820, Fair Value Measurement, to measure the fair value of its financial instruments, and\nASC 825, Financial Instruments, for disclosures on the fair value of its financial instruments. To increase consistency and comparability\nin fair value measurements and related disclosures, ASC 820 establishes a fair value hierarchy which prioritizes the inputs to valuation\ntechniques used to measure fair value into three broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted)\nin active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three levels of fair value\nhierarchy defined by ASC 820 are:
\n\n\u00a0
\n\n| Level\n 1 | \nQuoted\n market prices available in active markets for identical assets or liabilities as of the reporting date. |
| \u00a0 | \n\u00a0 |
| Level\n 2 | \nPricing\n inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the\n reporting date. |
| \u00a0 | \n\u00a0 |
| Level\n 3 | \nPricing\n inputs that are generally observable inputs and not corroborated by market data. |
\u00a0
\n\n\n\n\n\u00a0
\n\nThe\ncarrying amounts of the Company\u2019s financial assets and liabilities, such as cash and accounts payable approximate their fair values\ndue to the short maturity of these instruments.
\n\n\u00a0
\n\nThe\nfair value of option and warrant issuances are determined using the Black-Scholes pricing model and employing several inputs such as\nthe expected life of instrument, the exercise price, the expected risk-free interest rate, the expected dividend yield, the value of\nthe Company\u2019s common stock on issuance date, and the expected volatility of such common stock. The following table summarizes the\nrange of inputs used by the Company during the prior two fiscal years:
\n\n\u00a0SCHEDULE OF ASSUMPTIONS USED
\n\n| \u00a0 | \u00a0 | \n2021 | \u00a0 | \u00a0 | \n2020 | \u00a0 | ||
| Life of instrument | \u00a0 | \n\u00a0 | to years | \u00a0 | \u00a0 | \n\u00a0 | to years | \u00a0 |
| Volatility factors | \u00a0 | \n\u00a0 | to | \u00a0 | \u00a0 | \n\u00a0 | to | \u00a0 |
| Risk-free interest rates | \u00a0 | \n\u00a0 | % to % | \u00a0 | \u00a0 | \n\u00a0 | % to % | \u00a0 |
| Dividend yield | \u00a0 | \n\u00a0 | % | \u00a0 | \u00a0 | \n\u00a0 | % | \u00a0 |
\u00a0
\n\nThe\nexpected life of an instrument is calculated using the simplified method pursuant to Staff Accounting Bulletin Topic 14, Share-Based\nPayment, which allows for using the mid-point between the vesting date and expiration date. The volatility factors are based on the\nhistorical two-year movement of the Company\u2019s common stock prior to an instrument\u2019s issuance date. The risk-free interest\nrate is based on U.S. Treasury rates with maturity periods similar to the expected instruments life on the issuance date.
\n\n\u00a0
\n\nThe\nCompany amortizes the fair value of option and warrant issuances on a straight-line basis over the requisite service period of each instrument.
\n\n\u00a0
\n\nExtinguishment\nof Liabilities
\n\n\u00a0
\n\nThe\nCompany accounts for extinguishment of liabilities in accordance with ASC 405-20, Extinguishments of Liabilities. When the conditions\nfor extinguishment are met, the liabilities are written down to zero and a gain or loss is recognized.
\n\n\u00a0
\n\n\n\n\u00a0
\n\nThe\nCompany accounts for stock-based compensation using the fair value method as set forth in ASC 718, Compensation\u2014Stock Compensation,\nwhich requires a public entity to measure the cost of employee services received in exchange for an equity award based on the fair\nvalue of the award on the grant date, with limited exceptions. Such value will be incurred as compensation expense over the period an\nemployee is required to provide service in exchange for the award, usually the vesting period. No compensation cost is recognized for\nequity awards for which employees do not render the requisite service.
\n\n\u00a0
\n\n\n\n\n\u00a0
\n\nIncome\nTaxes
\n\n\u00a0
\n\nThe\nCompany uses the asset and liability method to account for income taxes in accordance with ASC 740, Income Taxes. Under this method,\ndeferred income tax assets and liabilities are recorded for the future tax consequences of differences between the tax basis and financial\nreporting basis of assets and liabilities, measured using enacted tax rates and laws that will be in effect when the differences are\nexpected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than\nnot that the assets will not be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in\nthe consolidated statements of operations in the period that includes the enactment date.
\n\n\u00a0
\n\nASC\n740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial statements\nuncertain tax positions taken or expected to be taken on a tax return. The Company did not take any uncertain tax positions and had no\nadjustments to unrecognized income tax liabilities or benefits for the years ended December 31, 2021 and 2020.
\n\n\u00a0
\n\nCertain\nof the Company\u2019s subsidiaries are subject to the provisions of Section 280E of the Internal Revenue Code, as amended, which prohibits\nbusinesses from deducting certain expenses associated with the trafficking of controlled substances within the meaning of Schedule I\nand II of the Controlled Substances Act. Such non-deductibility of certain ordinary business expenses results in permanent differences\nand can cause the Company\u2019s effective tax rate to be highly variable and not necessarily correlated with pre-tax income.\u00a0
\n\n\u00a0
\n\nRelated\nParty Transactions
\n\n\u00a0
\n\nThe\nCompany follows ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party\ntransactions.
\n\n\u00a0
\n\nIn\naccordance with ASC 850, the Company\u2019s financial statements include disclosures of material related party transactions, other than\ncompensation arrangements, expense allowances, and other similar items in the ordinary course of business, as well as transactions that\nare eliminated in the preparation of financial statements.
\n\n\u00a0
\n\nComprehensive\nIncome
\n\n\u00a0
\n\nThe\nCompany reports comprehensive income and its components following guidance set forth by ASC 220, Comprehensive Income, which establishes\nstandards for the reporting and display of comprehensive income and its components in the consolidated financial statements. There were\nno items of comprehensive income applicable to the Company during the period covered in the financial statements.
\n\n\u00a0
\n\n\n\n\u00a0
\n\nEarnings\nper common share is computed pursuant to ASC 260, Earnings Per Share. Basic earnings per share is computed by dividing net income\nby the weighted average number of shares of common stock outstanding during the period. Diluted net income per share is computed by dividing\nnet income by the sum of the weighted average number of shares of common stock outstanding plus the weighted average number of potentially\ndilutive securities during the period.
\n\n\u00a0
\n\nAt\nDecember 31, 2021 and 2020, there were potentially dilutive securities convertible into shares of common stock comprised of (i) stock\noptions \u2013 convertible into and shares, respectively, (ii) warrants \u2013 convertible into and\n shares, respectively, (iii) Series B preferred stock \u2013 convertible into shares in both periods, (iv) Series\nC preferred stock \u2013 convertible into and shares, respectively, (v) debentures payable \u2013 convertible into\n and shares, respectively, and (vi) promissory notes \u2013 convertible into and shares, respectively.
\n\n\u00a0
\n\nFor\nthe years ended December 31, 2021 and 2020, the aforementioned potentially dilutive securities increased the number of weighted average\ncommon shares outstanding on a diluted basis by approximately million and million net shares of common stock, respectively.\nSuch share amounts were reflected in the calculation of diluted net income per share for the years ended December 31, 2021 and 2020.
\n\n\u00a0
\n\nCommitments\nand Contingencies
\n\n\u00a0
\n\nThe\nCompany follows ASC 450, Contingencies, which requires the Company to assess the likelihood that a loss will be incurred from\nthe occurrence or non-occurrence of one or more future events. Such assessment inherently involves an exercise of judgment. In assessing\npossible loss contingencies from legal proceedings or unasserted claims, the Company evaluates the perceived merits of such proceedings\nor claims, and of the relief sought or expected to be sought.
\n\n\u00a0
\n\nIf\nthe assessment of a contingency indicates that it is probable that a material loss will be incurred and the amount of the liability can\nbe estimated, then the estimated liability would be accrued in the Company\u2019s financial statements. If the assessment indicates\nthat a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then\nthe nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.\nLoss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be\ndisclosed.
\n\n\u00a0
\n\nWhile\nnot assured, management does not believe, based upon information available at this time, that a loss contingency will have material adverse\neffect on the Company\u2019s financial position, results of operations or cash flows.
\n\n\u00a0
\n\n\n\n\n\u00a0
\n\nBeneficial\nConversion Features on Convertible Debt
\n\n\u00a0
\n\nConvertible\ninstruments that are not bifurcated as a derivative pursuant to ASC 815, Derivatives and Hedging, and not accounted for as a separate\nequity component under the cash conversion guidance are evaluated to determine whether their conversion prices create an embedded beneficial\nconversion feature at inception, or may become beneficial in the future due to potential adjustments.
\n\n\u00a0
\n\nA\nbeneficial conversion feature is a nondetachable conversion feature that is \u201cin-the-money\u201d at the commitment date. The in-the-money\nportion, also known as the intrinsic value, is recorded in equity, with an offsetting discount to the carrying amount of convertible\ndebt to which it is attached. The discount is amortized to interest expense over the life of the debt with adjustments to amortization\nupon full or partial conversions of the debt.
\n\n\u00a0
\n\nRisk\nand Uncertainties
\n\n\u00a0
\n\nThe\nCompany is subject to risks common to companies operating within the legal and medical cannabis industries, including, but not\nlimited to, federal laws, government regulations and jurisdictional laws.
\n\n\u00a0
\n\nNoncontrolling\nInterests
\n\n\u00a0
\n\nNoncontrolling\ninterests represent third-party minority ownership of the Company\u2019s consolidated subsidiaries. Net income attributable to noncontrolling\ninterests is shown in the consolidated statements of operations; and the value of net assets owned by noncontrolling interests are presented\nas a component of equity within the balance sheets.
\n\n\u00a0
\n\nOff\nBalance Sheet Arrangements
\n\n\u00a0
\n\nThe\nCompany does not have any off-balance sheet arrangements.
\n\n\u00a0
\n\nRecent\nAccounting Pronouncements
\n\n\u00a0
\n\nThe\nCompany has reviewed all recently issued, but not yet effective, accounting pronouncements, and does not believe the future adoption\nof any such pronouncements will have a material impact on its financial condition or the results of its operations.
\n\n\u00a0
\n\n\n\n\n\u00a0
\n\n"}]},{"name":"rpt:f-645","factDimensions":{"xbrl:concept":"us-gaap:BasisOfAccountingPolicyPolicyTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"Basis\nof Presentation
\n\n\u00a0
\n\nThe\naccompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States\nof America (\u201cGAAP\u201d).
\n\n\u00a0
\n\nCertain\nreclassifications have been made to prior periods\u2019 data to conform to the current period presentation. These reclassifications\nhad no effect on reported income (losses) or cash flows.
\n\n\u00a0
\n\n"}]},{"name":"rpt:f-646","factDimensions":{"xbrl:concept":"us-gaap:ConsolidationPolicyTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"Principles\nof Consolidation
\n\n\u00a0
\n\nThe\naccompanying consolidated financial statements include the accounts of MariMed Inc. and the following majority-owned subsidiaries\nat December 31, 2021:
\n\n\u00a0SCHEDULE OF MAJORITY OWNED SUBSIDIARIES
\n\n| Subsidiary: | \u00a0 | \nPercentage Owned | \u00a0 | |
| MariMed Advisors Inc. | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| Mia Development LLC | \u00a0 | \n\u00a0 | 89.5% | \u00a0 |
| Mari Holdings IL LLC | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| Mari Holdings MD LLC | \u00a0 | \n\u00a0 | 97.4% | \u00a0 |
| Mari Holdings NJ LLC | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| Mari Holdings NV LLC | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| Mari Holdings Metropolis LLC | \u00a0 | \n\u00a0 | 70.0% | \u00a0 |
| Mari Holdings Mt. Vernon LLC | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| Mari Mfg LLC | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| Hartwell Realty Holdings LLC | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| iRollie LLC | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| ARL Healthcare Inc. | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| KPG of Anna LLC | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| KPG of Harrisburg LLC | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| MariMed OH LLC | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| MariMed Hemp Inc. | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| MediTaurus LLC | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
\u00a0
\n\nIntercompany\naccounts and transactions have been eliminated.
\n\n\u00a0
\n\n"}]},{"name":"rpt:f-647","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"The\naccompanying consolidated financial statements include the accounts of MariMed Inc. and the following majority-owned subsidiaries\nat December 31, 2021:
\n\n\u00a0SCHEDULE OF MAJORITY OWNED SUBSIDIARIES
\n\n| Subsidiary: | \u00a0 | \nPercentage Owned | \u00a0 | |
| MariMed Advisors Inc. | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| Mia Development LLC | \u00a0 | \n\u00a0 | 89.5% | \u00a0 |
| Mari Holdings IL LLC | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| Mari Holdings MD LLC | \u00a0 | \n\u00a0 | 97.4% | \u00a0 |
| Mari Holdings NJ LLC | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| Mari Holdings NV LLC | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| Mari Holdings Metropolis LLC | \u00a0 | \n\u00a0 | 70.0% | \u00a0 |
| Mari Holdings Mt. Vernon LLC | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| Mari Mfg LLC | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| Hartwell Realty Holdings LLC | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| iRollie LLC | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| ARL Healthcare Inc. | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| KPG of Anna LLC | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| KPG of Harrisburg LLC | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| MariMed OH LLC | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| MariMed Hemp Inc. | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
| MediTaurus LLC | \u00a0 | \n\u00a0 | 100.0% | \u00a0 |
Use\nof Estimates
\n\n\u00a0
\n\nThe\npreparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported\namounts within the financial statements and disclosures thereof. Actual results could differ from these estimates or assumptions.
\n\n\u00a0
\n\n"}]},{"name":"rpt:f-666","factDimensions":{"xbrl:concept":"us-gaap:CashAndCashEquivalentsPolicyTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"Cash\nEquivalents
\n\n\u00a0
\n\nThe\nCompany considers all highly liquid investments with a maturity date of three months or less to be cash equivalents. The fair values\nof these investments approximate their carrying values.
\n\n\u00a0
\n\n\n\n
At December 31, 2021 and 2020, cash of approximately\n$5,101,000 and $101,000, respectively, was held in escrow. The 2021 balance was primarily comprised of a $5,000,000 escrow deposit in\nconnection with the acquisition of Kind Therapeutics USA Inc. as further discussed in Note 3 \u2013 Acquisitions.
\n\n\n
\u00a0
\n\nThe\nCompany\u2019s cash and cash equivalents are maintained with recognized financial institutions located in the United States. In the\nnormal course of business, the Company may carry balances with certain financial institutions that exceed federally insured limits. The\nCompany has not experienced losses on balances in excess of such limits and management believes the Company is not exposed to significant\nrisks in that regard.
\n\n\n\n\u00a0
\n\n"}]},{"name":"rpt:f-667","factDimensions":{"xbrl:concept":"us-gaap:RestrictedCashAndInvestments","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"5101000","decimals":0}]},{"name":"rpt:f-668","factDimensions":{"xbrl:concept":"us-gaap:RestrictedCashAndInvestments","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"101000","decimals":0}]},{"name":"rpt:f-669","factDimensions":{"xbrl:concept":"us-gaap:EscrowDeposit","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"MRMD:KindTherapeuticsUSAIncMember"},"factValues":[{"value":"5000000","decimals":0}]},{"name":"rpt:f-670","factDimensions":{"xbrl:concept":"us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"Accounts\nReceivable
\n\n\u00a0
\n\nAccounts\nreceivable consist of trade receivables and are carried at their estimated collectible amounts.
\n\n\u00a0
\n\nThe\nCompany provides credit to its clients in the form of payment terms. The Company limits its credit risk by performing credit evaluations\nof its clients and maintaining a reserve, if deemed necessary, for potential credit losses. Such evaluations include the review of a\nclient\u2019s outstanding balances with consideration towards such client\u2019s historical collection experience, as well as prevailing\neconomic and market conditions and other factors. Based on such evaluations, the Company maintained a reserve of approximately $41.4\nmillion and $40.0\nmillion at December 31, 2021 and 2020, respectively.\nFor further discussion on receivable reserves, please refer to Note 18 \u2013 Bad Debts and the Bankruptcy Claim section\nof Note 21 \u2013 Commitments and Contingencies.
\n\n\u00a0
\n\n\n\n\n\u00a0
\n\n"}]},{"name":"rpt:f-671","factDimensions":{"xbrl:concept":"us-gaap:BadDebtReserveForTaxPurposesOfQualifiedLender","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:ConcentrationRiskByBenchmarkAxis":"us-gaap:AccountsReceivableMember"},"factValues":[{"value":"41400000","decimals":-5}]},{"name":"rpt:f-672","factDimensions":{"xbrl:concept":"us-gaap:BadDebtReserveForTaxPurposesOfQualifiedLender","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:ConcentrationRiskByBenchmarkAxis":"us-gaap:AccountsReceivableMember"},"factValues":[{"value":"40000000.0","decimals":-5}]},{"name":"rpt:f-673","factDimensions":{"xbrl:concept":"us-gaap:InventoryPolicyTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"Inventory
\n\n\u00a0
\n\nInventory\nis carried at the lower of cost or net realizable value, with the cost being determined on a first-in, first-out (FIFO) basis. The Company\nallocates a certain percentage of overhead cost to its manufactured inventory; such allocation is based on square footage and other industry-standard\ncriteria. The Company reviews physical inventory for obsolescence and/or excess and will record a reserve if necessary. As of the date\nof this report, no reserve was deemed necessary.
\n\n\u00a0
\n\n"}]},{"name":"rpt:f-674","factDimensions":{"xbrl:concept":"us-gaap:InvestmentPolicyTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"Investments
\n\n\u00a0
\n\nInvestments\nare comprised of equity holding of public and private companies. These investments are recorded at fair value on the Company\u2019s\nconsolidated balance sheet, with changes to fair value included in income. Investments are evaluated for permanent impairment and are\nwritten down if such impairments are deemed to have occurred.
\n\n\u00a0
\n\n"}]},{"name":"rpt:f-675","factDimensions":{"xbrl:concept":"us-gaap:RevenueFromContractWithCustomerPolicyTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"Revenue\nRecognition
\n\n\u00a0
\n\nThe\nCompany recognizes revenue in accordance with the Financial Accounting Standards Board\u2019s Accounting Standards Codification (\u201cASC\u201d)\n606, Revenue from Contract with Customers, as amended by subsequently issued Accounting Standards Updates. This revenue standard\nrequires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration\nthat it expects to be entitled to in exchange for those goods or services. The recognition of revenue is determined by performing the\nfollowing consecutive steps:
\n\n\u00a0
\n\n| \u00a0 | \n\u25cf | \nIdentify\n the contract(s) with a customer; |
| \u00a0 | \n\u25cf | \nIdentify\n the performance obligations in the contract(s); |
| \u00a0 | \n\u25cf | \nDetermine\n the transaction price; |
| \u00a0 | \n\u25cf | \nAllocate\n the transaction price to the performance obligations in the contract(s); and |
| \u00a0 | \n\u25cf | \nRecognize\n revenue as the performance obligation is satisfied. |
\u00a0
\n\nAdditionally,\nwhen another party is involved in providing goods or services to the Company\u2019s clients, a determination is made as to who\u2014the\nCompany or the other party\u2014is acting in the capacity as the principal in the sale transaction, and who is merely the agent arranging\nfor goods or services to be provided by the other party.
\n\n\u00a0
\n\nThe\nCompany is typically considered the principal if it controls the specified good or service before such good or service is transferred\nto its client. The Company may also be deemed to be the principal even if it engages another party (an agent) to satisfy some of the\nperformance obligations on its behalf, provided the Company (i) takes on certain responsibilities, obligations, and risks, (ii) possesses\ncertain abilities and discretion, or (iii) other relevant indicators of the sale. If deemed an agent, the Company would not recognize\nrevenue for the performance obligations it does not satisfy.
\n\n\u00a0
\n\nThe\nCompany\u2019s main sources of revenue are comprised of the following:
\n\n\u00a0
\n\n| \u00a0 | \n\u25cf | \nProduct\n Sales \u2013 direct sales of cannabis and cannabis-infused products by the Company\u2019s retail dispensaries and wholesale operations\n in Massachusetts and Illinois, and sales of hemp and hemp-infused products. This revenue is recognized when products are delivered or at retail points-of-sale. |
| \u00a0 | \n\u00a0 | \n\u00a0 |
| \u00a0 | \n\u25cf | \nReal\n Estate \u2013 rental income and additional rental fees generated from leasing of the Company\u2019s state-of-the-art, regulatory-compliant\n cannabis facilities to its cannabis-licensed clients. Rental income is generally a fixed amount per month that escalates over the\n respective lease terms, while additional rental fees are based on a percentage of tenant revenues that exceed specified amounts. |
| \u00a0 | \n\u00a0 | \n\u00a0 |
| \u00a0 | \n\u25cf | \nManagement\n \u2013 fees for providing the Company\u2019s cannabis clients with comprehensive oversight of their cannabis cultivation, production,\n and dispensary operations. These fees are based on a percentage of such clients\u2019 revenue and are recognized after services\n have been performed. |
| \u00a0 | \n\u00a0 | \n\u00a0 |
| \u00a0 | \n\u25cf | \nSupply\n Procurement \u2013 the Company maintains volume discounts with top national vendors of cultivation and production resources, supplies,\n and equipment, which the Company acquires and resells to its clients or third parties within the cannabis industry. The Company recognizes\n this revenue after the delivery and acceptance of goods by the purchaser. |
| \u00a0 | \n\u00a0 | \n\u00a0 |
| \u00a0 | \n\u25cf | \nLicensing\n \u2013 royalties from the licensed distribution of the Company\u2019s branded products including Kalm Fusion and Betty\u2019s\n Eddies, and from sublicensing of contracted brands including Healer and Tikun Olam, to regulated dispensaries throughout the\n United States and Puerto Rico. The recognition of this revenue occurs when the products are delivered. |
\u00a0
\n\n\n\n\n\u00a0
\n\n"}]},{"name":"rpt:f-676","factDimensions":{"xbrl:concept":"us-gaap:ResearchAndDevelopmentExpensePolicy","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"Research\nand Development Costs
\n\n\u00a0
\n\nResearch\nand development costs are charged to operations as incurred.
\n\n\u00a0
\n\n"}]},{"name":"rpt:f-677","factDimensions":{"xbrl:concept":"us-gaap:PropertyPlantAndEquipmentPolicyTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"Property\nand Equipment
\n\n\u00a0
\n\nProperty\nand equipment are stated at cost less accumulated depreciation, with depreciation recognized on a straight-line basis over the shorter\nof the estimated useful life of the asset or the lease term, if applicable. When assets are retired or disposed, the cost and accumulated\ndepreciation are removed from the accounts, and any resulting gains or losses are included in income. Repairs and maintenance are charged\nto expense in the period incurred.
\n\n\u00a0
\n\nThe\nestimated useful lives of property and equipment are generally as follows: buildings and building improvements, forty years; tenant improvements,\nthe remaining duration of the related lease; furniture and fixtures, seven to ten years; machinery and equipment, ten years. Land is\nnot depreciated.
\n\n\u00a0
\n\nThe\nCompany\u2019s property and equipment are individually reviewed for impairment whenever events or changes in circumstances indicate\nthat the carrying amount of an asset may not be recoverable from the undiscounted future cash flows of such asset over the anticipated\nholding period. An impairment loss is measured by the excess of the asset\u2019s carrying amount over its estimated fair value.
\n\n\u00a0
\n\nImpairment\nanalyses are based on management\u2019s current plans, asset holding periods, and currently available market information. If these criteria\nchange, the Company\u2019s evaluation of impairment losses may be different and could have a material impact to the consolidated financial\nstatements.
\n\n\u00a0
\n\nFor\nthe years ended December 31, 2021 and 2020, based on the results of management\u2019s impairment analyses, there were no impairment\nlosses.
\n\n\u00a0
\n\n"}]},{"name":"rpt:f-678","factDimensions":{"xbrl:concept":"us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:PropertyPlantAndEquipmentByTypeAxis":"MRMD:TenantImprovementsMember"},"factValues":[{"value":"the remaining duration of the related lease"}]},{"name":"rpt:f-679","factDimensions":{"xbrl:concept":"us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:PropertyPlantAndEquipmentByTypeAxis":"us-gaap:FurnitureAndFixturesMember","srt:RangeAxis":"srt:MinimumMember"},"factValues":[{"value":"seven"}]},{"name":"rpt:f-680","factDimensions":{"xbrl:concept":"us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:PropertyPlantAndEquipmentByTypeAxis":"us-gaap:FurnitureAndFixturesMember","srt:RangeAxis":"srt:MaximumMember"},"factValues":[{"value":"ten"}]},{"name":"rpt:f-681","factDimensions":{"xbrl:concept":"us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:PropertyPlantAndEquipmentByTypeAxis":"us-gaap:MachineryAndEquipmentMember"},"factValues":[{"value":"ten"}]},{"name":"rpt:f-682","factDimensions":{"xbrl:concept":"us-gaap:AssetImpairmentCharges","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"0","decimals":0}]},{"name":"rpt:f-683","factDimensions":{"xbrl:concept":"us-gaap:AssetImpairmentCharges","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"0","decimals":0}]},{"name":"rpt:f-684","factDimensions":{"xbrl:concept":"us-gaap:LesseeLeasesPolicyTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"Leases
\n\n\u00a0
\n\nThe\nconsolidated financial statements reflect the Company\u2019s adoption of ASC 842, Leases, as amended by subsequent accounting\nstandards updates. Under ASC 842, arrangements that are determined to be leases with a term greater than one year are accounted\nfor by the recognition of right-of-use assets, that represent the Company\u2019s right to use an underlying asset for the lease term,\nand lease liabilities, that represent the Company\u2019s obligation to make lease payments arising from the lease. Non-lease components\nwithin lease agreements are accounted for separately.
\n\n\u00a0
\n\nRight-of-use\nassets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term, utilizing\nthe Company\u2019s incremental borrowing rate. The Company\u2019s lease terms may include options to extend or terminate the lease\nwhen it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line\nbasis over the lease term.
\n\n\u00a0
\n\n"}]},{"name":"rpt:f-685","factDimensions":{"xbrl:concept":"us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"Impairment\nof Long-Lived Assets
\n\n\u00a0
\n\nThe\nCompany evaluates the recoverability of its fixed assets and other assets in accordance with ASC 360-10-15, Impairment or Disposal\nof Long-Lived Assets. Impairment of long-lived assets is recognized when the net book value of such assets exceeds their expected\ncash flows, in which case the assets are written down to fair value, which is determined based on discounted future cash flows or appraised\nvalues.
\n\n\u00a0
\n\n"}]},{"name":"rpt:f-686","factDimensions":{"xbrl:concept":"us-gaap:FairValueOfFinancialInstrumentsPolicy","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"Fair\nValue of Financial Instruments
\n\n\u00a0
\n\nThe\nCompany follows the provisions of ASC 820, Fair Value Measurement, to measure the fair value of its financial instruments, and\nASC 825, Financial Instruments, for disclosures on the fair value of its financial instruments. To increase consistency and comparability\nin fair value measurements and related disclosures, ASC 820 establishes a fair value hierarchy which prioritizes the inputs to valuation\ntechniques used to measure fair value into three broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted)\nin active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three levels of fair value\nhierarchy defined by ASC 820 are:
\n\n\u00a0
\n\n| Level\n 1 | \nQuoted\n market prices available in active markets for identical assets or liabilities as of the reporting date. |
| \u00a0 | \n\u00a0 |
| Level\n 2 | \nPricing\n inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the\n reporting date. |
| \u00a0 | \n\u00a0 |
| Level\n 3 | \nPricing\n inputs that are generally observable inputs and not corroborated by market data. |
\u00a0
\n\n\n\n\n\u00a0
\n\nThe\ncarrying amounts of the Company\u2019s financial assets and liabilities, such as cash and accounts payable approximate their fair values\ndue to the short maturity of these instruments.
\n\n\u00a0
\n\nThe\nfair value of option and warrant issuances are determined using the Black-Scholes pricing model and employing several inputs such as\nthe expected life of instrument, the exercise price, the expected risk-free interest rate, the expected dividend yield, the value of\nthe Company\u2019s common stock on issuance date, and the expected volatility of such common stock. The following table summarizes the\nrange of inputs used by the Company during the prior two fiscal years:
\n\n\u00a0SCHEDULE OF ASSUMPTIONS USED
\n\n| \u00a0 | \u00a0 | \n2021 | \u00a0 | \u00a0 | \n2020 | \u00a0 | ||
| Life of instrument | \u00a0 | \n\u00a0 | to years | \u00a0 | \u00a0 | \n\u00a0 | to years | \u00a0 |
| Volatility factors | \u00a0 | \n\u00a0 | to | \u00a0 | \u00a0 | \n\u00a0 | to | \u00a0 |
| Risk-free interest rates | \u00a0 | \n\u00a0 | % to % | \u00a0 | \u00a0 | \n\u00a0 | % to % | \u00a0 |
| Dividend yield | \u00a0 | \n\u00a0 | % | \u00a0 | \u00a0 | \n\u00a0 | % | \u00a0 |
\u00a0
\n\nThe\nexpected life of an instrument is calculated using the simplified method pursuant to Staff Accounting Bulletin Topic 14, Share-Based\nPayment, which allows for using the mid-point between the vesting date and expiration date. The volatility factors are based on the\nhistorical two-year movement of the Company\u2019s common stock prior to an instrument\u2019s issuance date. The risk-free interest\nrate is based on U.S. Treasury rates with maturity periods similar to the expected instruments life on the issuance date.
\n\n\u00a0
\n\nThe\nCompany amortizes the fair value of option and warrant issuances on a straight-line basis over the requisite service period of each instrument.
\n\n\u00a0
\n\n"}]},{"name":"rpt:f-687","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfAssumptionsUsedTableTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\u00a0SCHEDULE OF ASSUMPTIONS USED
\n\n| \u00a0 | \u00a0 | \n2021 | \u00a0 | \u00a0 | \n2020 | \u00a0 | ||
| Life of instrument | \u00a0 | \n\u00a0 | to years | \u00a0 | \u00a0 | \n\u00a0 | to years | \u00a0 |
| Volatility factors | \u00a0 | \n\u00a0 | to | \u00a0 | \u00a0 | \n\u00a0 | to | \u00a0 |
| Risk-free interest rates | \u00a0 | \n\u00a0 | % to % | \u00a0 | \u00a0 | \n\u00a0 | % to % | \u00a0 |
| Dividend yield | \u00a0 | \n\u00a0 | % | \u00a0 | \u00a0 | \n\u00a0 | % | \u00a0 |
Extinguishment\nof Liabilities
\n\n\u00a0
\n\nThe\nCompany accounts for extinguishment of liabilities in accordance with ASC 405-20, Extinguishments of Liabilities. When the conditions\nfor extinguishment are met, the liabilities are written down to zero and a gain or loss is recognized.
\n\n\u00a0
\n\n"}]},{"name":"rpt:f-703","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\n\n\u00a0
\n\nThe\nCompany accounts for stock-based compensation using the fair value method as set forth in ASC 718, Compensation\u2014Stock Compensation,\nwhich requires a public entity to measure the cost of employee services received in exchange for an equity award based on the fair\nvalue of the award on the grant date, with limited exceptions. Such value will be incurred as compensation expense over the period an\nemployee is required to provide service in exchange for the award, usually the vesting period. No compensation cost is recognized for\nequity awards for which employees do not render the requisite service.
\n\n\u00a0
\n\n\n\n\n\u00a0
\n\n"}]},{"name":"rpt:f-704","factDimensions":{"xbrl:concept":"us-gaap:IncomeTaxPolicyTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"Income\nTaxes
\n\n\u00a0
\n\nThe\nCompany uses the asset and liability method to account for income taxes in accordance with ASC 740, Income Taxes. Under this method,\ndeferred income tax assets and liabilities are recorded for the future tax consequences of differences between the tax basis and financial\nreporting basis of assets and liabilities, measured using enacted tax rates and laws that will be in effect when the differences are\nexpected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than\nnot that the assets will not be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in\nthe consolidated statements of operations in the period that includes the enactment date.
\n\n\u00a0
\n\nASC\n740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial statements\nuncertain tax positions taken or expected to be taken on a tax return. The Company did not take any uncertain tax positions and had no\nadjustments to unrecognized income tax liabilities or benefits for the years ended December 31, 2021 and 2020.
\n\n\u00a0
\n\nCertain\nof the Company\u2019s subsidiaries are subject to the provisions of Section 280E of the Internal Revenue Code, as amended, which prohibits\nbusinesses from deducting certain expenses associated with the trafficking of controlled substances within the meaning of Schedule I\nand II of the Controlled Substances Act. Such non-deductibility of certain ordinary business expenses results in permanent differences\nand can cause the Company\u2019s effective tax rate to be highly variable and not necessarily correlated with pre-tax income.\u00a0
\n\n\u00a0
\n\n"}]},{"name":"rpt:f-705","factDimensions":{"xbrl:concept":"us-gaap:UnrecognizedTaxBenefits","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"0","decimals":0}]},{"name":"rpt:f-706","factDimensions":{"xbrl:concept":"us-gaap:UnrecognizedTaxBenefits","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"0","decimals":0}]},{"name":"rpt:f-707","factDimensions":{"xbrl:concept":"MRMD:RelatedPartyTransactionsPolicyTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"Related\nParty Transactions
\n\n\u00a0
\n\nThe\nCompany follows ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party\ntransactions.
\n\n\u00a0
\n\nIn\naccordance with ASC 850, the Company\u2019s financial statements include disclosures of material related party transactions, other than\ncompensation arrangements, expense allowances, and other similar items in the ordinary course of business, as well as transactions that\nare eliminated in the preparation of financial statements.
\n\n\u00a0
\n\n"}]},{"name":"rpt:f-708","factDimensions":{"xbrl:concept":"us-gaap:ComprehensiveIncomePolicyPolicyTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"Comprehensive\nIncome
\n\n\u00a0
\n\nThe\nCompany reports comprehensive income and its components following guidance set forth by ASC 220, Comprehensive Income, which establishes\nstandards for the reporting and display of comprehensive income and its components in the consolidated financial statements. There were\nno items of comprehensive income applicable to the Company during the period covered in the financial statements.
\n\n\u00a0
\n\n"}]},{"name":"rpt:f-709","factDimensions":{"xbrl:concept":"us-gaap:EarningsPerSharePolicyTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\n\n\u00a0
\n\nEarnings\nper common share is computed pursuant to ASC 260, Earnings Per Share. Basic earnings per share is computed by dividing net income\nby the weighted average number of shares of common stock outstanding during the period. Diluted net income per share is computed by dividing\nnet income by the sum of the weighted average number of shares of common stock outstanding plus the weighted average number of potentially\ndilutive securities during the period.
\n\n\u00a0
\n\nAt\nDecember 31, 2021 and 2020, there were potentially dilutive securities convertible into shares of common stock comprised of (i) stock\noptions \u2013 convertible into and shares, respectively, (ii) warrants \u2013 convertible into and\n shares, respectively, (iii) Series B preferred stock \u2013 convertible into shares in both periods, (iv) Series\nC preferred stock \u2013 convertible into and shares, respectively, (v) debentures payable \u2013 convertible into\n and shares, respectively, and (vi) promissory notes \u2013 convertible into and shares, respectively.
\n\n\u00a0
\n\nFor\nthe years ended December 31, 2021 and 2020, the aforementioned potentially dilutive securities increased the number of weighted average\ncommon shares outstanding on a diluted basis by approximately million and million net shares of common stock, respectively.\nSuch share amounts were reflected in the calculation of diluted net income per share for the years ended December 31, 2021 and 2020.
\n\n\u00a0
\n\n"}]},{"name":"rpt:f-710","factDimensions":{"xbrl:concept":"us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis":"us-gaap:EmployeeStockOptionMember"},"factValues":[{"value":"39821671"}]},{"name":"rpt:f-711","factDimensions":{"xbrl:concept":"us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis":"us-gaap:EmployeeStockOptionMember"},"factValues":[{"value":"9805750"}]},{"name":"rpt:f-712","factDimensions":{"xbrl:concept":"us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis":"us-gaap:WarrantMember"},"factValues":[{"value":"26351571"}]},{"name":"rpt:f-713","factDimensions":{"xbrl:concept":"us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis":"us-gaap:WarrantMember"},"factValues":[{"value":"16917168"}]},{"name":"rpt:f-714","factDimensions":{"xbrl:concept":"us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis":"MRMD:SeriesBPreferredStocksMember"},"factValues":[{"value":"4908333"}]},{"name":"rpt:f-715","factDimensions":{"xbrl:concept":"us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis":"MRMD:SeriesBPreferredStocksMember"},"factValues":[{"value":"4908333"}]},{"name":"rpt:f-716","factDimensions":{"xbrl:concept":"us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis":"MRMD:SeriesCPreferredStocksMember"},"factValues":[{"value":"31081080"}]},{"name":"rpt:f-717","factDimensions":{"xbrl:concept":"us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis":"MRMD:SeriesCPreferredStocksMember"},"factValues":[{"value":"0"}]},{"name":"rpt:f-718","factDimensions":{"xbrl:concept":"us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis":"us-gaap:ConvertibleDebtSecuritiesMember"},"factValues":[{"value":"0"}]},{"name":"rpt:f-719","factDimensions":{"xbrl:concept":"us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis":"us-gaap:ConvertibleDebtSecuritiesMember"},"factValues":[{"value":"4610645"}]},{"name":"rpt:f-720","factDimensions":{"xbrl:concept":"us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis":"MRMD:PromissoryNotesMember"},"factValues":[{"value":"1142857"}]},{"name":"rpt:f-721","factDimensions":{"xbrl:concept":"us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis":"MRMD:PromissoryNotesMember"},"factValues":[{"value":"15503282"}]},{"name":"rpt:f-722","factDimensions":{"xbrl:concept":"us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis":"us-gaap:CommonStockMember"},"factValues":[{"value":"45900000","decimals":-5}]},{"name":"rpt:f-723","factDimensions":{"xbrl:concept":"us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis":"us-gaap:CommonStockMember"},"factValues":[{"value":"57200000","decimals":-5}]},{"name":"rpt:f-724","factDimensions":{"xbrl:concept":"us-gaap:CommitmentsAndContingenciesPolicyTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"Commitments\nand Contingencies
\n\n\u00a0
\n\nThe\nCompany follows ASC 450, Contingencies, which requires the Company to assess the likelihood that a loss will be incurred from\nthe occurrence or non-occurrence of one or more future events. Such assessment inherently involves an exercise of judgment. In assessing\npossible loss contingencies from legal proceedings or unasserted claims, the Company evaluates the perceived merits of such proceedings\nor claims, and of the relief sought or expected to be sought.
\n\n\u00a0
\n\nIf\nthe assessment of a contingency indicates that it is probable that a material loss will be incurred and the amount of the liability can\nbe estimated, then the estimated liability would be accrued in the Company\u2019s financial statements. If the assessment indicates\nthat a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then\nthe nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.\nLoss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be\ndisclosed.
\n\n\u00a0
\n\nWhile\nnot assured, management does not believe, based upon information available at this time, that a loss contingency will have material adverse\neffect on the Company\u2019s financial position, results of operations or cash flows.
\n\n\u00a0
\n\n\n\n\n\u00a0
\n\n"}]},{"name":"rpt:f-725","factDimensions":{"xbrl:concept":"us-gaap:DebtPolicyTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"Beneficial\nConversion Features on Convertible Debt
\n\n\u00a0
\n\nConvertible\ninstruments that are not bifurcated as a derivative pursuant to ASC 815, Derivatives and Hedging, and not accounted for as a separate\nequity component under the cash conversion guidance are evaluated to determine whether their conversion prices create an embedded beneficial\nconversion feature at inception, or may become beneficial in the future due to potential adjustments.
\n\n\u00a0
\n\nA\nbeneficial conversion feature is a nondetachable conversion feature that is \u201cin-the-money\u201d at the commitment date. The in-the-money\nportion, also known as the intrinsic value, is recorded in equity, with an offsetting discount to the carrying amount of convertible\ndebt to which it is attached. The discount is amortized to interest expense over the life of the debt with adjustments to amortization\nupon full or partial conversions of the debt.
\n\n\u00a0
\n\n"}]},{"name":"rpt:f-726","factDimensions":{"xbrl:concept":"us-gaap:ConcentrationRiskCreditRisk","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"Risk\nand Uncertainties
\n\n\u00a0
\n\nThe\nCompany is subject to risks common to companies operating within the legal and medical cannabis industries, including, but not\nlimited to, federal laws, government regulations and jurisdictional laws.
\n\n\u00a0
\n\n"}]},{"name":"rpt:f-727","factDimensions":{"xbrl:concept":"MRMD:NoncontrollingInterestsPolicyTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"Noncontrolling\nInterests
\n\n\u00a0
\n\nNoncontrolling\ninterests represent third-party minority ownership of the Company\u2019s consolidated subsidiaries. Net income attributable to noncontrolling\ninterests is shown in the consolidated statements of operations; and the value of net assets owned by noncontrolling interests are presented\nas a component of equity within the balance sheets.
\n\n\u00a0
\n\n"}]},{"name":"rpt:f-728","factDimensions":{"xbrl:concept":"us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"Off\nBalance Sheet Arrangements
\n\n\u00a0
\n\nThe\nCompany does not have any off-balance sheet arrangements.
\n\n\u00a0
\n\n"}]},{"name":"rpt:f-729","factDimensions":{"xbrl:concept":"us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"Recent\nAccounting Pronouncements
\n\n\u00a0
\n\nThe\nCompany has reviewed all recently issued, but not yet effective, accounting pronouncements, and does not believe the future adoption\nof any such pronouncements will have a material impact on its financial condition or the results of its operations.
\n\n"}]},{"name":"rpt:f-730","factDimensions":{"xbrl:concept":"us-gaap:BusinessCombinationDisclosureTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"NOTE\n3 \u2013 ACQUISITIONS
\n\n\u00a0
\n\nThe\nHarvest Foundation LLC
\n\n\u00a0
\n\nIn\n2019, the Company entered into a purchase agreement to acquire 100%\nof the ownership interests of The Harvest Foundation LLC (\u201cHarvest\u201d), the Company\u2019s cannabis-licensed client in\nthe state of Nevada. The acquisition is conditioned upon state regulatory approval of the transaction and other closing\nconditions. Upon approval, and the fulfillment of other closing conditions, the ownership of Harvest will be transferred to the\nCompany, and the operations of Harvest will begin to be consolidated into the Company\u2019s financial statements. There\nis no assurance that the closing conditions to the Company\u2019s acquisition of\nHarvest, including regulatory approval, will be achieved or that the acquisition will be consummated.
\n\n\u00a0
\n\nThe\npurchase price is comprised of the issuance of (i) shares of the Company\u2019s common stock, in the aggregate, to two owners\nof Harvest, which as a good faith deposit, were issued upon execution of the purchase agreement, (ii) $1.2 million of the Company\u2019s\ncommon stock at closing, based on the closing price of the common stock on the day prior to legislative approval of the transaction,\nand (iii) warrants to purchase 400,000 shares of the Company\u2019s common stock at an exercise price equal to the closing price of\nthe Company\u2019s common stock on the day prior to legislative approval of the transaction. The issued shares were recorded at par\nvalue. Such shares are restricted and will be returned to the Company in the event the transaction does not close.
\n\n\u00a0
\n\nKind\nTherapeutics USA Inc.
\n\n\u00a0
\n\nIn\n2016, the Company and the members of Kind Therapeutics USA Inc., the Company\u2019s client in Maryland that holds licenses for\nthe cultivation, production, and dispensing of medical cannabis (\u201cKind\u201d), agreed to a partnership/joint venture whereby Kind\nwould be owned 70.0%\nby the Company and 30.0%\nby the members of Kind, subject to approval by the\nMaryland Medical Cannabis Commission (\u201cMMCC\u201d). In reliance thereon, the Company purchased, designed, and developed a 180,000\nsquare foot cultivation and production\nfacility in Hagerstown, MD for occupancy and use by Kind, which became operational in late 2017, and the Company further agreed to manage\nand finance all aspects of Kind\u2019s cannabis business, as Kind had no background or experience in the industry.
\n\n\u00a0
\n\nIn\n2018, prior to finalizing the documents confirming\nthe partnership/joint venture the Company and the members of Kind negotiated and entered into a memorandum of understanding (\u201cMOU\u201d)\nfor the Company to acquire 100%\nof the membership interests of Kind. Also at that time, the parties entered into a management services agreement for\nthe Company to provide Kind with comprehensive management services in connection with the business and operations of Kind, and\na 20-year\nlease agreement for Kind\u2019s utilization of the Company\u2019s 180,000\nsquare foot cultivation and production facility\nin Hagerstown, MD. Additionally, in 2019, the Company purchased a 9,000\nsquare foot building in Anne Arundel County,\nMD, which is currently under construction, for the development of a dispensary which would be leased to Kind.
\n\n\u00a0
\n\nIn\n2019, the members of Kind sought to renegotiate the terms of the MOU and subsequently sought to renege on both the original partnership/joint\nventure and the MOU. The Company engaged with the member of Kind in good faith in an attempt to reach updated terms acceptable\nto both parties, however the members of Kind failed to reciprocate in good faith, resulting in an impasse. Incrementally, both\nparties through counsel further sought to resolve the impasse, however such initiative resulted in both parties commencing legal proceedings.
\n\n\u00a0
\n\n\n\nIn December 2021, the Company entered into\na membership interest purchase agreement with the members of Kind to acquire 100% of the equity ownership of Kind in exchange for $13,500,000 payable in cash (subject to adjustment) and $6,500,000 payable by the issuance of four-year\n6.0% promissory notes to the members of Kind. The notes shall be secured by a first priority lien on the Company\u2019s property in\nHagerstown, MD. Upon execution of the membership interest purchase agreement, the Company deposited, in escrow, the sum of $5,000,000\nas a contract down-payment.
\n\n\u00a0
\n\nSimultaneously, the\nCompany entered into a membership interest purchase agreement with one of the members of Kind to acquire such member\u2019s entire equity\nownership interest in (i) Mari Holdings MD LLC (\u201cMari-MD\u201d), the Company\u2019s majority owned subsidiary that owns production\nand retail cannabis facilities in Hagerstown, MD and Annapolis, MD, and (ii) Mia Development LLC (\u201cMia\u201d), the Company\u2019s\nmajority owned subsidiary that owns production and retail cannabis facilities in Wilmington, DE. The purchase price for the interests in Mari-MD and Mia is $2,000,000 in\nthe aggregate, payable in cash. Giving effect to the purchase of these\ninterests, the Company will own approximately 99.7% and 94.3%, respectively, of Mari-MD and Mia.
\n\n\u00a0
\n\nThe closings under the foregoing agreements\nare subject to the fulfilment of closing conditions including, but not limited to, approval by the MMCC, which is pending. There is no assurance that the\napproval of the MMCC will be obtained or that the further closing conditions will be met. Simultaneous with the closing of the transactions\ncontemplated by the foregoing agreements, the aforementioned litigation between the parties will be dismissed. For further information,\nsee Note 21 \u2013 Commitment and Contingencies.
\n\n\n\n
\u00a0
\n\nMediTaurus\nLLC
\n\n\u00a0
\n\nIn\n2019, the Company acquired a 70.0%\nownership interest in MediTaurus LLC (\u201cMediTaurus\u201d),\na company formed by Jokubas Ziburkas PhD, a neuroscientist and leading authority on cannabidiol (\u201cCBD\u201d) and the endocannabinoid\nsystem, in exchange for $2.8\nmillion of cash and stock. The\nCompany currently sells CBD products developed by MediTaurus under its Florance\u2122 brand.
\n\n\u00a0
\n\nIn\nSeptember 2021, the Company acquired the remaining 30.0%\nownership interest of MediTaurus in exchange for\nshares of the Company\u2019s common stock, valued\nat approximately $94,000,\nand $10,000\nin cash. The carrying value of the noncontrolling\ninterest of approximately $975,000\nwas eliminated, and since there was no change\nin control of MediTaurus from this transaction, the resulting gain on bargain purchase was recognized in Additional Paid-In Capital\non the September 30, 2021 balance sheet. The shares and cash were issued and paid in November 2021. As part of this transaction,\nthe initial purchase agreement was amended whereby any and all future license fees and payments to MediTaurus were eliminated.
\n\n\u00a0
\n\nBeverly Asset Purchase
\n\n\u00a0
\n\nIn November 2021, the Company entered into an\nasset purchase agreement to acquire the cannabis license, property lease, and other assets and rights of, and to assume the liabilities\nand operating obligations associated with, a cannabis dispensary that is currently operating in Beverly, MA. The purchase price is comprised\nof shares of the Company\u2019s common stock and $5.1 million, with the cash amount to be paid over time on a monthly basis\nas a percentage of the business\u2019 monthly gross sales.
\n\n\u00a0
\n\n\n\nThe purchase is contingent upon the approval of\nthe Massachusetts Cannabis Control Commission, which is expected by the summer of 2022. Concurrent with the execution of this agreement,\nthe parties entered into a consulting agreement pursuant whereby the Company shall provide certain oversight services related to the\ndevelopment, staffing, and operation of the business in exchange for a monthly fee.
\n\n\n\u00a0
\n\n\n\n\n\u00a0
\n\n"}]},{"name":"rpt:f-731","factDimensions":{"xbrl:concept":"us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired","xbrl:period":"2019-09-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:BusinessAcquisitionAxis":"MRMD:TheHarvestFoundationLLCMember"},"factValues":[{"value":"1"}]},{"name":"rpt:f-732","factDimensions":{"xbrl:concept":"us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction","xbrl:period":"2019-08-01T00:00:00/2019-09-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:RelatedPartyTransactionsByRelatedPartyAxis":"MRMD:TwoOwnersMember","us-gaap:BusinessAcquisitionAxis":"MRMD:TheHarvestFoundationLLCMember"},"factValues":[{"value":"1000000"}]},{"name":"rpt:f-733","factDimensions":{"xbrl:concept":"us-gaap:SaleOfStockConsiderationReceivedOnTransaction","xbrl:period":"2019-08-01T00:00:00/2019-09-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:RelatedPartyTransactionsByRelatedPartyAxis":"MRMD:TwoOwnersMember","us-gaap:BusinessAcquisitionAxis":"MRMD:TheHarvestFoundationLLCMember"},"factValues":[{"value":"1200000","decimals":-5}]},{"name":"rpt:f-734","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights","xbrl:period":"2019-09-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:RelatedPartyTransactionsByRelatedPartyAxis":"MRMD:TwoOwnersMember","us-gaap:BusinessAcquisitionAxis":"MRMD:TheHarvestFoundationLLCMember"},"factValues":[{"value":"400000"}]},{"name":"rpt:f-735","factDimensions":{"xbrl:concept":"us-gaap:EquityMethodInvestmentOwnershipPercentage","xbrl:period":"2017-01-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:BusinessAcquisitionAxis":"MRMD:KindTherapeuticsUSAIncMember"},"factValues":[{"value":"0.70"}]},{"name":"rpt:f-736","factDimensions":{"xbrl:concept":"us-gaap:EquityMethodInvestmentOwnershipPercentage","xbrl:period":"2017-01-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:RelatedPartyTransactionsByRelatedPartyAxis":"MRMD:MembersKindTherapeuticsUSAIncMember"},"factValues":[{"value":"0.300"}]},{"name":"rpt:f-737","factDimensions":{"xbrl:concept":"us-gaap:AreaOfLand","xbrl:period":"2017-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"utr:sqft","us-gaap:BusinessAcquisitionAxis":"MRMD:KindTherapeuticsUSAIncMember"},"factValues":[{"value":"180000"}]},{"name":"rpt:f-738","factDimensions":{"xbrl:concept":"us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired","xbrl:period":"2018-12-22T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:BusinessAcquisitionAxis":"MRMD:KindTherapeuticsUSAIncMember"},"factValues":[{"value":"1"}]},{"name":"rpt:f-739","factDimensions":{"xbrl:concept":"us-gaap:LessorOperatingLeaseTermOfContract","xbrl:period":"2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:BusinessAcquisitionAxis":"MRMD:KindTherapeuticsUSAIncMember"},"factValues":[{"value":"P20Y"}]},{"name":"rpt:f-740","factDimensions":{"xbrl:concept":"us-gaap:AreaOfLand","xbrl:period":"2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"utr:sqft","us-gaap:BusinessAcquisitionAxis":"MRMD:KindTherapeuticsUSAIncMember"},"factValues":[{"value":"180000"}]},{"name":"rpt:f-741","factDimensions":{"xbrl:concept":"us-gaap:AreaOfLand","xbrl:period":"2019-11-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"utr:sqft","us-gaap:BusinessAcquisitionAxis":"MRMD:KindTherapeuticsUSAIncMember","srt:StatementGeographicalAxis":"MRMD:AnneArundelCountyMDMember"},"factValues":[{"value":"9000"}]},{"name":"rpt:f-742","factDimensions":{"xbrl:concept":"us-gaap:EquityMethodInvestmentOwnershipPercentage","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:BusinessAcquisitionAxis":"MRMD:KindTherapeuticsUSAIncMember"},"factValues":[{"value":"1"}]},{"name":"rpt:f-743","factDimensions":{"xbrl:concept":"us-gaap:PaymentsToAcquireManagementContractRights","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"MRMD:KindTherapeuticsUSAIncMember"},"factValues":[{"value":"13500000","decimals":0}]},{"name":"rpt:f-744","factDimensions":{"xbrl:concept":"us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"MRMD:KindTherapeuticsUSAIncMember","us-gaap:TypeOfArrangementAxis":"MRMD:SixPercentPromissoryNotesMember"},"factValues":[{"value":"6500000","decimals":0}]},{"name":"rpt:f-745","factDimensions":{"xbrl:concept":"us-gaap:EscrowDepositDisbursementsRelatedToPropertyAcquisition1","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"5000000","decimals":0}]},{"name":"rpt:f-746","factDimensions":{"xbrl:concept":"us-gaap:AssetAcquisitionPriceOfAcquisitionExpected","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:AssetAcquisitionAxis":"MRMD:MariHoldingsMDLLCAndMiaDevelopmentLLCMember"},"factValues":[{"value":"2000000","decimals":0}]},{"name":"rpt:f-747","factDimensions":{"xbrl:concept":"us-gaap:MinorityInterestOwnershipPercentageByParent","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","srt:OwnershipAxis":"MRMD:MariHoldingsMDLLCMember"},"factValues":[{"value":"0.997"}]},{"name":"rpt:f-748","factDimensions":{"xbrl:concept":"us-gaap:MinorityInterestOwnershipPercentageByParent","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","srt:OwnershipAxis":"MRMD:MiaDevelopmentLLCMember"},"factValues":[{"value":"0.943"}]},{"name":"rpt:f-749","factDimensions":{"xbrl:concept":"us-gaap:EquityMethodInvestmentOwnershipPercentage","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:BusinessAcquisitionAxis":"MRMD:MeditaurusLLCMember"},"factValues":[{"value":"0.700"}]},{"name":"rpt:f-750","factDimensions":{"xbrl:concept":"us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired","xbrl:period":"2019-12-29T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"MRMD:MeditaurusLLCMember"},"factValues":[{"value":"2800000","decimals":-5}]},{"name":"rpt:f-751","factDimensions":{"xbrl:concept":"us-gaap:BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:BusinessAcquisitionAxis":"MRMD:MeditaurusLLCMember"},"factValues":[{"value":"The\nCompany currently sells CBD products developed by MediTaurus under its Florance\u2122 brand"}]},{"name":"rpt:f-752","factDimensions":{"xbrl:concept":"us-gaap:EquityMethodInvestmentOwnershipPercentage","xbrl:period":"2021-10-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:BusinessAcquisitionAxis":"MRMD:MeditaurusLLCMember"},"factValues":[{"value":"0.300"}]},{"name":"rpt:f-753","factDimensions":{"xbrl:concept":"us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction","xbrl:period":"2021-09-01T00:00:00/2021-10-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:BusinessAcquisitionAxis":"MRMD:MeditaurusLLCMember"},"factValues":[{"value":"100000"}]},{"name":"rpt:f-754","factDimensions":{"xbrl:concept":"us-gaap:CommonStockValue","xbrl:period":"2021-10-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"MRMD:MeditaurusLLCMember"},"factValues":[{"value":"94000","decimals":0}]},{"name":"rpt:f-755","factDimensions":{"xbrl:concept":"us-gaap:CashAcquiredFromAcquisition","xbrl:period":"2021-09-01T00:00:00/2021-10-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"MRMD:MeditaurusLLCMember"},"factValues":[{"value":"10000","decimals":0}]},{"name":"rpt:f-756","factDimensions":{"xbrl:concept":"us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination","xbrl:period":"2021-09-01T00:00:00/2021-10-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"MRMD:MeditaurusLLCMember"},"factValues":[{"value":"975000","decimals":0}]},{"name":"rpt:f-757","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets","xbrl:period":"2021-11-01T00:00:00/2021-12-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:RelatedPartyTransactionsByRelatedPartyAxis":"MRMD:BeverlyAssetPurchaseMember"},"factValues":[{"value":"2000000"}]},{"name":"rpt:f-758","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets","xbrl:period":"2021-11-01T00:00:00/2021-12-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:RelatedPartyTransactionsByRelatedPartyAxis":"MRMD:BeverlyAssetPurchaseMember"},"factValues":[{"value":"5100000","decimals":-5}]},{"name":"rpt:f-759","factDimensions":{"xbrl:concept":"us-gaap:InvestmentHoldingsTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"NOTE\n4 \u2013 INVESTMENTS
\n\n\u00a0
\n\nAt\nDecember 31, 2021 and 2020, the Company\u2019s investments were comprised of the following:
\n\n\u00a0SCHEDULE OF INVESTMENTS
\n\n| \u00a0 | \u00a0 | \n2021 | \u00a0 | \u00a0 | \n2020 | \u00a0 | ||
| Current investments: | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 |
| Flowr Corp. (formerly Terrace Inc.) | \u00a0 | \n$ | 250,600 | \u00a0 | \u00a0 | \n$ | 1,357,193 | \u00a0 |
| \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 |
| Non-current investments: | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 |
| MembersRSVP LLC | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 | \n\u00a0 | 1,165,788 | \u00a0 | |
| \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 |
| Total investments | \u00a0 | \n$ | 250,600 | \u00a0 | \u00a0 | \n$ | 2,522,981 | \u00a0 |
\u00a0
\n\nFlowr\nCorp. (formerly Terrace Inc.)
\n\n\u00a0
\n\nIn\nDecember 2020, Terrace Inc., a Canadian cannabis entity in which the Company had an ownership interest of 8.95% (\u201cTerrace\u201d),\nwas acquired by Flowr Corp. (TSX.V: FLWR; OTC: FLWPF), a Toronto-headquartered cannabis company with operations in Canada, Europe, and\nAustralia (\u201cFlowr\u201d). Under the terms of the transaction, each shareholder of Terrace received of a share in Flowr\nfor each Terrace share held.
\n\n\u00a0
\n\nThis\ninvestment is carried at fair value. The decrease in fair value of this investment during the years ended December 31, 2021 and 2020\nof approximately $1,107,000 and $92,000, respectively, was reflected in the Change In Fair Value Of Investments on the statement\nof operations.
\n\n\u00a0
\n\nMembersRSVP\nLLC
\n\n\u00a0
\n\nDuring\n2020, the Company owned a 23.0% member interest in MembersRSVP LLC (\u201cMRSVP\u201d), an entity that developed cannabis-specific\ncustomer relationship management software, which was accounted for under the equity method. Based on the Company\u2019s equity in MRSVP\u2019s\nnet income during this period, the Company recorded earnings in 2020 of approximately $99,000, which comprised the balance of Equity\nin Earnings of Investments on the statement of operations.
\n\n\u00a0
\n\nIn\nJanuary 2021, the Company and MRSVP entered into an agreement whereby the Company assigned and transferred 11.0%\nof its member interests to MRSVP in exchange for a release from all further obligation by the Company to make future investments or payments\nand certain other non-monetary consideration. In addition to the reduction of the Company\u2019s ownership interest to 12.0%,\nthe Company relinquished its right to appoint a\nmember to the board of MRSVP. In light of the Company no longer having the ability to exercise significant influence over MRSVP, the\nCompany discontinued accounting for this investment under the equity method as of January 1, 2021.
\n\n\u00a0
\n\nIn\nSeptember 2021, MRSVP sold substantially all of its assets pursuant to an asset purchase agreement. In furtherance of the transaction,\nthe Company received cash proceeds of $1,475,000, representing the Company\u2019s pro rata share of the cash consideration received\nby MRSVP upon the closing of the transaction. As an ongoing member of MRSVP, the Company will receive its pro rata share of any additional\nconsideration received by MRSVP pursuant to the asset purchase agreement, which may include securities or other forms of non-cash or\nin-kind consideration and holdback amounts, if and when it is received and distributed by MRSVP.
\n\n\u00a0
\n\nUpon\nreceipt of the cash consideration, the Company reduced the investment balance to zero and recorded a gain of approximately $309,000 which\ncomprised Other non-operating expenses on the statement of operations.
\n\n\u00a0
\n\nIn February 2022, the Company received its\npro rata share of additional consideration received by MRSVP pursuant to the asset purchase agreement which is further discussed in Note\n22 \u2013 Subsequent Events.
\n\n\u00a0
\n\n\n\n\n\u00a0
\n\n"}]},{"name":"rpt:f-760","factDimensions":{"xbrl:concept":"us-gaap:InvestmentTableTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"At\nDecember 31, 2021 and 2020, the Company\u2019s investments were comprised of the following:
\n\n\u00a0SCHEDULE OF INVESTMENTS
\n\n| \u00a0 | \u00a0 | \n2021 | \u00a0 | \u00a0 | \n2020 | \u00a0 | ||
| Current investments: | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 |
| Flowr Corp. (formerly Terrace Inc.) | \u00a0 | \n$ | 250,600 | \u00a0 | \u00a0 | \n$ | 1,357,193 | \u00a0 |
| \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 |
| Non-current investments: | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 |
| MembersRSVP LLC | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 | \n\u00a0 | 1,165,788 | \u00a0 | |
| \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 |
| Total investments | \u00a0 | \n$ | 250,600 | \u00a0 | \u00a0 | \n$ | 2,522,981 | \u00a0 |
NOTE\n5 \u2013 DEFERRED RENTS RECEIVABLE
\n\n\u00a0
\n\nThe\nCompany is the lessor under operating leases which contain rent holidays, escalating rents over time, options to renew, requirements\nto pay property taxes, insurance and/or maintenance costs, and contingent rental payments based on a percentage of monthly tenant revenues.\nThe Company is not the lessor under any finance leases.
\n\n\u00a0
\n\nThe\nCompany recognizes fixed rental receipts from such lease agreements on a straight-line basis over the expected lease term. Differences\nbetween amounts received and amounts recognized are recorded under Deferred Rents Receivable on the balance sheet. Contingent\nrentals are recognized only after tenants\u2019 revenues are finalized and if such revenues exceed certain minimum levels.
\n\n\u00a0
\n\nThe\nCompany leases the following owned properties:
\n\n\u00a0
\n\n| \u00a0 | \n\u25cf | \nDelaware\n \u2013 a 45,000 square foot cannabis cultivation, processing, and dispensary facility which is leased to a cannabis-licensed client\n under a triple net lease that expires in 2035. |
| \u00a0 | \n\u00a0 | \n\u00a0 |
| \u00a0 | \n\u25cf | \nMaryland\n \u2013 a 180,000 square foot cultivation and processing facility which is leased to a licensed cannabis client under a triple net\n lease that expires in 2037. |
| \u00a0 | \n\u00a0 | \n\u00a0 |
| \u00a0 | \n\u25cf | \nMassachusetts\n \u2013 a 138,000 square foot industrial property of which approximately half of the available square footage is leased to a non-cannabis\n manufacturing company under a lease that expires in October 2022. |
\u00a0
\n\nThe\nCompany subleases the following properties:
\n\n\u00a0
\n\n| \u00a0 | \n\u25cf | \nDelaware\n \u2013 a 4,000\n square foot cannabis dispensary which\n is subleased to its cannabis-licensed client under a under a sublease expiring in April 2027. |
| \u00a0 | \n\u00a0 | \n\u00a0 |
| \u00a0 | \n\u25cf | \nDelaware\n \u2013 a 100,000\n square foot warehouse, of which the\n Company developed 60,000 square feet into a cultivation facility, and is developing the remaining space into\n processing facility, subleased to its cannabis-licensed client. The\n sublease expires in March 2030, with an option to extend the term for three additional five-year periods. |
| \u00a0 | \n\u00a0 | \n\u00a0 |
| \u00a0 | \n\u25cf | \nDelaware\n \u2013 a 12,000\n square foot cannabis production facility\n with offices which is subleased to its cannabis-licensed client. The\n sublease expires in January 2026 and contains an option to negotiate an extension at the end of the lease term. |
\u00a0
\n\nAs\nof December 31, 2021 and 2020, cumulative fixed rental receipts under such leases approximated $18.7 million and $13.9 million, respectively,\ncompared to revenue recognized on a straight-line basis of approximately $20.4 million and $15.8 million, respectively. Accordingly,\nthe deferred rents receivable balance approximated $1.7 million and $1.9 million at December 31, 2021 and 2020, respectively.
\n\n\u00a0
\n\nFuture\nminimum rental receipts for non-cancellable leases and subleases as of December 31, 2021 were:
\n\nSCHEDULE OF FUTURE MINIMUM RENTAL RECEIPTS FOR NON-CANCELABLE LEASES AND SUBLEASES
\n\n| 2022 | \u00a0 | \n$ | 4,854,549 | \u00a0 |
| 2023 | \u00a0 | \n\u00a0 | 4,563,372 | \u00a0 |
| 2024 | \u00a0 | \n\u00a0 | 4,625,608 | \u00a0 |
| 2025 | \u00a0 | \n\u00a0 | 4,695,107 | \u00a0 |
| 2026 | \u00a0 | \n\u00a0 | 3,915,790 | \u00a0 |
| Thereafter | \u00a0 | \n\u00a0 | 35,829,822 | \u00a0 |
| Total | \u00a0 | \n$ | 58,484,248 | \u00a0 |
\u00a0
\n\n\n\n\n\u00a0
\n\n"}]},{"name":"rpt:f-777","factDimensions":{"xbrl:concept":"us-gaap:AreaOfLand","xbrl:period":"2016-10-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"utr:sqft","srt:StatementGeographicalAxis":"stpr:DE"},"factValues":[{"value":"45000"}]},{"name":"rpt:f-778","factDimensions":{"xbrl:concept":"MRMD:LeaseExpirationDescription","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","srt:StatementGeographicalAxis":"stpr:DE"},"factValues":[{"value":"expires in 2035"}]},{"name":"rpt:f-779","factDimensions":{"xbrl:concept":"us-gaap:AreaOfLand","xbrl:period":"2017-02-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"utr:sqft","srt:StatementGeographicalAxis":"stpr:MD"},"factValues":[{"value":"180000"}]},{"name":"rpt:f-780","factDimensions":{"xbrl:concept":"MRMD:LeaseExpirationDescription","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","srt:StatementGeographicalAxis":"stpr:MD"},"factValues":[{"value":"expires in 2037"}]},{"name":"rpt:f-781","factDimensions":{"xbrl:concept":"us-gaap:AreaOfLand","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"utr:sqft","srt:StatementGeographicalAxis":"stpr:MA","srt:ProductOrServiceAxis":"MRMD:NonCannabisMember"},"factValues":[{"value":"138000"}]},{"name":"rpt:f-782","factDimensions":{"xbrl:concept":"MRMD:LeaseExpirationDescription","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","srt:StatementGeographicalAxis":"stpr:MA","srt:ProductOrServiceAxis":"MRMD:NonCannabisMember"},"factValues":[{"value":"expires in October 2022"}]},{"name":"rpt:f-783","factDimensions":{"xbrl:concept":"us-gaap:AreaOfLand","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"utr:sqft","srt:StatementGeographicalAxis":"stpr:DE","us-gaap:LeaseContractualTermAxis":"MRMD:RetailSpaceMember"},"factValues":[{"value":"4000"}]},{"name":"rpt:f-784","factDimensions":{"xbrl:concept":"us-gaap:AreaOfLand","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"utr:sqft","srt:StatementGeographicalAxis":"stpr:DE","us-gaap:LeaseContractualTermAxis":"srt:WarehouseMember"},"factValues":[{"value":"100000"}]},{"name":"rpt:f-785","factDimensions":{"xbrl:concept":"us-gaap:AreaOfLand","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"utr:sqft","srt:StatementGeographicalAxis":"stpr:DE","us-gaap:LeaseContractualTermAxis":"MRMD:CultivationAndProcessingFacilityMember"},"factValues":[{"value":"60000"}]},{"name":"rpt:f-786","factDimensions":{"xbrl:concept":"us-gaap:LessorOperatingLeaseOptionToExtend","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","srt:StatementGeographicalAxis":"stpr:DE","us-gaap:LeaseContractualTermAxis":"MRMD:CultivationAndProcessingFacilityMember"},"factValues":[{"value":"The\n sublease expires in March 2030, with an option to extend the term for three additional five-year periods."}]},{"name":"rpt:f-787","factDimensions":{"xbrl:concept":"us-gaap:AreaOfLand","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"utr:sqft","srt:StatementGeographicalAxis":"stpr:DE","us-gaap:LeaseContractualTermAxis":"MRMD:CannabisProductionFacilityMember"},"factValues":[{"value":"12000"}]},{"name":"rpt:f-788","factDimensions":{"xbrl:concept":"us-gaap:LessorOperatingLeaseOptionToExtend","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","srt:StatementGeographicalAxis":"stpr:DE","us-gaap:LeaseContractualTermAxis":"MRMD:CannabisProductionFacilityMember"},"factValues":[{"value":"The\n sublease expires in January 2026 and contains an option to negotiate an extension at the end of the lease term."}]},{"name":"rpt:f-789","factDimensions":{"xbrl:concept":"us-gaap:OperatingLeaseLeaseIncome","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"18700000","decimals":-5}]},{"name":"rpt:f-790","factDimensions":{"xbrl:concept":"us-gaap:OperatingLeaseLeaseIncome","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"13900000","decimals":-5}]},{"name":"rpt:f-791","factDimensions":{"xbrl:concept":"us-gaap:ContractWithCustomerLiabilityRevenueRecognized","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"20400000","decimals":-5}]},{"name":"rpt:f-792","factDimensions":{"xbrl:concept":"us-gaap:ContractWithCustomerLiabilityRevenueRecognized","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"15800000","decimals":-5}]},{"name":"rpt:f-793","factDimensions":{"xbrl:concept":"us-gaap:LoansAndLeasesReceivableDeferredIncome","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1700000","decimals":-5}]},{"name":"rpt:f-794","factDimensions":{"xbrl:concept":"us-gaap:LoansAndLeasesReceivableDeferredIncome","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1900000","decimals":-5}]},{"name":"rpt:f-795","factDimensions":{"xbrl:concept":"us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"Future\nminimum rental receipts for non-cancellable leases and subleases as of December 31, 2021 were:
\n\nSCHEDULE OF FUTURE MINIMUM RENTAL RECEIPTS FOR NON-CANCELABLE LEASES AND SUBLEASES
\n\n| 2022 | \u00a0 | \n$ | 4,854,549 | \u00a0 |
| 2023 | \u00a0 | \n\u00a0 | 4,563,372 | \u00a0 |
| 2024 | \u00a0 | \n\u00a0 | 4,625,608 | \u00a0 |
| 2025 | \u00a0 | \n\u00a0 | 4,695,107 | \u00a0 |
| 2026 | \u00a0 | \n\u00a0 | 3,915,790 | \u00a0 |
| Thereafter | \u00a0 | \n\u00a0 | 35,829,822 | \u00a0 |
| Total | \u00a0 | \n$ | 58,484,248 | \u00a0 |
NOTE\n6 \u2013 NOTES RECEIVABLE
\n\n\u00a0
\n\nAt\nDecember 31, 2021 and 2020, notes receivable, including accrued interest, consisted of the following:
\n\n\u00a0SCHEDULE\nOF RECEIVABLES AND ACCRUED INTEREST
\n\n| \u00a0 | \u00a0 | \n2021 | \u00a0 | \u00a0 | \n2020 | \u00a0 | ||
| First State Compassion Center (initial note) | \u00a0 | \n$ | 402,992 | \u00a0 | \u00a0 | \n$ | 468,985 | \u00a0 |
| First State Compassion Center (secondary note) | \u00a0 | \n\u00a0 | 7,843,910 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| Healer LLC | \u00a0 | \n\u00a0 | 866,368 | \u00a0 | \u00a0 | \n\u00a0 | 899,226 | \u00a0 |
| High Fidelity Inc. | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 | \n\u00a0 | 254,919 | \u00a0 | |
| Total notes receivable | \u00a0 | \n\u00a0 | 9,113,270 | \u00a0 | \u00a0 | \n\u00a0 | 1,623,130 | \u00a0 |
| Notes receivable, current portion | \u00a0 | \n\u00a0 | 126,713 | \u00a0 | \u00a0 | \n\u00a0 | 658,122 | \u00a0 |
| Notes receivable, less current portion | \u00a0 | \n$ | 8,986,557 | \u00a0 | \u00a0 | \n$ | 965,008 | \u00a0 |
\u00a0
\n\nFirst\nState Compassion Center
\n\n\u00a0
\n\nThe\nCompany\u2019s cannabis-licensed client in Delaware, First State Compassion Center (\u201cFSCC\u201d), issued a 10-year\npromissory note to the Company in May 2016 in the amount of $700,000\nbearing interest at a rate of 12.5%\nper annum, as amended. The monthly payments of approximately $10,000\nwill continue through April 2026, at which time\nthe note will be paid in full. At December 31, 2021 and 2020, the current portion of this note approximated $75,000\nand $66,000,\nrespectively, and was included in Notes Receivable, Current Portion on the respective balance sheets.
\n\n\n\n
\n\n\n\n
\u00a0
\n\nIn\nDecember 2021, financed trade accounts receivable balances from FSCC of approximately $7.8 million in the aggregate were converted\ninto notes receivable whereby FSCC issued promissory notes to the Company in the aggregate amount of approximately $7.8 million\nbearing interest at a rate of 6.0% per annum. The promissory notes call for the payment of principal and interest throughout the\nterm of the note which matures in December 2025. At December 31, 2021, the entire balance of the note was long-term.
\n\n\n
\u00a0
\n\nHealer\nLLC
\n\n\u00a0
\n\nIn\n2018 and 2019, the Company loaned an aggregate of $800,000\nto Healer LLC, an entity that provides cannabis\neducation, dosage programs, and products developed by Dr. Dustin Sulak, an integrative medicine physician and nationally renowned cannabis\npractitioner (\u201cHealer\u201d). Healer issued promissory notes to the Company for the aggregate amount loaned that bear interest\nat a rate of 6.0%\nper annum, with principal and interest payable\non maturity dates three years from the respective loan dates.
\n\n\u00a0
\n\nIn\nMarch 2021, the Company was issued a revised promissory note from Healer in the principal amount of approximately $894,000\nrepresenting the previous loans extended to Healer\nby the Company plus accrued interest through the revised promissory note issuance date. The revised promissory note bears interest at\na rate of 6.0%\nper annum and requires\nquarterly payments of interest through the maturity date in April 2026.
\n\n\u00a0
\n\nAdditionally,\nthe Company has the right to offset any licensing fees owed to Healer by the Company in the event Healer fails to make any payment when\ndue. In March 2021, the Company offset approximately $28,000 of licensing fees payable to Healer against the principal balance of the\nrevised promissory note, reducing the principal amount to approximately $866,000.
\n\n\u00a0
\n\nAt\nDecember 31, 2021 and 2020, the total amount of principal and accrued interest due under the aforementioned promissory notes approximated\n$866,000\nand $899,000,\nrespectively, of which approximately $52,000\nand $337,000,\nrespectively, was current.
\n\n\u00a0
\n\nHigh\nFidelity
\n\n\u00a0
\n\nIn\nAugust 2021, the Company was fully repaid on a loan to High Fidelity Inc., an entity with cannabis operations in the state of Vermont.\nThe loan had a principal balance of $250,000 and bore interest at a rate of 10.0% per annum,
\n\n\u00a0
\n\n\n\n\n\u00a0
\n\n"}]},{"name":"rpt:f-804","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"At\nDecember 31, 2021 and 2020, notes receivable, including accrued interest, consisted of the following:
\n\n\u00a0SCHEDULE\nOF RECEIVABLES AND ACCRUED INTEREST
\n\n| \u00a0 | \u00a0 | \n2021 | \u00a0 | \u00a0 | \n2020 | \u00a0 | ||
| First State Compassion Center (initial note) | \u00a0 | \n$ | 402,992 | \u00a0 | \u00a0 | \n$ | 468,985 | \u00a0 |
| First State Compassion Center (secondary note) | \u00a0 | \n\u00a0 | 7,843,910 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| Healer LLC | \u00a0 | \n\u00a0 | 866,368 | \u00a0 | \u00a0 | \n\u00a0 | 899,226 | \u00a0 |
| High Fidelity Inc. | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 | \n\u00a0 | 254,919 | \u00a0 | |
| Total notes receivable | \u00a0 | \n\u00a0 | 9,113,270 | \u00a0 | \u00a0 | \n\u00a0 | 1,623,130 | \u00a0 |
| Notes receivable, current portion | \u00a0 | \n\u00a0 | 126,713 | \u00a0 | \u00a0 | \n\u00a0 | 658,122 | \u00a0 |
| Notes receivable, less current portion | \u00a0 | \n$ | 8,986,557 | \u00a0 | \u00a0 | \n$ | 965,008 | \u00a0 |
NOTE\n7 \u2013 INVENTORY
\n\n\u00a0
\n\nAt\nDecember 31, 2021 and 2020, inventory was comprised of the following:
\n\n\u00a0SCHEDULE\nOF INVENTORY
\n\n| \u00a0 | \u00a0 | \n2021 | \u00a0 | \u00a0 | \n2020 | \u00a0 | ||
| Plants | \u00a0 | \n$ | 1,014,576 | \u00a0 | \u00a0 | \n$ | 3,352,425 | \u00a0 |
| Ingredients and other raw materials | \u00a0 | \n\u00a0 | 261,609 | \u00a0 | \u00a0 | \n\u00a0 | 176,338 | \u00a0 |
| Work-in-process | \u00a0 | \n\u00a0 | 4,661,542 | \u00a0 | \u00a0 | \n\u00a0 | 468,377 | \u00a0 |
| Finished goods | \u00a0 | \n\u00a0 | 3,830,129 | \u00a0 | \u00a0 | \n\u00a0 | 2,833,431 | \u00a0 |
| Total inventory | \u00a0 | \n$ | 9,767,856 | \u00a0 | \u00a0 | \n$ | 6,830,571 | \u00a0 |
\u00a0
\n\n"}]},{"name":"rpt:f-841","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfInventoryCurrentTableTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"At\nDecember 31, 2021 and 2020, inventory was comprised of the following:
\n\n\u00a0SCHEDULE\nOF INVENTORY
\n\n| \u00a0 | \u00a0 | \n2021 | \u00a0 | \u00a0 | \n2020 | \u00a0 | ||
| Plants | \u00a0 | \n$ | 1,014,576 | \u00a0 | \u00a0 | \n$ | 3,352,425 | \u00a0 |
| Ingredients and other raw materials | \u00a0 | \n\u00a0 | 261,609 | \u00a0 | \u00a0 | \n\u00a0 | 176,338 | \u00a0 |
| Work-in-process | \u00a0 | \n\u00a0 | 4,661,542 | \u00a0 | \u00a0 | \n\u00a0 | 468,377 | \u00a0 |
| Finished goods | \u00a0 | \n\u00a0 | 3,830,129 | \u00a0 | \u00a0 | \n\u00a0 | 2,833,431 | \u00a0 |
| Total inventory | \u00a0 | \n$ | 9,767,856 | \u00a0 | \u00a0 | \n$ | 6,830,571 | \u00a0 |
NOTE\n8 \u2013 PROPERTY AND EQUIPMENT
\n\n\u00a0
\n\nAt\nand December 31, 2021 and 2020, property and equipment consisted of the following:
\n\n\u00a0SCHEDULE\nOF PROPERTY AND EQUIPMENT
\n\n| \u00a0 | \u00a0 | \n2021 | \u00a0 | \u00a0 | \n2020 | \u00a0 | ||
| Land | \u00a0 | \n$ | 4,449,810 | \u00a0 | \u00a0 | \n$ | 3,988,810 | \u00a0 |
| Buildings and building improvements | \u00a0 | \n\u00a0 | 35,231,277 | \u00a0 | \u00a0 | \n\u00a0 | 29,309,856 | \u00a0 |
| Tenant improvements | \u00a0 | \n\u00a0 | 9,744,860 | \u00a0 | \u00a0 | \n\u00a0 | 8,844,974 | \u00a0 |
| Furniture and fixtures | \u00a0 | \n\u00a0 | 1,887,796 | \u00a0 | \u00a0 | \n\u00a0 | 619,880 | \u00a0 |
| Machinery and equipment | \u00a0 | \n\u00a0 | 7,220,962 | \u00a0 | \u00a0 | \n\u00a0 | 4,620,924 | \u00a0 |
| Construction in progress | \u00a0 | \n\u00a0 | 10,569,182 | \u00a0 | \u00a0 | \n\u00a0 | 3,140,807 | \u00a0 |
| \u00a0 | \u00a0 | \n\u00a0 | 69,103,887 | \u00a0 | \u00a0 | \n\u00a0 | 50,525,251 | \u00a0 |
| Less: accumulated depreciation | \u00a0 | \n\u00a0 | (6,953,741 | ) | \u00a0 | \n\u00a0 | (4,888,722 | ) |
| Property and equipment, net | \u00a0 | \n$ | 62,150,146 | \u00a0 | \u00a0 | \n$ | 45,636,529 | \u00a0 |
\u00a0
\n\nDuring\nthe year ended December 31, 2021 and 2020, additions to property and equipment approximated $18,579,000 and $4,688,000, respectively.
\n\n\u00a0
\n\nThe\n2021 additions were primarily comprised of (i) the development of facilities in Metropolis, IL and Milford, DE, and (ii)\npurchases of building improvements, machinery, and equipment at the facilities in Hagerstown, MD and New Bedford, MA. The 2020 additions\nconsisted primarily of (i) the commencement of construction in Mt. Vernon, IL, and (ii) machinery and equipment purchases for facilities\nin Massachusetts, Maryland, Illinois, and Delaware.
\n\n\u00a0
\n\nThe\nconstruction in progress balances of approximately $10,569,000 million and $3,141,000 at December 31, 2021 and 2020, respectively, consisted\nof the commencement of construction of properties in Milford, DE and Annapolis, MD.
\n\n\u00a0
\n\nDepreciation\nexpense for the year ended December 31, 2021 and 2020 approximated $2,098,000 and $1,792,000, respectively.
\n\n\u00a0
\n\n\n\n\n\u00a0
\n\n"}]},{"name":"rpt:f-848","factDimensions":{"xbrl:concept":"us-gaap:PropertyPlantAndEquipmentTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"At\nand December 31, 2021 and 2020, property and equipment consisted of the following:
\n\n\u00a0SCHEDULE\nOF PROPERTY AND EQUIPMENT
\n\n| \u00a0 | \u00a0 | \n2021 | \u00a0 | \u00a0 | \n2020 | \u00a0 | ||
| Land | \u00a0 | \n$ | 4,449,810 | \u00a0 | \u00a0 | \n$ | 3,988,810 | \u00a0 |
| Buildings and building improvements | \u00a0 | \n\u00a0 | 35,231,277 | \u00a0 | \u00a0 | \n\u00a0 | 29,309,856 | \u00a0 |
| Tenant improvements | \u00a0 | \n\u00a0 | 9,744,860 | \u00a0 | \u00a0 | \n\u00a0 | 8,844,974 | \u00a0 |
| Furniture and fixtures | \u00a0 | \n\u00a0 | 1,887,796 | \u00a0 | \u00a0 | \n\u00a0 | 619,880 | \u00a0 |
| Machinery and equipment | \u00a0 | \n\u00a0 | 7,220,962 | \u00a0 | \u00a0 | \n\u00a0 | 4,620,924 | \u00a0 |
| Construction in progress | \u00a0 | \n\u00a0 | 10,569,182 | \u00a0 | \u00a0 | \n\u00a0 | 3,140,807 | \u00a0 |
| \u00a0 | \u00a0 | \n\u00a0 | 69,103,887 | \u00a0 | \u00a0 | \n\u00a0 | 50,525,251 | \u00a0 |
| Less: accumulated depreciation | \u00a0 | \n\u00a0 | (6,953,741 | ) | \u00a0 | \n\u00a0 | (4,888,722 | ) |
| Property and equipment, net | \u00a0 | \n$ | 62,150,146 | \u00a0 | \u00a0 | \n$ | 45,636,529 | \u00a0 |
NOTE\n9 \u2013 INTANGIBLES
\n\n\u00a0
\n\nAt\nDecember 31, 2021 and 2020, intangible assets were comprised of (i) the carrying value of cannabis license fees, and (ii) goodwill arising\nfrom the Company\u2019s acquisitions.
\n\n\u00a0
\n\nThe\nCompany\u2019s cannabis licenses are issued from the states of Illinois and Massachusetts and require the payment of annual fees. These\nfees, comprised of a fixed component and a variable component based on the level of operations, are capitalized and amortized over the\nrespective twelve-month periods. At December 31, 2021 and 2020, the carrying value of these cannabis licenses approximated $163,000 and\n$161,000, respectively.
\n\n\u00a0
\n\nThe\ngoodwill associated with acquisitions is reviewed on a quarterly basis for impairment. Based on this review and other factors, the goodwill\nof approximately $2,068,000 December 31, 2021 and 2020 was deemed to be unimpaired.
\n\n\u00a0
\n\n"}]},{"name":"rpt:f-874","factDimensions":{"xbrl:concept":"us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis":"MRMD:CannabisLicensesMember"},"factValues":[{"value":"163000","decimals":0}]},{"name":"rpt:f-875","factDimensions":{"xbrl:concept":"us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis":"MRMD:CannabisLicensesMember"},"factValues":[{"value":"161000","decimals":0}]},{"name":"rpt:f-876","factDimensions":{"xbrl:concept":"us-gaap:Goodwill","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"2068000","decimals":0}]},{"name":"rpt:f-877","factDimensions":{"xbrl:concept":"us-gaap:Goodwill","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"2068000","decimals":0}]},{"name":"rpt:f-878","factDimensions":{"xbrl:concept":"us-gaap:MortgageNotesPayableDisclosureTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"NOTE\n10 \u2013 MORTGAGES
\n\n\u00a0
\n\nAt\nDecember 31, 2021 and 2020, mortgage balances, including accrued interest, were comprised of the following:
\n\n\u00a0SCHEDULE\nOF MORTGAGE AND ACCRUED INTEREST
\n\n| \u00a0 | \u00a0 | \n2021 | \u00a0 | \u00a0 | \n2020 | \u00a0 | ||
Bank of New England \n\u2013 New Bedford,\nMA and Middleboro, MA properties | \u00a0 | \n$ | 12,498,900 | \u00a0 | \u00a0 | \n$ | 12,834,090 | \u00a0 |
Bank of New England \n\u2013 Wilmington, DE property | \u00a0 | \n\u00a0 | 1,462,949 | \u00a0 | \u00a0 | \n\u00a0 | 1,575,658 | \u00a0 |
DuQuoin State Bank \n\u2013 Anna, IL and Harrisburg,\nIL properties | \u00a0 | \n\u00a0 | 778,084 | \u00a0 | \u00a0 | \n\u00a0 | 814,749 | \u00a0 |
DuQuoin State Bank \n\u2013 Metropolis, IL property | \u00a0 | \n\u00a0 | 2,657,600 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
South Porte Bank \n\u2013 Mt.\nVernon, IL property | \u00a0 | \n\u00a0 | 816,264 | \u00a0 | \u00a0 | \n\u00a0 | 906,653 | \u00a0 |
| Total mortgages payable | \u00a0 | \n\u00a0 | 18,213,797 | \u00a0 | \u00a0 | \n\u00a0 | 16,131,150 | \u00a0 |
| Mortgages payable, current portion | \u00a0 | \n\u00a0 | (1,400,331 | ) | \u00a0 | \n\u00a0 | (1,387,014 | ) |
| Mortgages payable, less current portion | \u00a0 | \n$ | 16,813,466 | \u00a0 | \u00a0 | \n$ | 14,744,136 | \u00a0 |
\u00a0
\n\nIn\nNovember 2017, the Company entered into a 10-year\nmortgage agreement with Bank of New England in the amount of $4,895,000\n(the \u201cInitial Mortgage\u201d) for the\npurchase of a 138,000\nsquare foot industrial property in New Bedford,\nMA, within which the Company has built a 70,000\nsquare foot cannabis cultivation and processing\nfacility. Pursuant to the Initial Mortgage, the Company made monthly payments of (i) interest-only from the mortgage date through May\n2019 at a rate equal to the prime rate plus 2.0%,\nwith a floor of 6.25%\nper annum, and (ii) principal and interest payments from May 2019 to July 2020 at a rate equal to the prime rate on May 2, 2019 plus\n2.0%,\nwith a floor of 6.25%\nper annum.
\n\n\u00a0
\n\nIn\nJuly 2020, at which time the Initial Mortgage had a remaining principal balance of approximately $4.8 million, the parties consummated\nan amended and restated mortgage agreement, secured by the Company\u2019s properties in New Bedford and Middleboro in the amount of\n$13.0 million bearing interest at a rate of 6.5% per annum that matures in August 2025 (the \u201cRefinanced Mortgage\u201d). Proceeds\nfrom the Refinanced Mortgage were used to pay down the Initial Mortgage and approximately $7.2 million of promissory notes as further\nin Note 11 \u2013 Promissory Notes. At December 31, 2021 and 2020, the outstanding principal balance of the Refinanced Mortgage\napproximated $12,499,000 and $12,834,000, respectively, of which approximately $358,000 and $335,000, respectively, was current.
\n\n\u00a0
\n\nThe\nCompany maintains another mortgage with Bank of New England from the 2016 purchase of a 45,070\nsquare foot building in Wilmington, DE which\nwas developed into a cannabis seed-to-sale facility and is currently leased to the Company\u2019s cannabis-licensed client in that state.\nThe\nmortgage matures in 2031 with monthly principal\nand interest payments at a rate of 5.25%\nper annum through September 2021, and thereafter the rate adjusting every five years to the then prime rate plus 1.5%\nwith a floor of 5.25%\nper annum. For the remainder of 2021, the interest rate on this mortgage remained at 5.25%. At December 31, 2021 and 2020, the\noutstanding principal balance on this mortgage approximated $1,463,000\nand $1,576,000,\nrespectively, of which approximately $130,000\nand $114,000,\nrespectively, was current.
\n\n\u00a0
\n\n\n\n\n\u00a0
\n\nIn\nMay 2016, the Company entered into a mortgage agreement with DuQuoin State Bank (\u201cDSB\u201d) for the purchase of properties in\nAnna, IL and Harrisburg, IL which the Company developed into two 3,400 square foot free-standing retail dispensaries. On May 5th\nof each year, this mortgage is due to be repaid unless it is renewed for another year at a rate determined by DSB\u2019s executive\ncommittee. The mortgage was renewed in May 2021 at a rate of 6.75% per annum. At December 31, 2021 and 2020, the outstanding principal\nbalance on this mortgage approximated $778,000 and $815,000 respectively, of which approximately $33,000 and $31,000, respectively, was\ncurrent.
\n\n\u00a0
\n\nIn\nJuly 2021, the Company purchased the land and building in which it operates its cannabis dispensary in Metropolis, IL. The purchase price\nconsisted of shares of the Company\u2019s common stock, which\nwere valued at $705,000\non the date of the transaction, and payoff of\nthe seller\u2019s remaining mortgage of approximately $1.6\nmillion. In connection with this purchase, the\nCompany entered into another mortgage agreement with DSB in the amount of $2.7\nmillion that matures\nin July 2041 and initially bears interest at a\nrate of 6.25%\nper annum which is adjusted each year based on a certain interest rate index plus a margin. As part of this transaction, the seller was\nprovided with a 30.0%\nownership interest in Mari Holdings Metropolis LLC\n(\u201cMetro\u201d), the Company\u2019s subsidiary that owns the property and related mortgage obligation, reducing the Company\u2019s\nownership interest in Metro to 70.0%.\nAt December 31, 2021, the outstanding principal\nbalance on this mortgage approximated $2,658,000,\nof which approximately $73,000\nwas current.
\n\n\u00a0
\n\nIn\nFebruary 2020, the Company entered into a mortgage agreement with South Porte Bank for the purchase and development of a property in\nMt. Vernon, IL. Pursuant to the amended mortgage agreement, the mortgage shall be repaid in monthly installments of principal and interest\nof approximately $6,000 which began in August 2021 and continues through its maturity in June 2022, at which time all remaining principal,\ninterest and fees shall be due.
\n\n\u00a0
\n\n"}]},{"name":"rpt:f-879","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfParticipatingMortgageLoansTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"At\nDecember 31, 2021 and 2020, mortgage balances, including accrued interest, were comprised of the following:
\n\n\u00a0SCHEDULE\nOF MORTGAGE AND ACCRUED INTEREST
\n\n| \u00a0 | \u00a0 | \n2021 | \u00a0 | \u00a0 | \n2020 | \u00a0 | ||
Bank of New England \n\u2013 New Bedford,\nMA and Middleboro, MA properties | \u00a0 | \n$ | 12,498,900 | \u00a0 | \u00a0 | \n$ | 12,834,090 | \u00a0 |
Bank of New England \n\u2013 Wilmington, DE property | \u00a0 | \n\u00a0 | 1,462,949 | \u00a0 | \u00a0 | \n\u00a0 | 1,575,658 | \u00a0 |
DuQuoin State Bank \n\u2013 Anna, IL and Harrisburg,\nIL properties | \u00a0 | \n\u00a0 | 778,084 | \u00a0 | \u00a0 | \n\u00a0 | 814,749 | \u00a0 |
DuQuoin State Bank \n\u2013 Metropolis, IL property | \u00a0 | \n\u00a0 | 2,657,600 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
South Porte Bank \n\u2013 Mt.\nVernon, IL property | \u00a0 | \n\u00a0 | 816,264 | \u00a0 | \u00a0 | \n\u00a0 | 906,653 | \u00a0 |
| Total mortgages payable | \u00a0 | \n\u00a0 | 18,213,797 | \u00a0 | \u00a0 | \n\u00a0 | 16,131,150 | \u00a0 |
| Mortgages payable, current portion | \u00a0 | \n\u00a0 | (1,400,331 | ) | \u00a0 | \n\u00a0 | (1,387,014 | ) |
| Mortgages payable, less current portion | \u00a0 | \n$ | 16,813,466 | \u00a0 | \u00a0 | \n$ | 14,744,136 | \u00a0 |
NOTE\n11 \u2013 PROMISSORY NOTES
\n\n\u00a0
\n\nPromissory\nNotes Issued by the Company and its MariMed Hemp Inc. Subsidiary
\n\n\u00a0
\n\nIn\nFebruary 2020, the Company and MariMed Hemp Inc., its wholly-owned subsidiary (\u201cMMH\u201d), amended a secured $10.0\nmillion promissory note (the $10.0M Note\u201d)\nissued to an unaffiliated party (the \u201cNoteholder\u201d) in 2019. The $10.0M Note, which provided for the repayment of principal\nplus a payment of $1.5\nmillion (the \u201c$1.5M Payment\u201d), was\namended whereby the Company and MMH issued a restated promissory note maturing\nin June 2020 in the principal amount of $11.5\nmillion (the \u201c$11.5M Note\u201d), comprised\nof the principal amount of the $10.0M Note and the $1.5M Payment. The $11.5M Note bore interest at a rate of 15.0%\nper annum, requiring periodic interest payments\nand minimum amortization payments of $3,000,000\nin the aggregate, which the Company made in the\nfirst half of 2020.
\n\n\u00a0
\n\nThe\nCompany entered into a second amendment agreement with the Noteholder in June 2020, whereby (i) $352,000\nof outstanding principal of the $11.5M Note was\nconverted into shares of the Company\u2019s common stock (which\ndid not result in a material extinguishment gain or loss as the conversion price approximated the price of the Company\u2019s common\nstock on the agreement date), and (ii) the Company and MMH issued a second amended and restated promissory note in the principal amount\nof approximately $8.8\nmillion, comprised of the outstanding principal\nand unpaid interest balances of the $11.5M Note, plus an extension fee of approximately $330,000,\nbearing interest at a rate of 15.0%\nper annum and maturing\nin June 2022 (the \u201c$8.8M Note\u201d). In\naddition, the Company issued -year\nwarrants to the Noteholder to purchase up to 750,000\nshares of common stock at an exercise price of\n$0.50\nper share. The fair value of these warrants on\nthe issuance date of approximately $66,000\nwas recorded as a discount to the $8.8M Note,\nand amortized to interest expense over the life of the $8.8M Note.
\n\n\u00a0
\n\nThe\nCompany made a required principal payment of $4,000,000 in July 2020 with a portion of proceeds of the Refinanced Mortgage previously\ndiscussed in Note 10 \u2013 Mortgages, and additional principal payments of $600,000 in the aggregate in calendar 2020. Accordingly,\nthe carrying value of the $8.8M Note was approximately $4.2 million at December 31, 2020.
\n\n\u00a0
\n\nThe\nNoteholder had the option to convert the $8.8M Note, in whole or in part, into shares of the Company\u2019s common stock at a conversion\nprice of $0.30 per share, subject to certain conversion limitations. This non-detachable conversion feature of the $8.8M Note had no\nintrinsic value on the agreement date, and therefore no beneficial conversion feature arose. In March 2021, the Noteholder converted\n$1,000,000 of principal and approximately $10,000 of accrued interest into shares of the Company\u2019s common stock, reducing\nthe carrying value of the $8.8M Note to approximately $3.2 million.
\n\n\u00a0
\n\nThe\nCompany entered into a third amendment agreement with the Noteholder in April 2021 whereby the Company and MMH issued a third amended\nand restated promissory note in the principal amount of approximately $3.2 million (the \u201c$3.2M Note\u201d) which bears interest\nat a rate of 0.12% per annum and matures in April 2023. The Noteholder has the option to convert, subject to certain conversion limitations,\nall or a portion of the $3.2M Note into shares of the Company\u2019s common stock at a conversion price of $0.35 per share, such conversion\nprice subject to adjustment in the event of certain transactions by the Company. The third amended agreement resulted in a decrease in\nthe fair value of the embedded conversion feature of the $3.2M Note and therefore no accounting was required for such conversion feature.
\n\n\u00a0
\n\nOn\nor after the one-year anniversary of the $3.2M Note, upon twenty days prior written notice to the Noteholder, the Company can prepay\nall of the outstanding principal and unpaid interest of the $3.2M Note, along with a prepayment premium equal to 10.0%\nof the principal amount being prepaid. The Noteholder\nshall remain entitled to convert the $3.2M Note during such notice period. On or after the one-year anniversary of the $3.2M Note, the\nNoteholder has the right to require the redemption in cash of up to $125,000\nof principal and unpaid interest thereon per\ncalendar month.
\n\n\u00a0
\n\nIn\n2021, the Noteholder converted approximately $2.8 million of principal on the $3.2M Note into shares of the Company\u2019s\ncommon stock, reducing the carrying value of the $3.2M Note to approximately $400,000 at December 31, 2021. All note conversions were\neffected in accordance with the terms of their respective note agreements, and therefore the Company was not required to record a gain\nor loss on such conversions.
\n\n\u00a0
\n\n\n\n\n\u00a0
\n\nPromissory\nNotes Issued Pursuant to an Exchange Agreement
\n\n\u00a0
\n\nIn\nFebruary 2020, pursuant to an exchange agreement as further described in Note 13 \u2013 Mezzanine Equity, the Company issued\ntwo promissory notes in the aggregate principal amount of approximately $4.4 million, bearing interest at 16.5% per annum and maturing\nin August 2021 (the \u201c$4.4M Notes\u201d), in exchange for a loan in the same amount. At December 31, 2020, the principal and accrued\ninterest balance of the $4.4M Notes approximated $4.6 million. In March 2021, utilizing a portion of the proceeds from the Hadron transaction\ndiscussed in Note 13 \u2013 Mezzanine Equity, the $4.4M Notes were fully paid down, along with accrued interest through the repayment\ndate.
\n\n\u00a0
\n\nPromissory\nNotes Issued for Operating Liquidity
\n\n\u00a0
\n\nIn\nApril 2020, the Company entered into a note extension agreement (the \u201cInitial Extension Agreement\u201d) with the unaffiliated\nholder (the \u201cHolding Party\u201d) of a secured $6.0 million promissory note (the \u201c$6.0M Note\u201d) issued by the Company\nin 2019. The $6.0M Note bore interest at a rate of 13.0% per annum and required the payment of a service fee of $900,000 (the \u201cService\nFee\u201d).
\n\n\u00a0
\n\nPursuant\nto the Initial Extension Agreement, (i) the $6.0M Note\u2019s due date was extended to September 2020, and the $6.0M Note was modified\nto include unpaid accrued interest of $845,000 through the modification date and interest at a rate of 10.0% per annum (the \u201c$6.8M\nNote\u201d), and (iii) a new convertible note in the amount of $900,000 (the \u201c$900k Note\u201d) was issued evidencing the Service\nFee, bearing interest at a rate of 12.0% per annum. The Company satisfied the $900k Note and accrued interest of $20,100 in full as of\nthe June 2020 maturity date by the payment in July 2020 of $460,050 in cash, representing one-half of the principal and accrued interest,\nand the issuance in June 2020 of shares of the Company\u2019s common stock, in payment of the other half of the principal\nand accrued interest.
\n\n\u00a0
\n\nPrior\nto the issuance of the $6.0M Note, the Company raised $3.0\nmillion from the issuance of a secured promissory note to the Holding Party in 2018, bearing interest at a rate of 10.0%\nper annum (the \u201c$3.0M Note\u201d). The\nmaturity date of the $3.0M Note, initially in March 2020, was extended for an additional six months in accordance with its terms, with\nthe interest rate increasing to 12.0%\nper\nannum during the extension period. Pursuant to the Initial Extension Agreement, the maturity date of the $3.0M Note was extended to December\n2020.
\n\n\u00a0
\n\n\n\n\n\u00a0
\n\nThe\nCompany and the Holding Party entered into a second note extension agreement in October 2020 (the \u201cSecond Extension Agreement\u201d)\nwhereby the Company (i) paid $1 million of principal and all outstanding accrued interest of approximately $333,000 on the $6.8M Note;\n(ii) issued an amended and restated senior secured promissory note in the principal amount of $5,845,000 (the \u201c$5.8M Note\u201d)\nto replace the $6.8M Note; and (iii) amended and restated the $3M Note (the \u201cNew $3.0M Note\u201d, and together with the $5.8M\nNote, the \u201cAmended Notes\u201d). The Amended Notes bore interest at a rate of 12.0% per annum with initial maturity dates in September\n2022.
\n\n\u00a0
\n\nIn\nconsideration of the Second Extension Agreement, the Company (i) issued -year warrants to the Holding Party\u2019s designees to\npurchase up to 5,000,000 shares of the Company\u2019s common stock at an exercise price of $0.25 per share; (ii) paid the Holding Party\na fee of $100,000; and (iii) extended the security interest in certain Company properties and the pledge of certain equity interests\nto secure the Amended Notes. The Company recorded a discount on the Amended Notes of approximately $573,000 based on the fair value of\nsuch warrants on the issuance date, of which approximately $75,000 was amortized as of the end of 2020, and the remainder to be amortized\nover the life of the Amended Notes. Accordingly, the carrying value of the Amended Notes approximated $8.3 million at December 31, 2020,\nof which $1.9 million was current.
\n\n\u00a0
\n\nThe\nCompany made a required principal payment of $400,000 on the $5.8M Note in February 2021. In March 2021, utilizing a portion of the proceeds\nfrom the Hadron transaction discussed in Note 13 \u2013 Mezzanine Equity, the Amended Notes were fully paid down, along with\naccrued interest through the repayment date. In addition, the remaining discount of approximately $450,000 on this note was fully amortized\non the payment date.
\n\n\u00a0
\n\nPromissory\nNotes Issued to Purchase Commercial Vehicles
\n\n\u00a0
\n\nIn\nAugust 2020, the Company entered into a note agreement with First Citizens\u2019 Federal Credit Union for the purchase of a commercial\nvehicle. The note bears interest at a rate of 5.74%\nper annum and matures\nin July 2026. At December 31, 2021 and\n2020, the balance of this note approximated $26,000\nand $30,000,\nrespectively, of which approximately $5,000\nwas current in both periods.
\n\n\u00a0
\n\nIn\nJune 2021, the Company entered into a note agreement with Ally Financial for the purchase of a second commercial vehicle. The note bears\ninterest at the rate of 10.0%\nper annum and matures in May 2027. At December\n31, 2021, the balance of this note approximated $33,000,\nof which approximately $5,000\nwas current.
\n\n\u00a0
\n\nPromissory\nNote Issued by MMH
\n\n\u00a0
\n\nIn\nSeptember 2020, the Company paid down $500,000 of principal on a $1,000,000 promissory note (the \u201c$1.0M Note\u201d) issued by\nMMH in 2019 to an unaffiliated party. At December 31, 2020, $500,000 of principal on the $1.0M Note remained outstanding.
\n\n\u00a0
\n\nIn\nMarch 2021, the Company paid interest on the $1.0M Note of $200,000, and utilizing a portion of the proceeds from the Hadron transaction\ndiscussed in Note 12 \u2013 Mezzanine Equity, paid off remaining principal of $500,000.
\n\n\u00a0
\n\nAt\nDecember 31, 2021, the Company was carrying an accrued interest balance of approximately $125,000 to cover interest due on the $1.0M\nNote as of such date.
\n\n\u00a0
\n\nOther\nPromissory Note Issuances
\n\n\u00a0
\n\nIn\naddition to the above transactions, at the start of 2020, the Company was carrying $3,190,000 of principal on promissory notes bearing\ninterest at rates ranging from 6.5% to 18.0% per annum (the \u201cExisting Notes\u201d). During 2020, the Company (i) raised approximately\n$2,147,000 from the issuance of new promissory notes bearing interest at interest rates of 12.0% and 15.0% per annum (the \u201cNew\n2020 Notes\u201d), (ii) repaid $2,100,000 of the Existing Notes, (iii) retired $500,000 of the Existing Notes through the issuance of\ncommon stock at a conversion price equal to the market price of the Company\u2019s common stock on the conversion date of $0.32 per\nshare, and (iv) repaid $700,000 of the New 2020 Notes. Accordingly, the remaining balance on the Existing Notes and New 2020 Notes approximated\n$2,037,000 in the aggregate at December 31, 2020. This balance along with accrued interest through the repayment date of approximately\n$200,000 were fully paid down in March 2021 utilizing a portion of the proceeds from the Hadron transaction discussed in Note 13 \u2013\nMezzanine Equity.
\n\n\u00a0
\n\n\n\n\n\u00a0
\n\nDebt\nMaturities
\n\n\u00a0
\n\nAs\nof December 31, 2021, the aggregate scheduled maturities of the Company\u2019s total debt outstanding were:
\n\n\u00a0SCHEDULE\nOF MATURITY TABLES
\n\n| \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 |
| 2022 | \u00a0 | \n$ | 1,410,222 | \u00a0 |
| 2023 | \u00a0 | \n\u00a0 | 1,032,523 | \u00a0 |
| 2024 | \u00a0 | \n\u00a0 | 670,613 | \u00a0 |
| 2025 | \u00a0 | \n\u00a0 | 717,209 | \u00a0 |
| 2026 | \u00a0 | \n\u00a0 | 760,988 | \u00a0 |
| Thereafter | \u00a0 | \n\u00a0 | 14,080,474 | \u00a0 |
| Total | \u00a0 | \n$ | 18,672,029 | \u00a0 |
\u00a0
\n\n"}]},{"name":"rpt:f-940","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentFaceAmount","xbrl:period":"2020-03-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","dei:LegalEntityAxis":"MRMD:MariMedHempIncMember","us-gaap:DebtInstrumentAxis":"MRMD:TenMillionSecuredPromissoryNotesMember"},"factValues":[{"value":"10000000.0","decimals":-5}]},{"name":"rpt:f-941","factDimensions":{"xbrl:concept":"us-gaap:RepaymentsOfNotesPayable","xbrl:period":"2020-02-01T00:00:00/2020-03-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:TenMillionSecuredPromissoryNotesMember","dei:LegalEntityAxis":"MRMD:MariMedHempIncMember"},"factValues":[{"value":"1500000","decimals":-5}]},{"name":"rpt:f-942","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentMaturityDateDescription","xbrl:period":"2020-02-27T00:00:00/2020-03-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:DebtInstrumentAxis":"MRMD:ElevenPointFiveMillionNoteMember","dei:LegalEntityAxis":"MRMD:MariMedHempIncMember"},"factValues":[{"value":"maturing\nin June 2020"}]},{"name":"rpt:f-943","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentFaceAmount","xbrl:period":"2020-03-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:ElevenPointFiveMillionNoteMember","dei:LegalEntityAxis":"MRMD:MariMedHempIncMember"},"factValues":[{"value":"11500000","decimals":-5}]},{"name":"rpt:f-944","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentInterestRateDuringPeriod","xbrl:period":"2020-02-01T00:00:00/2020-03-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:DebtInstrumentAxis":"MRMD:ElevenPointFiveMillionNoteMember","dei:LegalEntityAxis":"MRMD:MariMedHempIncMember"},"factValues":[{"value":"0.15"}]},{"name":"rpt:f-945","factDimensions":{"xbrl:concept":"us-gaap:AmortizationOfDebtDiscountPremium","xbrl:period":"2020-02-01T00:00:00/2020-03-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:AwardTypeAxis":"MRMD:ElevenPointFiveMillionNoteMember","dei:LegalEntityAxis":"MRMD:MariMedHempIncMember","srt:RangeAxis":"srt:MinimumMember"},"factValues":[{"value":"3000000","decimals":0}]},{"name":"rpt:f-946","factDimensions":{"xbrl:concept":"us-gaap:DebtConversionConvertedInstrumentAmount1","xbrl:period":"2020-06-01T00:00:00/2020-07-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:ElevenPointFiveMillionNoteMember","us-gaap:TypeOfArrangementAxis":"MRMD:SecondAmendmentAgreementMember"},"factValues":[{"value":"352000","decimals":0}]},{"name":"rpt:f-947","factDimensions":{"xbrl:concept":"us-gaap:DebtConversionConvertedInstrumentSharesIssued1","xbrl:period":"2020-06-01T00:00:00/2020-07-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:DebtInstrumentAxis":"MRMD:ElevenPointFiveMillionNoteMember","us-gaap:TypeOfArrangementAxis":"MRMD:SecondAmendmentAgreementMember"},"factValues":[{"value":"1900000"}]},{"name":"rpt:f-948","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentFaceAmount","xbrl:period":"2020-07-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:EightPointEightMillionNoteMember","us-gaap:TypeOfArrangementAxis":"MRMD:SecondAmendmentAgreementMember"},"factValues":[{"value":"8800000","decimals":-5}]},{"name":"rpt:f-949","factDimensions":{"xbrl:concept":"MRMD:ExtensionFees","xbrl:period":"2020-06-01T00:00:00/2020-07-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:EightPointEightMillionNoteMember","us-gaap:TypeOfArrangementAxis":"MRMD:SecondAmendmentAgreementMember"},"factValues":[{"value":"330000","decimals":0}]},{"name":"rpt:f-950","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentInterestRateDuringPeriod","xbrl:period":"2020-06-01T00:00:00/2020-07-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:DebtInstrumentAxis":"MRMD:EightPointEightMillionNoteMember","us-gaap:TypeOfArrangementAxis":"MRMD:SecondAmendmentAgreementMember"},"factValues":[{"value":"0.15"}]},{"name":"rpt:f-951","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentMaturityDateDescription","xbrl:period":"2020-06-01T00:00:00/2020-07-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:DebtInstrumentAxis":"MRMD:EightPointEightMillionNoteMember","us-gaap:TypeOfArrangementAxis":"MRMD:SecondAmendmentAgreementMember"},"factValues":[{"value":"maturing\nin June 2022"}]},{"name":"rpt:f-952","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights","xbrl:period":"2020-07-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:DebtInstrumentAxis":"MRMD:EightPointEightMillionNoteMember","us-gaap:TypeOfArrangementAxis":"MRMD:SecondAmendmentAgreementMember"},"factValues":[{"value":"750000"}]},{"name":"rpt:f-953","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1","xbrl:period":"2020-07-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:DebtInstrumentAxis":"MRMD:EightPointEightMillionNoteMember","us-gaap:TypeOfArrangementAxis":"MRMD:SecondAmendmentAgreementMember"},"factValues":[{"value":"0.50"}]},{"name":"rpt:f-954","factDimensions":{"xbrl:concept":"us-gaap:FairValueAdjustmentOfWarrants","xbrl:period":"2020-06-01T00:00:00/2020-07-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:EightPointEightMillionNoteMember","us-gaap:TypeOfArrangementAxis":"MRMD:SecondAmendmentAgreementMember"},"factValues":[{"value":"66000","decimals":0}]},{"name":"rpt:f-955","factDimensions":{"xbrl:concept":"us-gaap:RepaymentsOfLongTermDebt","xbrl:period":"2020-07-01T00:00:00/2020-08-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:EightPointEightMillionNoteMember"},"factValues":[{"value":"4000000","decimals":0}]},{"name":"rpt:f-956","factDimensions":{"xbrl:concept":"MRMD:DebtInstrumentAdditionalPrincipalPayment","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:EightPointEightMillionNoteMember"},"factValues":[{"value":"600000","decimals":0}]},{"name":"rpt:f-957","factDimensions":{"xbrl:concept":"us-gaap:LongTermDebt","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:EightPointEightMillionNoteMember"},"factValues":[{"value":"4200000","decimals":-5}]},{"name":"rpt:f-958","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentConvertibleConversionPrice1","xbrl:period":"2021-04-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:DebtInstrumentAxis":"MRMD:EightPointEightMillionNoteMember"},"factValues":[{"value":"0.30"}]},{"name":"rpt:f-959","factDimensions":{"xbrl:concept":"us-gaap:DebtConversionConvertedInstrumentAmount1","xbrl:period":"2021-03-01T00:00:00/2021-04-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:EightPointEightMillionNoteMember"},"factValues":[{"value":"1000000","decimals":0}]},{"name":"rpt:f-960","factDimensions":{"xbrl:concept":"us-gaap:InterestPayableCurrentAndNoncurrent","xbrl:period":"2021-04-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:EightPointEightMillionNoteMember"},"factValues":[{"value":"10000","decimals":0}]},{"name":"rpt:f-961","factDimensions":{"xbrl:concept":"us-gaap:DebtConversionConvertedInstrumentSharesIssued1","xbrl:period":"2021-03-01T00:00:00/2021-04-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:DebtInstrumentAxis":"MRMD:EightPointEightMillionNoteMember"},"factValues":[{"value":"3365972"}]},{"name":"rpt:f-962","factDimensions":{"xbrl:concept":"us-gaap:LongTermDebt","xbrl:period":"2021-04-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:EightPointEightMillionNoteMember"},"factValues":[{"value":"3200000","decimals":-5}]},{"name":"rpt:f-963","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentFaceAmount","xbrl:period":"2021-05-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:ThreePointTwoMillionNoteMember","us-gaap:TypeOfArrangementAxis":"MRMD:ThirdAmendmentAgreementMember"},"factValues":[{"value":"3200000","decimals":-5}]},{"name":"rpt:f-964","factDimensions":{"xbrl:concept":"us-gaap:DebtConversionConvertedInstrumentRate","xbrl:period":"2021-04-01T00:00:00/2021-05-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:DebtInstrumentAxis":"MRMD:ThreePointTwoMillionNoteMember","us-gaap:TypeOfArrangementAxis":"MRMD:ThirdAmendmentAgreementMember"},"factValues":[{"value":"0.0012"}]},{"name":"rpt:f-965","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentMaturityDateDescription","xbrl:period":"2021-04-01T00:00:00/2021-05-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:DebtInstrumentAxis":"MRMD:ThreePointTwoMillionNoteMember","us-gaap:TypeOfArrangementAxis":"MRMD:ThirdAmendmentAgreementMember"},"factValues":[{"value":"matures in April 2023"}]},{"name":"rpt:f-966","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentConvertibleConversionPrice1","xbrl:period":"2021-05-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:DebtInstrumentAxis":"MRMD:ThreePointTwoMillionNoteMember","us-gaap:TypeOfArrangementAxis":"MRMD:ThirdAmendmentAgreementMember"},"factValues":[{"value":"0.35"}]},{"name":"rpt:f-967","factDimensions":{"xbrl:concept":"MRMD:PercentageOfPrepaymentDebt","xbrl:period":"2021-04-01T00:00:00/2021-05-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:DebtInstrumentAxis":"MRMD:ThreePointTwoMillionNoteMember","us-gaap:TypeOfArrangementAxis":"MRMD:ThirdAmendmentAgreementMember"},"factValues":[{"value":"0.100"}]},{"name":"rpt:f-968","factDimensions":{"xbrl:concept":"MRMD:RedemptionOfPrincipalAndUnpaidInterest","xbrl:period":"2021-04-01T00:00:00/2021-05-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:ThreePointTwoMillionNoteMember","us-gaap:TypeOfArrangementAxis":"MRMD:ThirdAmendmentAgreementMember"},"factValues":[{"value":"125000","decimals":0}]},{"name":"rpt:f-969","factDimensions":{"xbrl:concept":"us-gaap:DebtConversionConvertedInstrumentAmount1","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:ThreePointTwoMillionNoteMember"},"factValues":[{"value":"2800000","decimals":-5}]},{"name":"rpt:f-970","factDimensions":{"xbrl:concept":"us-gaap:DebtConversionConvertedInstrumentSharesIssued1","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:DebtInstrumentAxis":"MRMD:ThreePointTwoMillionNoteMember"},"factValues":[{"value":"8033296"}]},{"name":"rpt:f-971","factDimensions":{"xbrl:concept":"us-gaap:LongTermDebt","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:ThreePointTwoMillionNoteMember"},"factValues":[{"value":"400000","decimals":0}]},{"name":"rpt:f-972","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentFaceAmount","xbrl:period":"2020-03-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:FourPointFourMillionNotesMember","us-gaap:TypeOfArrangementAxis":"MRMD:ExchangeAgreementMember"},"factValues":[{"value":"4400000","decimals":-5}]},{"name":"rpt:f-973","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentInterestRateDuringPeriod","xbrl:period":"2020-02-01T00:00:00/2020-03-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:DebtInstrumentAxis":"MRMD:FourPointFourMillionNotesMember","us-gaap:TypeOfArrangementAxis":"MRMD:ExchangeAgreementMember"},"factValues":[{"value":"0.165"}]},{"name":"rpt:f-974","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentMaturityDateDescription","xbrl:period":"2020-02-01T00:00:00/2020-03-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:DebtInstrumentAxis":"MRMD:FourPointFourMillionNotesMember","us-gaap:TypeOfArrangementAxis":"MRMD:ExchangeAgreementMember"},"factValues":[{"value":"maturing\nin August 2021"}]},{"name":"rpt:f-975","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentFaceAmount","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:FourPointFourMillionNotesMember","us-gaap:TypeOfArrangementAxis":"MRMD:ExchangeAgreementMember"},"factValues":[{"value":"4600000","decimals":-5}]},{"name":"rpt:f-976","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentFaceAmount","xbrl:period":"2020-05-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:SixMillionNoteMember","us-gaap:TypeOfArrangementAxis":"MRMD:InitialExtensionAgreementMember"},"factValues":[{"value":"6000000.0","decimals":-5}]},{"name":"rpt:f-977","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentInterestRateDuringPeriod","xbrl:period":"2020-04-01T00:00:00/2020-05-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:DebtInstrumentAxis":"MRMD:SixMillionNoteMember","us-gaap:TypeOfArrangementAxis":"MRMD:InitialExtensionAgreementMember"},"factValues":[{"value":"0.130"}]},{"name":"rpt:f-978","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentFeeAmount","xbrl:period":"2020-05-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:SixMillionNoteMember","us-gaap:TypeOfArrangementAxis":"MRMD:InitialExtensionAgreementMember"},"factValues":[{"value":"900000","decimals":0}]},{"name":"rpt:f-979","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentIncreaseAccruedInterest","xbrl:period":"2020-04-01T00:00:00/2020-05-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:SixPointEightMillionNoteMember","us-gaap:TypeOfArrangementAxis":"MRMD:InitialExtensionAgreementMember"},"factValues":[{"value":"845000","decimals":0}]},{"name":"rpt:f-980","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentInterestRateDuringPeriod","xbrl:period":"2020-04-01T00:00:00/2020-05-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:DebtInstrumentAxis":"MRMD:SixPointEightMillionNoteMember","us-gaap:TypeOfArrangementAxis":"MRMD:InitialExtensionAgreementMember"},"factValues":[{"value":"0.100"}]},{"name":"rpt:f-981","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentFeeAmount","xbrl:period":"2020-05-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:NineHundredKNoteMember","us-gaap:TypeOfArrangementAxis":"MRMD:InitialExtensionAgreementMember"},"factValues":[{"value":"900000","decimals":0}]},{"name":"rpt:f-982","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentInterestRateDuringPeriod","xbrl:period":"2020-04-01T00:00:00/2020-05-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:DebtInstrumentAxis":"MRMD:NineHundredKNoteMember","us-gaap:TypeOfArrangementAxis":"MRMD:InitialExtensionAgreementMember"},"factValues":[{"value":"0.120"}]},{"name":"rpt:f-983","factDimensions":{"xbrl:concept":"us-gaap:InterestPayableCurrentAndNoncurrent","xbrl:period":"2020-05-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:NineHundredKNoteMember","us-gaap:TypeOfArrangementAxis":"MRMD:InitialExtensionAgreementMember"},"factValues":[{"value":"20100","decimals":0}]},{"name":"rpt:f-984","factDimensions":{"xbrl:concept":"MRMD:PrincipalAndAccruedInterest","xbrl:period":"2020-08-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:NineHundredKNoteMember","us-gaap:TypeOfArrangementAxis":"MRMD:InitialExtensionAgreementMember"},"factValues":[{"value":"460050","decimals":0}]},{"name":"rpt:f-985","factDimensions":{"xbrl:concept":"us-gaap:DebtConversionConvertedInstrumentSharesIssued1","xbrl:period":"2020-06-01T00:00:00/2020-07-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:DebtInstrumentAxis":"MRMD:NineHundredKNoteMember","us-gaap:TypeOfArrangementAxis":"MRMD:InitialExtensionAgreementMember"},"factValues":[{"value":"2525596"}]},{"name":"rpt:f-986","factDimensions":{"xbrl:concept":"us-gaap:ProceedsFromNotesPayable","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:ThreeMillionNoteMember"},"factValues":[{"value":"3000000.0","decimals":-5}]},{"name":"rpt:f-987","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentInterestRateDuringPeriod","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:DebtInstrumentAxis":"MRMD:ThreeMillionNoteMember"},"factValues":[{"value":"0.100"}]},{"name":"rpt:f-988","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentMaturityDateDescription","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:DebtInstrumentAxis":"MRMD:ThreeMillionNoteMember"},"factValues":[{"value":"The\nmaturity date of the $3.0M Note, initially in March 2020, was extended for an additional six months in accordance with its terms, with\nthe interest rate increasing to"}]},{"name":"rpt:f-989","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentInterestRateIncreaseDecrease","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:DebtInstrumentAxis":"MRMD:ThreeMillionNoteMember"},"factValues":[{"value":"0.120"}]},{"name":"rpt:f-990","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentFaceAmount","xbrl:period":"2020-11-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:SixPointEightMillionNoteMember","us-gaap:TypeOfArrangementAxis":"MRMD:SecondExtensionAgreementMember"},"factValues":[{"value":"1000000","decimals":-6}]},{"name":"rpt:f-991","factDimensions":{"xbrl:concept":"us-gaap:InterestPayableCurrentAndNoncurrent","xbrl:period":"2020-11-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:SixPointEightMillionNoteMember","us-gaap:TypeOfArrangementAxis":"MRMD:SecondExtensionAgreementMember"},"factValues":[{"value":"333000000000","decimals":-6}]},{"name":"rpt:f-992","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentFaceAmount","xbrl:period":"2020-11-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:FivePointEightMillionNoteMember","us-gaap:TypeOfArrangementAxis":"MRMD:SecondExtensionAgreementMember"},"factValues":[{"value":"5845000000000","decimals":-6}]},{"name":"rpt:f-993","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentInterestRateDuringPeriod","xbrl:period":"2020-10-01T00:00:00/2020-11-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:DebtInstrumentAxis":"MRMD:PromissoryNotesMember","us-gaap:TypeOfArrangementAxis":"MRMD:ThirdAmendmentAgreementMember"},"factValues":[{"value":"0.120"}]},{"name":"rpt:f-994","factDimensions":{"xbrl:concept":"MRMD:DebtInstrumentExtendedMaturityDescription","xbrl:period":"2020-10-30T00:00:00/2020-11-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:DebtInstrumentAxis":"MRMD:PromissoryNotesMember","us-gaap:TypeOfArrangementAxis":"MRMD:ThirdAmendmentAgreementMember"},"factValues":[{"value":"maturity dates in September\n2022"}]},{"name":"rpt:f-995","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights","xbrl:period":"2020-11-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:TypeOfArrangementAxis":"MRMD:SecondExtensionAgreementMember"},"factValues":[{"value":"5000000"}]},{"name":"rpt:f-996","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1","xbrl:period":"2020-11-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:TypeOfArrangementAxis":"MRMD:SecondExtensionAgreementMember"},"factValues":[{"value":"0.25"}]},{"name":"rpt:f-997","factDimensions":{"xbrl:concept":"us-gaap:PaymentsOfStockIssuanceCosts","xbrl:period":"2020-10-01T00:00:00/2020-11-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:TypeOfArrangementAxis":"MRMD:SecondExtensionAgreementMember"},"factValues":[{"value":"100000","decimals":0}]},{"name":"rpt:f-998","factDimensions":{"xbrl:concept":"us-gaap:InterestAndDebtExpense","xbrl:period":"2020-10-01T00:00:00/2020-11-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:TypeOfArrangementAxis":"MRMD:SecondExtensionAgreementMember"},"factValues":[{"value":"573000","decimals":0}]},{"name":"rpt:f-999","factDimensions":{"xbrl:concept":"us-gaap:AmortizationOfDebtDiscountPremium","xbrl:period":"2020-12-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:TypeOfArrangementAxis":"MRMD:SecondExtensionAgreementMember"},"factValues":[{"value":"75000","decimals":0}]},{"name":"rpt:f-1000","factDimensions":{"xbrl:concept":"us-gaap:LongTermDebt","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:TypeOfArrangementAxis":"MRMD:SecondExtensionAgreementMember"},"factValues":[{"value":"8300000","decimals":-5}]},{"name":"rpt:f-1001","factDimensions":{"xbrl:concept":"us-gaap:LongTermDebtCurrent","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:TypeOfArrangementAxis":"MRMD:SecondExtensionAgreementMember"},"factValues":[{"value":"1900000","decimals":-5}]},{"name":"rpt:f-1002","factDimensions":{"xbrl:concept":"us-gaap:RepaymentsOfNotesPayable","xbrl:period":"2021-02-01T00:00:00/2021-03-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:FivePointEightMillionNoteMember","us-gaap:TypeOfArrangementAxis":"MRMD:SecondExtensionAgreementMember"},"factValues":[{"value":"400000","decimals":0}]},{"name":"rpt:f-1003","factDimensions":{"xbrl:concept":"us-gaap:AmortizationOfDebtDiscountPremium","xbrl:period":"2021-03-01T00:00:00/2021-04-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:FivePointEightMillionNoteMember","us-gaap:TypeOfArrangementAxis":"MRMD:SecondExtensionAgreementMember"},"factValues":[{"value":"450000","decimals":0}]},{"name":"rpt:f-1004","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentInterestRateDuringPeriod","xbrl:period":"2020-08-01T00:00:00/2020-09-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:DebtInstrumentAxis":"MRMD:PromissoryNotesMember","us-gaap:TypeOfArrangementAxis":"MRMD:FirstCitizensFederalCreditUnionMember"},"factValues":[{"value":"0.0574"}]},{"name":"rpt:f-1005","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentMaturityDateDescription","xbrl:period":"2020-08-01T00:00:00/2020-09-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:DebtInstrumentAxis":"MRMD:PromissoryNotesMember","us-gaap:TypeOfArrangementAxis":"MRMD:FirstCitizensFederalCreditUnionMember"},"factValues":[{"value":"matures\nin July 2026"}]},{"name":"rpt:f-1006","factDimensions":{"xbrl:concept":"us-gaap:NotesPayable","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:PromissoryNotesMember","us-gaap:TypeOfArrangementAxis":"MRMD:FirstCitizensFederalCreditUnionMember"},"factValues":[{"value":"26000","decimals":0}]},{"name":"rpt:f-1007","factDimensions":{"xbrl:concept":"us-gaap:NotesPayable","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:PromissoryNotesMember","us-gaap:TypeOfArrangementAxis":"MRMD:FirstCitizensFederalCreditUnionMember"},"factValues":[{"value":"30000","decimals":0}]},{"name":"rpt:f-1008","factDimensions":{"xbrl:concept":"us-gaap:NotesPayableCurrent","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:PromissoryNotesMember","us-gaap:TypeOfArrangementAxis":"MRMD:FirstCitizensFederalCreditUnionMember"},"factValues":[{"value":"5000","decimals":0}]},{"name":"rpt:f-1009","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentInterestRateDuringPeriod","xbrl:period":"2021-06-01T00:00:00/2021-07-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:TypeOfArrangementAxis":"MRMD:NoteAgreementMember"},"factValues":[{"value":"0.100"}]},{"name":"rpt:f-1010","factDimensions":{"xbrl:concept":"us-gaap:NotesPayable","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:TypeOfArrangementAxis":"MRMD:NoteAgreementMember"},"factValues":[{"value":"33000","decimals":0}]},{"name":"rpt:f-1011","factDimensions":{"xbrl:concept":"us-gaap:NotesPayableCurrent","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:TypeOfArrangementAxis":"MRMD:NoteAgreementMember"},"factValues":[{"value":"5000","decimals":0}]},{"name":"rpt:f-1012","factDimensions":{"xbrl:concept":"us-gaap:RepaymentsOfNotesPayable","xbrl:period":"2020-01-01T00:00:00/2020-10-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:OneMillionNoteMember","dei:LegalEntityAxis":"MRMD:MariMedHempIncMember"},"factValues":[{"value":"500000","decimals":0}]},{"name":"rpt:f-1013","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentFaceAmount","xbrl:period":"2019-10-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:OneMillionNoteMember","dei:LegalEntityAxis":"MRMD:MariMedHempIncMember"},"factValues":[{"value":"1000000","decimals":0}]},{"name":"rpt:f-1014","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentFaceAmount","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:OneMillionNoteMember","dei:LegalEntityAxis":"MRMD:MariMedHempIncMember"},"factValues":[{"value":"500000","decimals":0}]},{"name":"rpt:f-1015","factDimensions":{"xbrl:concept":"us-gaap:InterestExpenseDebt","xbrl:period":"2021-03-01T00:00:00/2021-04-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:OneMillionNoteMember","dei:LegalEntityAxis":"MRMD:HadronHealthcareMasterFundMember"},"factValues":[{"value":"200000","decimals":0}]},{"name":"rpt:f-1016","factDimensions":{"xbrl:concept":"us-gaap:RepaymentsOfNotesPayable","xbrl:period":"2021-03-01T00:00:00/2021-04-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:OneMillionNoteMember","dei:LegalEntityAxis":"MRMD:HadronHealthcareMasterFundMember"},"factValues":[{"value":"500000","decimals":0}]},{"name":"rpt:f-1017","factDimensions":{"xbrl:concept":"us-gaap:InterestPayableCurrentAndNoncurrent","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:OneMillionNoteMember","dei:LegalEntityAxis":"MRMD:MariMedHempIncMember"},"factValues":[{"value":"125000","decimals":0}]},{"name":"rpt:f-1018","factDimensions":{"xbrl:concept":"us-gaap:NotesPayableFairValueDisclosure","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:ExistingNotesMember"},"factValues":[{"value":"3190000","decimals":0}]},{"name":"rpt:f-1019","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentInterestRateDuringPeriod","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","srt:RangeAxis":"srt:MinimumMember","us-gaap:DebtInstrumentAxis":"MRMD:ExistingNotesMember"},"factValues":[{"value":"0.065"}]},{"name":"rpt:f-1020","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentInterestRateDuringPeriod","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","srt:RangeAxis":"srt:MaximumMember","us-gaap:DebtInstrumentAxis":"MRMD:ExistingNotesMember"},"factValues":[{"value":"0.180"}]},{"name":"rpt:f-1021","factDimensions":{"xbrl:concept":"us-gaap:ProceedsFromNotesPayable","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:NewPromissoryNotesMember"},"factValues":[{"value":"2147000","decimals":0}]},{"name":"rpt:f-1022","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentInterestRateDuringPeriod","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","srt:RangeAxis":"srt:MinimumMember","us-gaap:DebtInstrumentAxis":"MRMD:NewPromissoryNotesMember"},"factValues":[{"value":"0.120"}]},{"name":"rpt:f-1023","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentInterestRateDuringPeriod","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","srt:RangeAxis":"srt:MaximumMember","us-gaap:DebtInstrumentAxis":"MRMD:NewPromissoryNotesMember"},"factValues":[{"value":"0.150"}]},{"name":"rpt:f-1024","factDimensions":{"xbrl:concept":"us-gaap:RepaymentsOfNotesPayable","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:ExistingNotesMember"},"factValues":[{"value":"2100000","decimals":0}]},{"name":"rpt:f-1025","factDimensions":{"xbrl:concept":"us-gaap:DebtConversionConvertedInstrumentAmount1","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:ExistingNotesMember"},"factValues":[{"value":"500000","decimals":0}]},{"name":"rpt:f-1026","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentConvertibleConversionPrice1","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:DebtInstrumentAxis":"MRMD:ExistingNotesMember"},"factValues":[{"value":"0.32"}]},{"name":"rpt:f-1027","factDimensions":{"xbrl:concept":"us-gaap:RepaymentsOfNotesPayable","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:NewPromissoryNotesMember"},"factValues":[{"value":"700000","decimals":0}]},{"name":"rpt:f-1028","factDimensions":{"xbrl:concept":"us-gaap:NotesPayableFairValueDisclosure","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:ExistingNotesandNewPromissoryNotesMember"},"factValues":[{"value":"2037000","decimals":0}]},{"name":"rpt:f-1029","factDimensions":{"xbrl:concept":"us-gaap:RepaymentsOfNotesPayable","xbrl:period":"2021-03-01T00:00:00/2021-04-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:ExistingNotesandNewPromissoryNotesMember"},"factValues":[{"value":"200000","decimals":0}]},{"name":"rpt:f-1030","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"As\nof December 31, 2021, the aggregate scheduled maturities of the Company\u2019s total debt outstanding were:
\n\n\u00a0SCHEDULE\nOF MATURITY TABLES
\n\n| \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 |
| 2022 | \u00a0 | \n$ | 1,410,222 | \u00a0 |
| 2023 | \u00a0 | \n\u00a0 | 1,032,523 | \u00a0 |
| 2024 | \u00a0 | \n\u00a0 | 670,613 | \u00a0 |
| 2025 | \u00a0 | \n\u00a0 | 717,209 | \u00a0 |
| 2026 | \u00a0 | \n\u00a0 | 760,988 | \u00a0 |
| Thereafter | \u00a0 | \n\u00a0 | 14,080,474 | \u00a0 |
| Total | \u00a0 | \n$ | 18,672,029 | \u00a0 |
\u00a0
\n\n"}]},{"name":"rpt:f-1031","factDimensions":{"xbrl:concept":"us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1410222","decimals":0}]},{"name":"rpt:f-1032","factDimensions":{"xbrl:concept":"us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1032523","decimals":0}]},{"name":"rpt:f-1033","factDimensions":{"xbrl:concept":"us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"670613","decimals":0}]},{"name":"rpt:f-1034","factDimensions":{"xbrl:concept":"us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"717209","decimals":0}]},{"name":"rpt:f-1035","factDimensions":{"xbrl:concept":"us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"760988","decimals":0}]},{"name":"rpt:f-1036","factDimensions":{"xbrl:concept":"us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"14080474","decimals":0}]},{"name":"rpt:f-1037","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentCarryingAmount","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"18672029","decimals":0}]},{"name":"rpt:f-1038","factDimensions":{"xbrl:concept":"MRMD:DebenturePayableTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"NOTE\n12 \u2013 DEBENTURES PAYABLE
\n\n\u00a0
\n\nIn\na series of transactions from the period October 2018 through February 2020, the Company sold an aggregate of $21.0 million of convertible\ndebentures (the \u201c$21M Debentures\u201d) to an unaffiliated investor pursuant to an amended securities purchase agreement. The\nfollowing table as of December 31, 2021 summarizes the purchase dates and selected terms of each debenture agreement that comprised the\n$21M Debentures:
\n\nSCHEDULE OF DEBENTURE TRANSACTION\u00a0
\n\nIssue \nDate | \u00a0 | \nMaturity \nDate | \u00a0 | \nInitial Principal | \u00a0 | \u00a0 | \nInterest \nRate | \u00a0 | \nIssue \nDiscount | \u00a0 | \u00a0 | \nWarrant \nDiscount | \u00a0 | \u00a0 | \nBeneficial \nConversion \nFeature | \u00a0 | ||||
| 10/17/18 | \u00a0 | \n10/16/20 | \u00a0 | \n$ | 5,000,000 | \u00a0 | \u00a0 | \n6.0% | \u00a0 | \n\u00a0 | 1.0% | \u00a0 | \n$ | 457,966 | \u00a0 | \u00a0 | \n$ | 1,554,389 | \u00a0 | |
| 11/07/18 | \u00a0 | \n11/06/20 | \u00a0 | \n\u00a0 | 5,000,000 | \u00a0 | \u00a0 | \n6.0% | \u00a0 | \n\u00a0 | 1.0% | \u00a0 | \n\u00a0 | 599,867 | \u00a0 | \u00a0 | \n\u00a0 | 4,015,515 | \u00a0 | |
| 05/08/19 | \u00a0 | \n05/07/21 | \u00a0 | \n\u00a0 | 5,000,000 | \u00a0 | \u00a0 | \n6.0% | \u00a0 | \n\u00a0 | 1.0% | \u00a0 | \n\u00a0 | 783,701 | \u00a0 | \u00a0 | \n\u00a0 | 2,537,235 | \u00a0 | |
| 06/28/19 | \u00a0 | \n06/27/21 | \u00a0 | \n\u00a0 | 2,500,000 | \u00a0 | \u00a0 | \n0.0% | \u00a0 | \n\u00a0 | 7.0% | \u00a0 | \n\u00a0 | 145,022 | \u00a0 | \u00a0 | \n\u00a0 | 847,745 | \u00a0 | |
| 08/20/19 | \u00a0 | \n08/19/21 | \u00a0 | \n\u00a0 | 2,500,000 | \u00a0 | \u00a0 | \n0.0% | \u00a0 | \n\u00a0 | 7.0% | \u00a0 | \n\u00a0 | 219,333 | \u00a0 | \u00a0 | \n\u00a0 | 850,489 | \u00a0 | |
| 02/21/20 | \u00a0 | \n02/20/21 | \u00a0 | \n\u00a0 | 1,000,000 | \u00a0 | \u00a0 | \n6.5% | \u00a0 | \n\u00a0 | 6.5% | \u00a0 | \n\u00a0 | 28,021 | \u00a0 | \u00a0 | \n\u00a0 | 379,183 | \u00a0 |
\u00a0
\n\nAs\nof December 31, 2021, the holder of the $21M Debentures (the \u201cHolder\u201d) had converted all of the $21M Debentures into the\nCompany\u2019s common stock at conversion prices equal to 80.0%\nof a calculated average of the daily volume-weighted\nprice preceding the date of conversion. Specifically, over the life of the $21M Debentures, the Holder converted, in several transactions,\nan aggregate of $21.0\nmillion of principal and approximately $836,000\nof accrued interest into shares of common stock at conversion prices ranging\nfrom $0.11\nto $3.06\nper share. Of these conversions, (i) during 2020,\nan aggregate of $9.7\nmillion of principal and approximately $365,000\nof accrued interest was converted into shares of common stock at conversion prices ranging\nfrom $0.11\nand $0.34\nper share, and (ii) during 2021, an aggregate\nof $1.3\nmillion of principal and approximately $56,000\nof accrued interest was converted into shares of common stock at a conversion price\nof $0.29\nper share.
\n\n\u00a0
\n\nAll\nof the aforementioned conversions were effected in accordance with the terms of the debenture agreements, and therefore the Company was\nnot required to record a gain or loss on such conversions. The conversions were limited in any given month to certain agreed-upon amounts\nbased on the conversion price, and the Holder was also limited from beneficially owning more than 4.99% of the Company\u2019s outstanding\ncommon stock.
\n\n\u00a0
\n\nIn\nconjunction with the issuance of the $21M Debentures, the Company issued the Holder -year warrants to purchase an aggregate of 1,354,675\nshares of the Company\u2019s common stock at exercise prices ranging from $0.75 to $5.50 per share, of which warrants to purchase 180,000\nshares of common stock at an exercise price of $0.75 were issued in 2020. The fair value of the warrants of approximately $2.2 million\nwas recorded as a discount to the carrying amount of the $21M Debentures and are amortized to interest expense over the respective term\nof the individual debentures comprising the $21M Debentures.
\n\n\u00a0
\n\n\n\n\n\u00a0
\n\nBased\non the conversion prices of the $21M Debentures in relation to the market value of the Company\u2019s common stock, the $21M Debentures\nprovided the Holder with a beneficial conversion feature, as the embedded conversion option was in-the-money on the commitment date.\nThe aggregate intrinsic value of the beneficial conversion feature of approximately $10.2 million was recorded as a discount to the carrying\namount of the $21M Debentures, and amortized to interest expense over the respective term of the individual debentures comprising the\n$21M Debentures.
\n\n\u00a0
\n\nDuring\n2020, amortization of the beneficial conversion features, after adjustment for the aforementioned conversions, approximated $3.2 million;\namortization of the warrant discounts approximated $805,000; amortization of original issue discounts approximated $321,000; and interest\nexpense approximated $224,000. At December 31, 2020, the aggregate outstanding principal balance of the $21M Debentures was $1.3 million.\nAlso on such date, the unamortized balances of the beneficial conversion features, the warrant discounts, and original issue discounts\nwere approximately $177,000, $39,000, and $52,000, respectively. Accordingly, at December 31, 2020, the carrying value of the $21M Debentures\napproximated $1,032,000, all of which was current.
\n\n\u00a0
\n\nDuring\n2021, amortization of the beneficial conversion features, after adjustment for the aforementioned conversions, approximated $177,000;\namortization of the warrant discounts approximated $39,000; amortization of original issue discounts approximated $52,000; and interest\nexpense approximated $1,000.
\n\n\u00a0
\n\n\n\n\n\u00a0
\n\n"}]},{"name":"rpt:f-1039","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentFaceAmount","xbrl:period":"2020-03-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:TwentyOneMillionConvertibleDebenturesMember"},"factValues":[{"value":"21000000.0","decimals":-5}]},{"name":"rpt:f-1040","factDimensions":{"xbrl:concept":"MRMD:ScheduleOfDebentureTransactionTableTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"SCHEDULE OF DEBENTURE TRANSACTION\u00a0
\n\nIssue \nDate | \u00a0 | \nMaturity \nDate | \u00a0 | \nInitial Principal | \u00a0 | \u00a0 | \nInterest \nRate | \u00a0 | \nIssue \nDiscount | \u00a0 | \u00a0 | \nWarrant \nDiscount | \u00a0 | \u00a0 | \nBeneficial \nConversion \nFeature | \u00a0 | ||||
| 10/17/18 | \u00a0 | \n10/16/20 | \u00a0 | \n$ | 5,000,000 | \u00a0 | \u00a0 | \n6.0% | \u00a0 | \n\u00a0 | 1.0% | \u00a0 | \n$ | 457,966 | \u00a0 | \u00a0 | \n$ | 1,554,389 | \u00a0 | |
| 11/07/18 | \u00a0 | \n11/06/20 | \u00a0 | \n\u00a0 | 5,000,000 | \u00a0 | \u00a0 | \n6.0% | \u00a0 | \n\u00a0 | 1.0% | \u00a0 | \n\u00a0 | 599,867 | \u00a0 | \u00a0 | \n\u00a0 | 4,015,515 | \u00a0 | |
| 05/08/19 | \u00a0 | \n05/07/21 | \u00a0 | \n\u00a0 | 5,000,000 | \u00a0 | \u00a0 | \n6.0% | \u00a0 | \n\u00a0 | 1.0% | \u00a0 | \n\u00a0 | 783,701 | \u00a0 | \u00a0 | \n\u00a0 | 2,537,235 | \u00a0 | |
| 06/28/19 | \u00a0 | \n06/27/21 | \u00a0 | \n\u00a0 | 2,500,000 | \u00a0 | \u00a0 | \n0.0% | \u00a0 | \n\u00a0 | 7.0% | \u00a0 | \n\u00a0 | 145,022 | \u00a0 | \u00a0 | \n\u00a0 | 847,745 | \u00a0 | |
| 08/20/19 | \u00a0 | \n08/19/21 | \u00a0 | \n\u00a0 | 2,500,000 | \u00a0 | \u00a0 | \n0.0% | \u00a0 | \n\u00a0 | 7.0% | \u00a0 | \n\u00a0 | 219,333 | \u00a0 | \u00a0 | \n\u00a0 | 850,489 | \u00a0 | |
| 02/21/20 | \u00a0 | \n02/20/21 | \u00a0 | \n\u00a0 | 1,000,000 | \u00a0 | \u00a0 | \n6.5% | \u00a0 | \n\u00a0 | 6.5% | \u00a0 | \n\u00a0 | 28,021 | \u00a0 | \u00a0 | \n\u00a0 | 379,183 | \u00a0 |
NOTE\n13 \u2013 MEZZANINE EQUITY
\n\n\u00a0
\n\nSeries\nB Convertible Preferred Stock
\n\n\u00a0
\n\nIn\nFebruary 2020, the Company entered into an exchange agreement with two institutional shareholders (the \u201cTIS Exchange Agreement\u201d)\nwhereby the Company (i) exchanged shares of the Company\u2019s common stock previously acquired by the two institutional shareholders\nfor an equal number of shares of newly designated Series B convertible preferred stock, and (ii) issued the $4.4M Notes previously discussed\nin Note 11 \u2013 Promissory Notes.
\n\n\u00a0
\n\nIn\nconnection with the TIS Exchange Agreement, the Company filed (i) a certificate of designation with respect to the rights and preferences\nof the Series B convertible preferred stock, and (ii) a certificate of elimination to return all shares of the Series A convertible preferred\nstock, of which no shares were issued or outstanding at the time of filing, to the status of authorized and unissued shares of undesignated\npreferred stock.
\n\n\u00a0
\n\nThe\nholders of Series B convertible preferred stock (the \u201cSeries B Holders\u201d) are entitled to cast the number of votes equal to\nthe number of shares of common stock into which the shares of Series B convertible preferred stock are convertible, together with the\nholders of common stock as a single class, on most matters. However, the affirmative vote or consent of the Series B Holders voting separately\nas a class is required for certain acts taken by the Company, including the amendment or repeal of certain charter provisions, liquidation\nor winding up of the Company, creation of stock senior to the Series B convertible preferred stock, and/or other acts defined in the\ncertificate of designation.
\n\n\u00a0
\n\nThe\nSeries B convertible preferred stock shall, with respect to dividend rights and rights on liquidation, winding up and dissolution, rank\nsenior to the Company\u2019s common stock. The Company shall not declare, pay, or set aside any dividends on shares of any other class\nor series of capital stock of the Company unless the Series B Holders then outstanding shall first receive, or simultaneously receive,\na dividend on each outstanding share of Series B convertible preferred stock in an amount calculated pursuant to the certificate of designation.
\n\n\u00a0
\n\nIn\nthe event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the Series B Holders then outstanding\nshall be entitled to be paid out of the assets of the Company available for distribution to its stockholders before any payment shall\nbe made to the holders of common stock by reason of their ownership thereof, an amount per share equal to $, plus any dividends declared\nbut unpaid thereon, with any remaining assets distributed pro-rata among the holders of the shares of Series B convertible preferred\nstock and common stock, based on the number of shares held by each such holder, treating for this purpose all such securities as if they\nhad been converted to common stock.
\n\n\u00a0
\n\nAt\nany time on or prior to the six-year anniversary of the issuance date of the Series B convertible preferred stock, (i) the Series B Holders\nhave the option to convert their shares of Series B convertible preferred stock into common stock at a conversion price of $3.00 per\nshare, without the payment of additional consideration, and (ii) the Company has the option to convert all, but not less than all, shares\nof Series B convertible preferred stock into common stock at a conversion price of $3.00 if the daily volume weighted average price of\ncommon stock (the \u201cVWAP\u201d) exceeds $4.00 per share for at least twenty consecutive trading days prior to the date on which\nthe Company gives notice of such conversion to the Series B Holders.
\n\n\u00a0
\n\nOn\nthe day following the six-year anniversary of the issuance of the Series B convertible preferred stock, all outstanding shares of Series\nB convertible preferred stock shall automatically convert into common stock as follows:
\n\n\u00a0
\n\n\n\n
\u00a0
\n\n\n\n
\u00a0
\n\nThe\nCompany shall at all times when the Series B convertible preferred stock is outstanding, reserve and keep available out of its authorized\nbut unissued capital stock, for the purpose of effecting the conversion of the Series B convertible preferred stock, such number of its\nduly authorized shares of common stock as shall from time to time be sufficient to effect the conversion of all outstanding Series B\nconvertible preferred stock.
\n\n\u00a0
\n\n\n\n\n\u00a0
\n\nSeries\nC Convertible Preferred Stock
\n\n\u00a0
\n\nIn\nMarch 2021, the Company entered into a securities purchase agreement with Hadron Healthcare Master Fund (\u201cHadron\u201d) with respect\nto a financing facility of up to $ million in exchange for newly-designated Series C convertible preferred stock of the Company and\nwarrants to purchase the Company\u2019s common stock.
\n\n\u00a0
\n\nAt\nthe closing of the transaction in March 2021, Hadron purchased $23.0 million of Units at a price of $ per Unit. Each Unit is comprised\nof one share of Series C preferred stock and a -year warrant to purchase two and one-half shares of common stock. Accordingly, the\nCompany issued to Hadron shares of Series C preferred stock and warrants to purchase up to an aggregate of 15,540,540 shares\nof common stock. Each share of Series C preferred stock is convertible, at Hadron\u2019s option, into five shares of common stock, and\neach warrant is exercisable at an exercise price of $1.087 per share. The warrants shall be subject to early termination if certain milestones\nare attained, and the market value of the Company\u2019s common stock reaches certain predetermined levels. The fair value of the warrants\nof approximately $9.5 million on the issuance date was allocated to the proceeds and recorded as additional paid-in capital. The Company\nincurred costs of approximately $387,000 relative to the issuance of the aforementioned shares to Hadron which was recorded as a reduction\nto additional paid-in capital in March 2021.
\n\n\u00a0
\n\nIn\nconnection with the closing of the transaction, the Company filed a certificate of designation with respect to the rights and preferences\nof the Series C convertible preferred stock. Such stock is zero coupon, non-voting. and has a liquidation preference equal to its investment\namount plus declared but unpaid dividends. Holders of Series C convertible preferred stock are entitled to receive dividends on an as-converted\nbasis.
\n\n\u00a0
\n\nOf\nthe $23.0 million of proceeds received by the Company in March 2021, approximately (i) $7.8 million was designated to fund construction\nand upgrades of certain of the Company\u2019s owned and managed facilities, which was expended in 2021, and (ii) $15.2 million was used\nto pay down debt and obligations, comprised of principal and interest on the $4.4M Notes, the $1.0M Note, the New $3.0M Note, the $5.8M\nNote, the Existing Notes, the New 2020 Notes (all referred to in Note 11 \u2013 Promissory Notes), and a portion of the Due\nTo Related Parties balance discussed in Note 19 \u2013 Related Party Transactions.
\n\n\u00a0
\n\nA\nportion of the balance of the facility is available to fund the Kind acquisition previously discussed in Note 3 \u2013 Acquisitions,\nprovided such acquisition is consummated, including obtaining the necessary regulatory approvals, no later than the end of 2022.\nSuch funds shall be provided by Hadron on the same aforementioned terms as the initial proceeds.
\n\n\u00a0
\n\nProvided\nthat as at least 50.0%\nof the shares of Series C convertible preferred\nstock remain outstanding, the holders shall have the right to appoint one observer to the Company\u2019s board and to each of its board\ncommittees, and appoint a member to the Company\u2019s board if and when a seat becomes available, at which time the observer roles\nshall terminate.
\n\n\u00a0
\n\nThe\ntransaction imposes certain covenants on the Company with respect to the incurrence of new indebtedness, the issuance of additional shares\nof any designation of preferred stock, and the payment of distributions.
\n\n\u00a0
\n\n\n\n\n\u00a0
\n\n"}]},{"name":"rpt:f-1120","factDimensions":{"xbrl:concept":"MRMD:StockIssuedDuringPeriodSharesExchanged1","xbrl:period":"2020-02-01T00:00:00/2020-03-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:StatementClassOfStockAxis":"MRMD:SeriesBConvertiblePreferredStockMember","us-gaap:TypeOfArrangementAxis":"MRMD:ExchangeAgreementMember","dei:LegalEntityAxis":"MRMD:TwoInstitutionalShareholdersMember"},"factValues":[{"value":"4908333"}]},{"name":"rpt:f-1121","factDimensions":{"xbrl:concept":"us-gaap:SharesIssuedPricePerShare","xbrl:period":"2020-03-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:StatementClassOfStockAxis":"MRMD:SeriesBHoldersMember"},"factValues":[{"value":"3.00"}]},{"name":"rpt:f-1122","factDimensions":{"xbrl:concept":"us-gaap:PreferredStockConvertibleConversionPrice","xbrl:period":"2020-03-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:StatementClassOfStockAxis":"MRMD:SeriesBHoldersMember"},"factValues":[{"value":"3.00"}]},{"name":"rpt:f-1123","factDimensions":{"xbrl:concept":"MRMD:SeriesBPreferredStockConversionPriceDescription","xbrl:period":"2020-02-01T00:00:00/2020-03-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:StatementClassOfStockAxis":"MRMD:SeriesBConvertiblePreferredStockMember","us-gaap:AwardTypeAxis":"MRMD:VolumeWeightedAveragepriceLessThanOrEqualToPerShareMember"},"factValues":[{"value":"If\nthe sixty-day VWAP is less than or equal to $0.50 per share, the Company shall have the option to (i) convert all shares of Series B\nconvertible preferred stock into common stock at a conversion price of $1.00 per share, and pay cash to the Series B Holders equal to\nthe difference between the 60-day VWAP and $3.00 per share, or (ii) pay cash to the Series B Holders equal to $3.00 per share."}]},{"name":"rpt:f-1124","factDimensions":{"xbrl:concept":"MRMD:SeriesBPreferredStockConversionPriceDescription","xbrl:period":"2020-02-01T00:00:00/2020-03-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:StatementClassOfStockAxis":"MRMD:SeriesBConvertiblePreferredStockMember","us-gaap:AwardTypeAxis":"MRMD:VolumeWeightedAveragepriceGreaterThanPerShareMember"},"factValues":[{"value":"If\nthe sixty-day VWAP is greater than $0.50 per share, the Company shall have the option to (i) convert all shares of Series B convertible\npreferred stock into common stock at a conversion price per share equal to the quotient of $3.00 per share divided by the sixty-day VWAP,\nor (ii) pay cash to the Series B Holders equal to $3.00 per share, or (iii) convert all shares of Series B convertible preferred stock\ninto common stock at a conversion price per share equal to the sixty-day VWAP per share and pay cash to the Series B Holders at the difference\nbetween $3.00 per share and the sixty-day VWAP per share."}]},{"name":"rpt:f-1125","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodSharesNewIssues","xbrl:period":"2021-03-01T00:00:00/2021-04-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:StatementClassOfStockAxis":"MRMD:SeriesCConvertiblePreferredStockMember","us-gaap:TypeOfArrangementAxis":"MRMD:SecuritiesPurchaseAgreementMember","us-gaap:CreditFacilityAxis":"MRMD:HadronHealthcareMasterFundMember","srt:RangeAxis":"srt:MaximumMember"},"factValues":[{"value":"46000000.0","decimals":-5}]},{"name":"rpt:f-1126","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodValueNewIssues","xbrl:period":"2021-03-01T00:00:00/2021-04-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementClassOfStockAxis":"MRMD:SeriesCConvertiblePreferredStockMember","us-gaap:CreditFacilityAxis":"MRMD:HadronHealthcareMasterFundMember","us-gaap:TypeOfArrangementAxis":"MRMD:SecuritiesPurchaseAgreementMember"},"factValues":[{"value":"23000000.0","decimals":-5}]},{"name":"rpt:f-1127","factDimensions":{"xbrl:concept":"us-gaap:SharesIssuedPricePerShare","xbrl:period":"2021-04-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:StatementClassOfStockAxis":"MRMD:SeriesCConvertiblePreferredStockMember","us-gaap:CreditFacilityAxis":"MRMD:HadronHealthcareMasterFundMember","us-gaap:TypeOfArrangementAxis":"MRMD:SecuritiesPurchaseAgreementMember"},"factValues":[{"value":"3.70"}]},{"name":"rpt:f-1128","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodSharesNewIssues","xbrl:period":"2021-03-01T00:00:00/2021-04-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:StatementClassOfStockAxis":"MRMD:SeriesCConvertiblePreferredStockMember","us-gaap:CreditFacilityAxis":"MRMD:HadronHealthcareMasterFundMember","us-gaap:StatementEquityComponentsAxis":"us-gaap:WarrantMember"},"factValues":[{"value":"6216216"}]},{"name":"rpt:f-1129","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights","xbrl:period":"2021-04-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:CreditFacilityAxis":"MRMD:HadronHealthcareMasterFundMember","srt:RangeAxis":"srt:MaximumMember","us-gaap:StatementEquityComponentsAxis":"us-gaap:CommonStockMember"},"factValues":[{"value":"15540540"}]},{"name":"rpt:f-1130","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1","xbrl:period":"2021-04-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:CreditFacilityAxis":"MRMD:HadronHealthcareMasterFundMember","us-gaap:StatementEquityComponentsAxis":"us-gaap:WarrantMember"},"factValues":[{"value":"1.087"}]},{"name":"rpt:f-1131","factDimensions":{"xbrl:concept":"us-gaap:FairValueAdjustmentOfWarrants","xbrl:period":"2021-03-01T00:00:00/2021-04-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:CreditFacilityAxis":"MRMD:HadronHealthcareMasterFundMember","us-gaap:StatementEquityComponentsAxis":"us-gaap:WarrantMember"},"factValues":[{"value":"9500000","decimals":-5}]},{"name":"rpt:f-1132","factDimensions":{"xbrl:concept":"us-gaap:PaymentsOfStockIssuanceCosts","xbrl:period":"2021-03-01T00:00:00/2021-04-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:CreditFacilityAxis":"MRMD:HadronHealthcareMasterFundMember","us-gaap:StatementEquityComponentsAxis":"us-gaap:WarrantMember"},"factValues":[{"value":"387000","decimals":0}]},{"name":"rpt:f-1133","factDimensions":{"xbrl:concept":"us-gaap:ProceedsFromIssuanceOrSaleOfEquity","xbrl:period":"2021-03-01T00:00:00/2021-04-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"23000000.0","decimals":-5}]},{"name":"rpt:f-1134","factDimensions":{"xbrl:concept":"us-gaap:PaymentsForConstructionInProcess","xbrl:period":"2021-03-01T00:00:00/2021-04-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"7800000","decimals":-5}]},{"name":"rpt:f-1135","factDimensions":{"xbrl:concept":"us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations","xbrl:period":"2021-01-01T00:00:00/2021-07-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:AwardTypeAxis":"MRMD:ThreeMillionNoteMember"},"factValues":[{"value":"15200000","decimals":-5}]},{"name":"rpt:f-1136","factDimensions":{"xbrl:concept":"MRMD:OutstandingPercentage","xbrl:period":"2021-03-01T00:00:00/2021-04-01T00:00:00","xbrl:entity":"cik:0001522767","srt:RangeAxis":"srt:MinimumMember","us-gaap:StatementClassOfStockAxis":"MRMD:SeriesCConvertiblePreferredStockMember"},"factValues":[{"value":"0.500"}]},{"name":"rpt:f-1137","factDimensions":{"xbrl:concept":"us-gaap:StockholdersEquityNoteDisclosureTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"NOTE\n14 \u2013 STOCKHOLDERS\u2019 EQUITY
\n\n\u00a0
\n\nStockholder\nResolutions
\n\n\u00a0
\n\nAt\nthe Company\u2019s 2021 annual meeting of stockholders in September 2021 (the \u201cAnnual Meeting\u201d), stockholders approved an\namendment to the Company\u2019s certificate of incorporation increasing the number of authorized shares of common stock from \nto .
\n\n\u00a0
\n\nAlso\nat the Annual Meeting, stockholders approved an amendment to the Company\u2019s Amended and Restated 2018 Stock Award and Incentive\nPlan (the \u201cPlan\u201d) increasing the aggregate number shares reserved for issuance under the Plan from to .
\n\n\u00a0
\n\nUndesignated\nPreferred Stock
\n\n\u00a0
\n\nIn\nFebruary 2020, the Company filed a certificate of elimination to return all shares of formerly designated Series A convertible preferred\nstock to the status of authorized and unissued shares of undesignated preferred stock.
\n\n\u00a0
\n\nCommon\nStock
\n\n\u00a0
\n\nIn\nFebruary 2020, pursuant to the TIS Exchange Agreement discussed in Note 13 \u2013 Mezzanine Equity, the shares of common\nstock exchanged for shares of Series B convertible preferred stock were treated as an increase to treasury stock of $ ($\nper share), and then immediately cancelled, thereby reducing treasury stock to zero, with corresponding reductions to common stock of\napproximately $ (the par value of the exchanged common shares) and additional paid-in capital of approximately $.
\n\n\u00a0
\n\nIn\n2021 and 2020, the Company granted and shares of common stock, respectively, to an employee\nfor services in lieu of salary. The fair value of these shares of approximately $in 2021 and $in 2020 was charged to compensation expense.\nOf the shares granted in 2020, shares, with a fair value of approximately $,\nwere yet to be issued at December 31, 2020, and were included in Common Stock Subscribed But Not Issued on the balance sheet at\nthat date.
\n\n\u00a0
\n\nIn\n2021, the Company granted shares of restricted common stock to three employees. The fair value of these restricted shares of\napproximately $ was charged to compensation expense. No shares of restricted common stock were issued in 2020.
\n\n\u00a0
\n\nIn\n2021 and 2020, the Company issued and shares of common stock, respectively, to settle obligations of $51,000 and approximately\n$699,000, respectively. Based on the price of the Company\u2019s common stock on the settlement dates, the Company incurred non-cash\nlosses of approximately $2,500 in 2021 and $45,000 in 2020, which were reflected under Loss On Obligations Settled with Equity on\nthe statement of operations for each period.
\n\n\u00a0
\n\nIn\n2021, the Company issued (i) shares of common stock valued at approximately $1,016,000 in exchange for consulting services,\nand (ii) shares valued at approximately $92,000 to pay for licensing fees. No such services or fees were paid with common stock\nin 2020.
\n\n\u00a0
\n\nIn\n2021, shares\nof common stock were returned to the Company from the adjustment of a previously converted debenture. In 2020, shares of common\nstock granted to employees and shares of common stock issued from the exercise of stock options by a related party, were returned\nby the holders of such common stock.
\n\n\u00a0
\n\nIn 2021, the Company issued shares of common stock as part\nof the purchase price for land and buildings located in Metropolis, IL. stock was issued to purchased fixed assets in 2020.
\n\n\n\u00a0
\n\n\n\n
\n\n
In\n2021 and 2020, the Company issued and shares of common stock, respectively, associated with previously issued subscriptions\non common stock with a value of approximately $5,000 and $1,168,000, respectively.
\n\n\u00a0
\n\n\n\n
As previously disclosed\nin Note 3 \u2013 Acquisitions, the Company issued shares of common stock as part of the purchase price to acquire the remaining\n30.0% ownership interest of MediTaurus.
\n\n\n
\u00a0
\n\nAs\npreviously disclosed in Note 11 \u2013 Promissory Notes, the Company issued (i) shares of common stock in 2020 to extinguish\n$352,000 of principal on the $11.5M Note, (ii) shares common stock in 2020 upon the conversion of $460,050 of principal and\ninterest on the $900k Note, (iii) shares of common stock in 2020 to retire $500,000 of the Existing Notes, (iv) shares\nof common stock in 2021 upon the conversion of approximately $1,010,000 of principal and interest on the $8.8M Note, (v) shares\nof common stock in 2021 upon the conversion of approximately $2,812,000 of principal on the $3.2M Note,
\n\n\u00a0
\n\nAs\npreviously disclosed in Note 12 \u2013 Debentures Payable, the holder of the $21M Debentures converted (i) approximately $10.1\nmillion of principal and interest in 2020 into shares of common stock, and (ii) approximately $1.4 million of principal and\ninterest in 2021 into shares of common stock.
\n\n\u00a0
\n\nAs\nfurther disclosed in Note 15 \u2013 Options, in 2021 and 2020, and shares of common stock, respectively, were\nissued in connection with the exercise of stock options.
\n\n\u00a0
\n\nAs\nfurther disclosed in Note 16 \u2013 Warrants, warrants to purchase shares of common stock were exercised in 2021. \nwarrants were exercised in 2020.
\n\n\u00a0
\n\nCommon\nStock Issuance Obligations
\n\n\u00a0
\n\nAt\nDecember 31, 2020, the Company was obligated to issue shares of common stock, valued at approximately $, in connection with\nstock grants to an employee. These shares were issued in February 2021. The Company had no such obligation at December 31, 2021.
\n\n\u00a0
\n\n\n\n\n\u00a0
\n\n"}]},{"name":"rpt:f-1138","factDimensions":{"xbrl:concept":"us-gaap:CommonStockSharesAuthorized","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"500000000"}]},{"name":"rpt:f-1139","factDimensions":{"xbrl:concept":"us-gaap:CommonStockSharesAuthorized","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"700000000"}]},{"name":"rpt:f-1140","factDimensions":{"xbrl:concept":"us-gaap:CommonStockSharesAuthorized","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:PlanNameAxis":"MRMD:AmendedAndRestatedTwoThousandEighteenStockAwardAndIncentivePlanMember"},"factValues":[{"value":"40000000"}]},{"name":"rpt:f-1141","factDimensions":{"xbrl:concept":"us-gaap:CommonStockSharesAuthorized","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:PlanNameAxis":"MRMD:AmendedAndRestatedTwoThousandEighteenStockAwardAndIncentivePlanMember"},"factValues":[{"value":"70000000"}]},{"name":"rpt:f-1142","factDimensions":{"xbrl:concept":"us-gaap:ConversionOfStockSharesConverted1","xbrl:period":"2020-02-01T00:00:00/2020-03-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:StatementClassOfStockAxis":"MRMD:SeriesBConvertiblePreferredStockMember","us-gaap:TypeOfArrangementAxis":"MRMD:ExchangeAgreementMember","dei:LegalEntityAxis":"MRMD:TwoInstitutionalShareholdersMember"},"factValues":[{"value":"4908333"}]},{"name":"rpt:f-1143","factDimensions":{"xbrl:concept":"us-gaap:TreasuryStockPreferredValue","xbrl:period":"2020-03-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementClassOfStockAxis":"MRMD:SeriesBConvertiblePreferredStockMember","us-gaap:TypeOfArrangementAxis":"MRMD:ExchangeAgreementMember","dei:LegalEntityAxis":"MRMD:TwoInstitutionalShareholdersMember"},"factValues":[{"value":"14725000","decimals":0}]},{"name":"rpt:f-1144","factDimensions":{"xbrl:concept":"us-gaap:SharesIssuedPricePerShare","xbrl:period":"2020-03-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:StatementClassOfStockAxis":"MRMD:SeriesBConvertiblePreferredStockMember","us-gaap:TypeOfArrangementAxis":"MRMD:ExchangeAgreementMember","dei:LegalEntityAxis":"MRMD:TwoInstitutionalShareholdersMember"},"factValues":[{"value":"3.00"}]},{"name":"rpt:f-1145","factDimensions":{"xbrl:concept":"us-gaap:TreasuryStockCommonValue","xbrl:period":"2020-03-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementClassOfStockAxis":"MRMD:SeriesBConvertiblePreferredStockMember","us-gaap:TypeOfArrangementAxis":"MRMD:ExchangeAgreementMember","dei:LegalEntityAxis":"MRMD:TwoInstitutionalShareholdersMember"},"factValues":[{"value":"5000","decimals":0}]},{"name":"rpt:f-1146","factDimensions":{"xbrl:concept":"us-gaap:AdditionalPaidInCapital","xbrl:period":"2020-03-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementClassOfStockAxis":"MRMD:SeriesBConvertiblePreferredStockMember","us-gaap:TypeOfArrangementAxis":"MRMD:ExchangeAgreementMember","dei:LegalEntityAxis":"MRMD:TwoInstitutionalShareholdersMember"},"factValues":[{"value":"14720000","decimals":0}]},{"name":"rpt:f-1147","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:StatementEquityComponentsAxis":"MRMD:CommonStocksMember"},"factValues":[{"value":"11374"}]},{"name":"rpt:f-1148","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:StatementEquityComponentsAxis":"MRMD:CommonStocksMember"},"factValues":[{"value":"109210"}]},{"name":"rpt:f-1149","factDimensions":{"xbrl:concept":"MRMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossValue","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"MRMD:CommonStocksMember"},"factValues":[{"value":"9000","decimals":0}]},{"name":"rpt:f-1150","factDimensions":{"xbrl:concept":"MRMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossValue","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"MRMD:CommonStocksMember"},"factValues":[{"value":"21000","decimals":0}]},{"name":"rpt:f-1151","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:StatementEquityComponentsAxis":"MRMD:CommonStockSubscribedButNotIssuedMember"},"factValues":[{"value":"11413"}]},{"name":"rpt:f-1152","factDimensions":{"xbrl:concept":"MRMD:FairValueOfGrantedShares","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"MRMD:CommonStockSubscribedButNotIssuedMember"},"factValues":[{"value":"5000","decimals":0}]},{"name":"rpt:f-1153","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:RestrictedStockMember"},"factValues":[{"value":"245217"}]},{"name":"rpt:f-1154","factDimensions":{"xbrl:concept":"MRMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossValue","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:AwardTypeAxis":"us-gaap:RestrictedStockMember"},"factValues":[{"value":"226000","decimals":0}]},{"name":"rpt:f-1155","factDimensions":{"xbrl:concept":"MRMD:CommonStockIssuedToSettleObligationsShares","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"us-gaap:CommonStockMember"},"factValues":[{"value":"71691","decimals":0}]},{"name":"rpt:f-1156","factDimensions":{"xbrl:concept":"MRMD:CommonStockIssuedToSettleObligationsShares","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"us-gaap:CommonStockMember"},"factValues":[{"value":"4400000","decimals":0}]},{"name":"rpt:f-1157","factDimensions":{"xbrl:concept":"MRMD:CommonStockIssuedToSettleObligationsValue","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"us-gaap:CommonStockMember"},"factValues":[{"value":"51000","decimals":0}]},{"name":"rpt:f-1158","factDimensions":{"xbrl:concept":"MRMD:CommonStockIssuedToSettleObligationsValue","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"us-gaap:CommonStockMember"},"factValues":[{"value":"699000","decimals":0}]},{"name":"rpt:f-1159","factDimensions":{"xbrl:concept":"us-gaap:LitigationSettlementExpense","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"MRMD:LossOnObligationsSettledWithEquityMember"},"factValues":[{"value":"2500","decimals":0}]},{"name":"rpt:f-1160","factDimensions":{"xbrl:concept":"us-gaap:LitigationSettlementExpense","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"MRMD:LossOnObligationsSettledWithEquityMember"},"factValues":[{"value":"45000","decimals":0}]},{"name":"rpt:f-1161","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodSharesIssuedForServices","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:IncomeStatementLocationAxis":"MRMD:ConsultingServicesMember"},"factValues":[{"value":"1125000"}]},{"name":"rpt:f-1162","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodValueIssuedForServices","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:IncomeStatementLocationAxis":"MRMD:ConsultingServicesMember"},"factValues":[{"value":"1016000","decimals":0}]},{"name":"rpt:f-1163","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodSharesNewIssues","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:IncomeStatementLocationAxis":"MRMD:LicensingFeesMember"},"factValues":[{"value":"109308"}]},{"name":"rpt:f-1164","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodValueNewIssues","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:IncomeStatementLocationAxis":"MRMD:LicensingFeesMember"},"factValues":[{"value":"92000","decimals":0}]},{"name":"rpt:f-1165","factDimensions":{"xbrl:concept":"MRMD:CommonStockShareSubscribedButUnissued","xbrl:period":"2021-08-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"79815","decimals":0}]},{"name":"rpt:f-1166","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:StatementEquityComponentsAxis":"us-gaap:CommonStockMember"},"factValues":[{"value":"90000"}]},{"name":"rpt:f-1167","factDimensions":{"xbrl:concept":"MRMD:StockIssuedDuringPeriodSharesStockOptionsExercised1","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:StatementEquityComponentsAxis":"us-gaap:CommonStockMember"},"factValues":[{"value":"1297447"}]},{"name":"rpt:f-1168","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:StatementEquityComponentsAxis":"us-gaap:CommonStockMember"},"factValues":[{"value":"750000"}]},{"name":"rpt:f-1169","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:StatementEquityComponentsAxis":"us-gaap:CommonStockMember"},"factValues":[{"value":"0"}]},{"name":"rpt:f-1170","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodSharesNewIssues","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:StatementEquityComponentsAxis":"MRMD:PreviouslyIssuedSubscriptionOnCommonStockMember"},"factValues":[{"value":"11413"}]},{"name":"rpt:f-1171","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodSharesNewIssues","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:StatementEquityComponentsAxis":"MRMD:PreviouslyIssuedSubscriptionOnCommonStockMember"},"factValues":[{"value":"3236857"}]},{"name":"rpt:f-1172","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodValueNewIssues","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"MRMD:PreviouslyIssuedSubscriptionOnCommonStockMember"},"factValues":[{"value":"5000","decimals":0}]},{"name":"rpt:f-1173","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodValueNewIssues","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"MRMD:PreviouslyIssuedSubscriptionOnCommonStockMember"},"factValues":[{"value":"1168000","decimals":0}]},{"name":"rpt:f-1174","factDimensions":{"xbrl:concept":"us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction","xbrl:period":"2021-09-01T00:00:00/2021-10-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:BusinessAcquisitionAxis":"MRMD:MeditaurusLLCMember"},"factValues":[{"value":"100000"}]},{"name":"rpt:f-1175","factDimensions":{"xbrl:concept":"us-gaap:EquityMethodInvestmentOwnershipPercentage","xbrl:period":"2021-10-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:BusinessAcquisitionAxis":"MRMD:MeditaurusLLCMember"},"factValues":[{"value":"0.300"}]},{"name":"rpt:f-1176","factDimensions":{"xbrl:concept":"us-gaap:DebtConversionConvertedInstrumentSharesIssued1","xbrl:period":"2020-06-01T00:00:00/2020-07-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"MRMD:ElevenPointFiveMillionNoteMember","us-gaap:TypeOfArrangementAxis":"MRMD:SecondAmendmentAgreementMember"},"factValues":[{"value":"1900000"}]},{"name":"rpt:f-1177","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentFaceAmount","xbrl:period":"2020-07-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:AwardTypeAxis":"MRMD:ElevenPointFiveMillionNoteMember","us-gaap:TypeOfArrangementAxis":"MRMD:SecondAmendmentAgreementMember"},"factValues":[{"value":"352000","decimals":0}]},{"name":"rpt:f-1178","factDimensions":{"xbrl:concept":"us-gaap:DebtConversionConvertedInstrumentSharesIssued1","xbrl:period":"2020-06-01T00:00:00/2020-07-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:TypeOfArrangementAxis":"MRMD:ExtensionAgreementMember","us-gaap:AwardTypeAxis":"MRMD:NineHundredKNoteMember"},"factValues":[{"value":"2525596"}]},{"name":"rpt:f-1179","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentPeriodicPayment","xbrl:period":"2020-06-01T00:00:00/2020-07-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:TypeOfArrangementAxis":"MRMD:ExtensionAgreementMember","us-gaap:AwardTypeAxis":"MRMD:NineHundredKNoteMember"},"factValues":[{"value":"460050","decimals":0}]},{"name":"rpt:f-1180","factDimensions":{"xbrl:concept":"us-gaap:DebtConversionConvertedInstrumentSharesIssued1","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:DebtInstrumentAxis":"MRMD:ExistingNotesMember"},"factValues":[{"value":"1739759"}]},{"name":"rpt:f-1181","factDimensions":{"xbrl:concept":"us-gaap:DebtConversionConvertedInstrumentAmount1","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:ExistingNotesMember"},"factValues":[{"value":"500000","decimals":0}]},{"name":"rpt:f-1182","factDimensions":{"xbrl:concept":"us-gaap:DebtConversionConvertedInstrumentSharesIssued1","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"MRMD:EightPointEightMillionNoteMember"},"factValues":[{"value":"3365972"}]},{"name":"rpt:f-1183","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentPeriodicPayment","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:AwardTypeAxis":"MRMD:EightPointEightMillionNoteMember"},"factValues":[{"value":"1010000","decimals":0}]},{"name":"rpt:f-1184","factDimensions":{"xbrl:concept":"us-gaap:DebtConversionConvertedInstrumentSharesIssued1","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"MRMD:ThreePointTwoMillionNoteMember"},"factValues":[{"value":"8033296"}]},{"name":"rpt:f-1185","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentPeriodicPayment","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:AwardTypeAxis":"MRMD:ThreePointTwoMillionNoteMember"},"factValues":[{"value":"2812000","decimals":0}]},{"name":"rpt:f-1186","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentFaceAmount","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:TwentyOneMillionHoldersMember"},"factValues":[{"value":"10100000","decimals":-5}]},{"name":"rpt:f-1187","factDimensions":{"xbrl:concept":"us-gaap:DebtConversionConvertedInstrumentSharesIssued1","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:DebtInstrumentAxis":"MRMD:TwentyOneMillionHoldersMember"},"factValues":[{"value":"77766559"}]},{"name":"rpt:f-1188","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentFaceAmount","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:TwentyOneMillionHoldersMember"},"factValues":[{"value":"1400000","decimals":-5}]},{"name":"rpt:f-1189","factDimensions":{"xbrl:concept":"us-gaap:DebtConversionConvertedInstrumentSharesIssued1","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:DebtInstrumentAxis":"MRMD:TwentyOneMillionHoldersMember"},"factValues":[{"value":"4610645"}]},{"name":"rpt:f-1190","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:OptionMember","us-gaap:StatementClassOfStockAxis":"us-gaap:CommonStockMember"},"factValues":[{"value":"277373"}]},{"name":"rpt:f-1191","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:OptionMember","us-gaap:StatementClassOfStockAxis":"us-gaap:CommonStockMember"},"factValues":[{"value":"550000"}]},{"name":"rpt:f-1192","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:WarrantMember"},"factValues":[{"value":"980062"}]},{"name":"rpt:f-1193","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:WarrantMember"},"factValues":[{"value":"0"}]},{"name":"rpt:f-1194","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:StatementClassOfStockAxis":"MRMD:CommonStockIssuanceObligationsMember"},"factValues":[{"value":"11413"}]},{"name":"rpt:f-1195","factDimensions":{"xbrl:concept":"MRMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossValue","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementClassOfStockAxis":"MRMD:CommonStockIssuanceObligationsMember"},"factValues":[{"value":"5000","decimals":0}]},{"name":"rpt:f-1196","factDimensions":{"xbrl:concept":"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\n\n\u00a0
\n\nDuring\n2021, the Company granted - and -year options to purchase up to shares of common stock at exercise prices ranging\nfrom $ to $ per share. The fair value of these options of approximately $18,690,000 in the aggregate is being amortized to compensation\nexpense over the respective option vesting periods, of which approximately $ was amortized in 2021. Additionally, compensation\nexpense in 2021 for options issued in previous years, and continuing to be amortized over their respective vesting periods, approximated\n$.
\n\n\u00a0
\n\nDuring\n2020, -year options to purchase up to shares of common stock were issued to employees at exercise prices ranging from $\nto $ per share. The fair value of these options of approximately $501,000 in the aggregate is being amortized to compensation expense\nover their respective vesting periods, of which approximately $ was amortized in 2020. Additionally, compensation expense in 2020\nfor options issued in previous years, and continuing to be amortized over their respective vesting periods, approximated $.
\n\n\u00a0
\n\nDuring\n2021, options to purchase shares of common stock were exercised at prices ranging from $ to $ per share. Of these exercised\noptions, were exercised on a cashless basis with the exercise prices paid via the surrender of shares of common stock.
\n\n\u00a0
\n\nDuring\n2019, options to purchase shares of common stock were exercised at prices ranging from $ to $ per share. Of these exercised\noptions, were exercised on a cashless basis with the exercise prices paid via the surrender of shares of common stock.
\n\n\u00a0
\n\nDuring\n2021 and 2020, options to purchase and shares of common stock, respectively, were forfeited or expired, resulting in\nan aggregate reduction of amortized compensation expense of approximately $42,000 in 2021 and $113,000 in 2020.
\n\n\u00a0
\n\n\n\nSCHEDULE OF STOCK OPTIONS OUTSTANDING AND EXERCISABLE\u00a0
\n\n| Exercise Price | \u00a0 | \u00a0 | \nShares Under Option | \u00a0 | \u00a0 | \nRemaining Life | \u00a0 | |||||||
| per Share | \u00a0 | \u00a0 | \nOutstanding | \u00a0 | \u00a0 | \nExercisable | \u00a0 | \u00a0 | \nin Years | \u00a0 | ||||
| $ | 0.140 | \u00a0 | \u00a0 | \n\u00a0 | 80,000 | \u00a0 | \u00a0 | \n\u00a0 | 80,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.149 | \u00a0 | \u00a0 | \n\u00a0 | 500,000 | \u00a0 | \u00a0 | \n\u00a0 | 500,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.169 | \u00a0 | \u00a0 | \n\u00a0 | 200,000 | \u00a0 | \u00a0 | \n\u00a0 | 200,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.225 | \u00a0 | \u00a0 | \n\u00a0 | 2,000,000 | \u00a0 | \u00a0 | \n\u00a0 | 1,437,500 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.250 | \u00a0 | \u00a0 | \n\u00a0 | 50,000 | \u00a0 | \u00a0 | \n\u00a0 | 50,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.250 | \u00a0 | \u00a0 | \n\u00a0 | 20,000 | \u00a0 | \u00a0 | \n\u00a0 | 20,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.250 | \u00a0 | \u00a0 | \n\u00a0 | 50,000 | \u00a0 | \u00a0 | \n\u00a0 | 25,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.250 | \u00a0 | \u00a0 | \n\u00a0 | 800,000 | \u00a0 | \u00a0 | \n\u00a0 | 800,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.250 | \u00a0 | \u00a0 | \n\u00a0 | 80,000 | \u00a0 | \u00a0 | \n\u00a0 | 80,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.300 | \u00a0 | \u00a0 | \n\u00a0 | 398,000 | \u00a0 | \u00a0 | \n\u00a0 | 398,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.417 | \u00a0 | \u00a0 | \n\u00a0 | 900,000 | \u00a0 | \u00a0 | \n\u00a0 | 900,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.505 | \u00a0 | \u00a0 | \n\u00a0 | 100,000 | \u00a0 | \u00a0 | \n\u00a0 | 75,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.505 | \u00a0 | \u00a0 | \n\u00a0 | 800,000 | \u00a0 | \u00a0 | \n\u00a0 | 300,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.590 | \u00a0 | \u00a0 | \n\u00a0 | 15,000 | \u00a0 | \u00a0 | \n\u00a0 | 15,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.690 | \u00a0 | \u00a0 | \n\u00a0 | 15,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | ||
| $ | 0.693 | \u00a0 | \u00a0 | \n\u00a0 | 500,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | ||
| $ | 0.700 | \u00a0 | \u00a0 | \n\u00a0 | 650,000 | \u00a0 | \u00a0 | \n\u00a0 | 50,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.740 | \u00a0 | \u00a0 | \n\u00a0 | 520,000 | \u00a0 | \u00a0 | \n\u00a0 | 425,625 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.755 | \u00a0 | \u00a0 | \n\u00a0 | 1,050,000 | \u00a0 | \u00a0 | \n\u00a0 | 550,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.770 | \u00a0 | \u00a0 | \n\u00a0 | 200,000 | \u00a0 | \u00a0 | \n\u00a0 | 200,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.800 | \u00a0 | \u00a0 | \n\u00a0 | 25,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | ||
| $ | 0.830 | \u00a0 | \u00a0 | \n\u00a0 | 287,000 | \u00a0 | \u00a0 | \n\u00a0 | 215,250 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.830 | \u00a0 | \u00a0 | \n\u00a0 | 600,000 | \u00a0 | \u00a0 | \n\u00a0 | 150,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.840 | \u00a0 | \u00a0 | \n\u00a0 | 878,921 | \u00a0 | \u00a0 | \n\u00a0 | 600,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.840 | \u00a0 | \u00a0 | \n\u00a0 | 99,000 | \u00a0 | \u00a0 | \n\u00a0 | 39,600 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.850 | \u00a0 | \u00a0 | \n\u00a0 | 90,000 | \u00a0 | \u00a0 | \n\u00a0 | 41,250 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.850 | \u00a0 | \u00a0 | \n\u00a0 | 72,500 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | ||
| $ | 0.870 | \u00a0 | \u00a0 | \n\u00a0 | 250,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | ||
| $ | 0.880 | \u00a0 | \u00a0 | \n\u00a0 | 11,550,000 | \u00a0 | \u00a0 | \n\u00a0 | 5,925,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.880 | \u00a0 | \u00a0 | \n\u00a0 | 15,000 | \u00a0 | \u00a0 | \n\u00a0 | 625 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.880 | \u00a0 | \u00a0 | \n\u00a0 | 410,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | ||
| $ | 0.890 | \u00a0 | \u00a0 | \n\u00a0 | 10,000 | \u00a0 | \u00a0 | \n\u00a0 | 2,500 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.892 | \u00a0 | \u00a0 | \n\u00a0 | 40,000 | \u00a0 | \u00a0 | \n\u00a0 | 20,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.895 | \u00a0 | \u00a0 | \n\u00a0 | 25,000 | \u00a0 | \u00a0 | \n\u00a0 | 18,750 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.898 | \u00a0 | \u00a0 | \n\u00a0 | 11,250,000 | \u00a0 | \u00a0 | \n\u00a0 | 5,625,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.900 | \u00a0 | \u00a0 | \n\u00a0 | 50,000 | \u00a0 | \u00a0 | \n\u00a0 | 50,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.910 | \u00a0 | \u00a0 | \n\u00a0 | 50,000 | \u00a0 | \u00a0 | \n\u00a0 | 50,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.920 | \u00a0 | \u00a0 | \n\u00a0 | 300,000 | \u00a0 | \u00a0 | \n\u00a0 | 18,750 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.928 | \u00a0 | \u00a0 | \n\u00a0 | 500,000 | \u00a0 | \u00a0 | \n\u00a0 | 100,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.950 | \u00a0 | \u00a0 | \n\u00a0 | 50,000 | \u00a0 | \u00a0 | \n\u00a0 | 50,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.970 | \u00a0 | \u00a0 | \n\u00a0 | 100,000 | \u00a0 | \u00a0 | \n\u00a0 | 75,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.983 | \u00a0 | \u00a0 | \n\u00a0 | 145,000 | \u00a0 | \u00a0 | \n\u00a0 | 36,250 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.990 | \u00a0 | \u00a0 | \n\u00a0 | 500,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | ||
| $ | 0.992 | \u00a0 | \u00a0 | \n\u00a0 | 300,000 | \u00a0 | \u00a0 | \n\u00a0 | 300,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 1.000 | \u00a0 | \u00a0 | \n\u00a0 | 15,000 | \u00a0 | \u00a0 | \n\u00a0 | 15,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 1.000 | \u00a0 | \u00a0 | \n\u00a0 | 125,000 | \u00a0 | \u00a0 | \n\u00a0 | 125,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 1.350 | \u00a0 | \u00a0 | \n\u00a0 | 100,000 | \u00a0 | \u00a0 | \n\u00a0 | 100,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 1.950 | \u00a0 | \u00a0 | \n\u00a0 | 375,000 | \u00a0 | \u00a0 | \n\u00a0 | 375,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 2.320 | \u00a0 | \u00a0 | \n\u00a0 | 100,000 | \u00a0 | \u00a0 | \n\u00a0 | 100,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 2.450 | \u00a0 | \u00a0 | \n\u00a0 | 2,000,000 | \u00a0 | \u00a0 | \n\u00a0 | 2,000,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 2.500 | \u00a0 | \u00a0 | \n\u00a0 | 100,000 | \u00a0 | \u00a0 | \n\u00a0 | 100,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 2.650 | \u00a0 | \u00a0 | \n\u00a0 | 200,000 | \u00a0 | \u00a0 | \n\u00a0 | 200,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 2.850 | \u00a0 | \u00a0 | \n\u00a0 | 56,250 | \u00a0 | \u00a0 | \n\u00a0 | 56,250 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 2.850 | \u00a0 | \u00a0 | \n\u00a0 | 100,000 | \u00a0 | \u00a0 | \n\u00a0 | 100,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 3.000 | \u00a0 | \u00a0 | \n\u00a0 | 25,000 | \u00a0 | \u00a0 | \n\u00a0 | 25,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 3.725 | \u00a0 | \u00a0 | \n\u00a0 | 100,000 | \u00a0 | \u00a0 | \n\u00a0 | 100,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \n\u00a0 | 39,821,671 | \u00a0 | \u00a0 | \n\u00a0 | 22,720,350 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 |
\u00a0
\n\n\n\n\n\u00a0
\n\n"}]},{"name":"rpt:f-1197","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","srt:RangeAxis":"srt:MaximumMember","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember"},"factValues":[{"value":"30873921"}]},{"name":"rpt:f-1198","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","srt:RangeAxis":"srt:MinimumMember","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember"},"factValues":[{"value":"0.30"}]},{"name":"rpt:f-1199","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","srt:RangeAxis":"srt:MaximumMember","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember"},"factValues":[{"value":"1.00"}]},{"name":"rpt:f-1200","factDimensions":{"xbrl:concept":"MRMD:FairValueOfOptionsGranted","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember"},"factValues":[{"value":"18690000","decimals":0}]},{"name":"rpt:f-1201","factDimensions":{"xbrl:concept":"MRMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAmortizedFairValue","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember"},"factValues":[{"value":"12281000","decimals":0}]},{"name":"rpt:f-1202","factDimensions":{"xbrl:concept":"us-gaap:AllocatedShareBasedCompensationExpense","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember"},"factValues":[{"value":"235000","decimals":0}]},{"name":"rpt:f-1203","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","srt:RangeAxis":"srt:MaximumMember","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember"},"factValues":[{"value":"4494500"}]},{"name":"rpt:f-1204","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","srt:RangeAxis":"srt:MinimumMember","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember"},"factValues":[{"value":"0.14"}]},{"name":"rpt:f-1205","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","srt:RangeAxis":"srt:MaximumMember","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember"},"factValues":[{"value":"0.30"}]},{"name":"rpt:f-1206","factDimensions":{"xbrl:concept":"MRMD:FairValueOfOptionsGranted","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember"},"factValues":[{"value":"501000","decimals":0}]},{"name":"rpt:f-1207","factDimensions":{"xbrl:concept":"MRMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAmortizedFairValue","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember"},"factValues":[{"value":"282000","decimals":0}]},{"name":"rpt:f-1208","factDimensions":{"xbrl:concept":"us-gaap:AllocatedShareBasedCompensationExpense","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember"},"factValues":[{"value":"801000","decimals":0}]},{"name":"rpt:f-1209","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"MRMD:EmployeeStockOptionOneMember"},"factValues":[{"value":"496000"}]},{"name":"rpt:f-1210","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","srt:RangeAxis":"srt:MinimumMember","us-gaap:AwardTypeAxis":"MRMD:EmployeeStockOptionOneMember"},"factValues":[{"value":"0.14"}]},{"name":"rpt:f-1211","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","srt:RangeAxis":"srt:MaximumMember","us-gaap:AwardTypeAxis":"MRMD:EmployeeStockOptionOneMember"},"factValues":[{"value":"0.63"}]},{"name":"rpt:f-1212","factDimensions":{"xbrl:concept":"MRMD:StockOptionsExercisedCashlessShares","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"MRMD:EmployeeStockOptionOneMember"},"factValues":[{"value":"325000"}]},{"name":"rpt:f-1213","factDimensions":{"xbrl:concept":"MRMD:ExercisePaidSurrenderSharesOfCommonStock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"MRMD:EmployeeStockOptionOneMember"},"factValues":[{"value":"218627"}]},{"name":"rpt:f-1214","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"MRMD:EmployeeStockOptionOneMember"},"factValues":[{"value":"3667499"}]},{"name":"rpt:f-1215","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","srt:RangeAxis":"srt:MinimumMember","us-gaap:AwardTypeAxis":"MRMD:EmployeeStockOptionOneMember"},"factValues":[{"value":"0.8"}]},{"name":"rpt:f-1216","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","srt:RangeAxis":"srt:MaximumMember","us-gaap:AwardTypeAxis":"MRMD:EmployeeStockOptionOneMember"},"factValues":[{"value":"0.77"}]},{"name":"rpt:f-1217","factDimensions":{"xbrl:concept":"MRMD:StockOptionsExercisedCashlessShares","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"MRMD:EmployeeStockOptionOneMember"},"factValues":[{"value":"2167499"}]},{"name":"rpt:f-1218","factDimensions":{"xbrl:concept":"MRMD:ExercisePaidSurrenderSharesOfCommonStock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"MRMD:EmployeeStockOptionOneMember"},"factValues":[{"value":"405691"}]},{"name":"rpt:f-1219","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember"},"factValues":[{"value":"362000"}]},{"name":"rpt:f-1220","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember"},"factValues":[{"value":"200000"}]},{"name":"rpt:f-1221","factDimensions":{"xbrl:concept":"us-gaap:AdjustmentForAmortization","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember"},"factValues":[{"value":"42000","decimals":0}]},{"name":"rpt:f-1222","factDimensions":{"xbrl:concept":"us-gaap:AdjustmentForAmortization","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember"},"factValues":[{"value":"113000","decimals":0}]},{"name":"rpt:f-1223","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\n\nSCHEDULE OF STOCK OPTIONS OUTSTANDING AND EXERCISABLE\u00a0
\n\n| Exercise Price | \u00a0 | \u00a0 | \nShares Under Option | \u00a0 | \u00a0 | \nRemaining Life | \u00a0 | |||||||
| per Share | \u00a0 | \u00a0 | \nOutstanding | \u00a0 | \u00a0 | \nExercisable | \u00a0 | \u00a0 | \nin Years | \u00a0 | ||||
| $ | 0.140 | \u00a0 | \u00a0 | \n\u00a0 | 80,000 | \u00a0 | \u00a0 | \n\u00a0 | 80,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.149 | \u00a0 | \u00a0 | \n\u00a0 | 500,000 | \u00a0 | \u00a0 | \n\u00a0 | 500,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.169 | \u00a0 | \u00a0 | \n\u00a0 | 200,000 | \u00a0 | \u00a0 | \n\u00a0 | 200,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.225 | \u00a0 | \u00a0 | \n\u00a0 | 2,000,000 | \u00a0 | \u00a0 | \n\u00a0 | 1,437,500 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.250 | \u00a0 | \u00a0 | \n\u00a0 | 50,000 | \u00a0 | \u00a0 | \n\u00a0 | 50,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.250 | \u00a0 | \u00a0 | \n\u00a0 | 20,000 | \u00a0 | \u00a0 | \n\u00a0 | 20,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.250 | \u00a0 | \u00a0 | \n\u00a0 | 50,000 | \u00a0 | \u00a0 | \n\u00a0 | 25,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.250 | \u00a0 | \u00a0 | \n\u00a0 | 800,000 | \u00a0 | \u00a0 | \n\u00a0 | 800,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.250 | \u00a0 | \u00a0 | \n\u00a0 | 80,000 | \u00a0 | \u00a0 | \n\u00a0 | 80,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.300 | \u00a0 | \u00a0 | \n\u00a0 | 398,000 | \u00a0 | \u00a0 | \n\u00a0 | 398,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.417 | \u00a0 | \u00a0 | \n\u00a0 | 900,000 | \u00a0 | \u00a0 | \n\u00a0 | 900,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.505 | \u00a0 | \u00a0 | \n\u00a0 | 100,000 | \u00a0 | \u00a0 | \n\u00a0 | 75,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.505 | \u00a0 | \u00a0 | \n\u00a0 | 800,000 | \u00a0 | \u00a0 | \n\u00a0 | 300,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.590 | \u00a0 | \u00a0 | \n\u00a0 | 15,000 | \u00a0 | \u00a0 | \n\u00a0 | 15,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.690 | \u00a0 | \u00a0 | \n\u00a0 | 15,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | ||
| $ | 0.693 | \u00a0 | \u00a0 | \n\u00a0 | 500,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | ||
| $ | 0.700 | \u00a0 | \u00a0 | \n\u00a0 | 650,000 | \u00a0 | \u00a0 | \n\u00a0 | 50,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.740 | \u00a0 | \u00a0 | \n\u00a0 | 520,000 | \u00a0 | \u00a0 | \n\u00a0 | 425,625 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.755 | \u00a0 | \u00a0 | \n\u00a0 | 1,050,000 | \u00a0 | \u00a0 | \n\u00a0 | 550,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.770 | \u00a0 | \u00a0 | \n\u00a0 | 200,000 | \u00a0 | \u00a0 | \n\u00a0 | 200,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.800 | \u00a0 | \u00a0 | \n\u00a0 | 25,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | ||
| $ | 0.830 | \u00a0 | \u00a0 | \n\u00a0 | 287,000 | \u00a0 | \u00a0 | \n\u00a0 | 215,250 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.830 | \u00a0 | \u00a0 | \n\u00a0 | 600,000 | \u00a0 | \u00a0 | \n\u00a0 | 150,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.840 | \u00a0 | \u00a0 | \n\u00a0 | 878,921 | \u00a0 | \u00a0 | \n\u00a0 | 600,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.840 | \u00a0 | \u00a0 | \n\u00a0 | 99,000 | \u00a0 | \u00a0 | \n\u00a0 | 39,600 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.850 | \u00a0 | \u00a0 | \n\u00a0 | 90,000 | \u00a0 | \u00a0 | \n\u00a0 | 41,250 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.850 | \u00a0 | \u00a0 | \n\u00a0 | 72,500 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | ||
| $ | 0.870 | \u00a0 | \u00a0 | \n\u00a0 | 250,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | ||
| $ | 0.880 | \u00a0 | \u00a0 | \n\u00a0 | 11,550,000 | \u00a0 | \u00a0 | \n\u00a0 | 5,925,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.880 | \u00a0 | \u00a0 | \n\u00a0 | 15,000 | \u00a0 | \u00a0 | \n\u00a0 | 625 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.880 | \u00a0 | \u00a0 | \n\u00a0 | 410,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | ||
| $ | 0.890 | \u00a0 | \u00a0 | \n\u00a0 | 10,000 | \u00a0 | \u00a0 | \n\u00a0 | 2,500 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.892 | \u00a0 | \u00a0 | \n\u00a0 | 40,000 | \u00a0 | \u00a0 | \n\u00a0 | 20,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.895 | \u00a0 | \u00a0 | \n\u00a0 | 25,000 | \u00a0 | \u00a0 | \n\u00a0 | 18,750 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.898 | \u00a0 | \u00a0 | \n\u00a0 | 11,250,000 | \u00a0 | \u00a0 | \n\u00a0 | 5,625,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.900 | \u00a0 | \u00a0 | \n\u00a0 | 50,000 | \u00a0 | \u00a0 | \n\u00a0 | 50,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.910 | \u00a0 | \u00a0 | \n\u00a0 | 50,000 | \u00a0 | \u00a0 | \n\u00a0 | 50,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.920 | \u00a0 | \u00a0 | \n\u00a0 | 300,000 | \u00a0 | \u00a0 | \n\u00a0 | 18,750 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.928 | \u00a0 | \u00a0 | \n\u00a0 | 500,000 | \u00a0 | \u00a0 | \n\u00a0 | 100,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.950 | \u00a0 | \u00a0 | \n\u00a0 | 50,000 | \u00a0 | \u00a0 | \n\u00a0 | 50,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.970 | \u00a0 | \u00a0 | \n\u00a0 | 100,000 | \u00a0 | \u00a0 | \n\u00a0 | 75,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.983 | \u00a0 | \u00a0 | \n\u00a0 | 145,000 | \u00a0 | \u00a0 | \n\u00a0 | 36,250 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 0.990 | \u00a0 | \u00a0 | \n\u00a0 | 500,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | ||
| $ | 0.992 | \u00a0 | \u00a0 | \n\u00a0 | 300,000 | \u00a0 | \u00a0 | \n\u00a0 | 300,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 1.000 | \u00a0 | \u00a0 | \n\u00a0 | 15,000 | \u00a0 | \u00a0 | \n\u00a0 | 15,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 1.000 | \u00a0 | \u00a0 | \n\u00a0 | 125,000 | \u00a0 | \u00a0 | \n\u00a0 | 125,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 1.350 | \u00a0 | \u00a0 | \n\u00a0 | 100,000 | \u00a0 | \u00a0 | \n\u00a0 | 100,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 1.950 | \u00a0 | \u00a0 | \n\u00a0 | 375,000 | \u00a0 | \u00a0 | \n\u00a0 | 375,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 2.320 | \u00a0 | \u00a0 | \n\u00a0 | 100,000 | \u00a0 | \u00a0 | \n\u00a0 | 100,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 2.450 | \u00a0 | \u00a0 | \n\u00a0 | 2,000,000 | \u00a0 | \u00a0 | \n\u00a0 | 2,000,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 2.500 | \u00a0 | \u00a0 | \n\u00a0 | 100,000 | \u00a0 | \u00a0 | \n\u00a0 | 100,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 2.650 | \u00a0 | \u00a0 | \n\u00a0 | 200,000 | \u00a0 | \u00a0 | \n\u00a0 | 200,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 2.850 | \u00a0 | \u00a0 | \n\u00a0 | 56,250 | \u00a0 | \u00a0 | \n\u00a0 | 56,250 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 2.850 | \u00a0 | \u00a0 | \n\u00a0 | 100,000 | \u00a0 | \u00a0 | \n\u00a0 | 100,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 3.000 | \u00a0 | \u00a0 | \n\u00a0 | 25,000 | \u00a0 | \u00a0 | \n\u00a0 | 25,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| $ | 3.725 | \u00a0 | \u00a0 | \n\u00a0 | 100,000 | \u00a0 | \u00a0 | \n\u00a0 | 100,000 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \n\u00a0 | 39,821,671 | \u00a0 | \u00a0 | \n\u00a0 | 22,720,350 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 |
NOTE\n16 \u2013 WARRANTS
\n\n\u00a0
\n\nDuring\n2021, the Company issued warrants to Hadron to purchase up to 15,540,540 shares of common stock at an exercise price of $1.087 per share,\nexpiring four years from issuance, as part of the Hadron transaction previously discussed in Note 13 \u2013 Mezzanine Equity.\nThe fair value of these warrants on the issuance date of approximately $9.5 million was allocated to the warrant of the $23.0 million\nof proceeds from the Hadron transaction and recorded in additional paid in capital. Also during 2021, the Company issued warrants to\npurchase up to 2,100,000 shares of common stock at exercise prices ranging from $0.50 to $0.83 per share, expiring three and five years\nfrom issuance. The fair value of these warrants on their issuance dates approximated $1,487,000 in the aggregate which was charged to\ncompensation expense.
\n\n\u00a0
\n\nDuring\n2020, in conjunction with the $21M Debentures discussed in Note 12 \u2013 Debentures Payable, the Company issued -year warrants\nto purchase up to 180,000 shares of common stock at an exercise price of $0.75 per share. Also during 2020, as discussed in Note 11\u2013\nPromissory Notes, (i) in conjunction with the $8.8M Note, the Company issued -year warrants to purchase up to 750,000 shares\nof common stock at an exercise price of $0.50 per share, and (ii) in consideration of the Second Extension Agreement, the Company issued\n-year warrants to purchase up to 5,000,000 shares of the Company\u2019s common stock at an exercise price of $0.25 per share. The\nfair value of these warrants on their issuance dates approximated $639,000 in the aggregate, of which approximately $10,000 was amortized\nto interest expense in the period and the remainder to be amortized over the terms of the respective debt instruments.
\n\n\u00a0
\n\nDuring\n2021, warrants to purchase 1,237,500 shares of common stock were exercised at exercise prices ranging from $0.11 to $0.55 per share.\nOf these exercised warrants, were exercised on a cashless basis with the exercise prices paid via the surrender of shares\nof common stock. No warrants were exercised in 2020.
\n\n\u00a0
\n\nDuring\n2021, warrants to purchase 6,968,637 shares of common stock with exercise prices ranging from $0.90 to $5.50 per share were forfeited\nor expired. During 2020, warrants to purchase 817,939 shares of common stock with exercise prices ranging from $0.40 to $2.25 per share\nwere forfeited or expired.
\n\n\u00a0
\n\nAt\nDecember 31, 2021 and 2020, warrants to purchase up to 26,351,571 and 16,917,168 shares of common stock, respectively, were outstanding\nwith exercise prices ranging from $0.11 to $5.50 per share across both periods.
\n\n\u00a0
\n\n"}]},{"name":"rpt:f-1444","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"MRMD:WarrantOneMember"},"factValues":[{"value":"15540540"}]},{"name":"rpt:f-1445","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:AwardTypeAxis":"MRMD:WarrantOneMember"},"factValues":[{"value":"1.087"}]},{"name":"rpt:f-1446","factDimensions":{"xbrl:concept":"us-gaap:FairValueAdjustmentOfWarrants","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:AwardTypeAxis":"MRMD:WarrantOneMember"},"factValues":[{"value":"9500000","decimals":-5}]},{"name":"rpt:f-1447","factDimensions":{"xbrl:concept":"us-gaap:ProceedsFromIssuanceOfWarrants","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:AwardTypeAxis":"MRMD:WarrantOneMember"},"factValues":[{"value":"23000000.0","decimals":-5}]},{"name":"rpt:f-1448","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"MRMD:WarrantTwoMember"},"factValues":[{"value":"2100000"}]},{"name":"rpt:f-1449","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","srt:RangeAxis":"srt:MinimumMember","us-gaap:AwardTypeAxis":"MRMD:WarrantTwoMember"},"factValues":[{"value":"0.50"}]},{"name":"rpt:f-1450","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","srt:RangeAxis":"srt:MaximumMember","us-gaap:AwardTypeAxis":"MRMD:WarrantTwoMember"},"factValues":[{"value":"0.83"}]},{"name":"rpt:f-1451","factDimensions":{"xbrl:concept":"us-gaap:FairValueAdjustmentOfWarrants","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:AwardTypeAxis":"MRMD:WarrantTwoMember"},"factValues":[{"value":"1487000","decimals":0}]},{"name":"rpt:f-1452","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:DebtInstrumentAxis":"MRMD:DebenturePayableMember"},"factValues":[{"value":"180000"}]},{"name":"rpt:f-1453","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:DebtInstrumentAxis":"MRMD:DebenturePayableMember"},"factValues":[{"value":"0.75"}]},{"name":"rpt:f-1454","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:DebtInstrumentAxis":"MRMD:EightPointEightMillionMember"},"factValues":[{"value":"750000"}]},{"name":"rpt:f-1455","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:DebtInstrumentAxis":"MRMD:EightPointEightMillionMember"},"factValues":[{"value":"0.50"}]},{"name":"rpt:f-1456","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:DebtInstrumentAxis":"MRMD:PromissoryNotesMember","us-gaap:TypeOfArrangementAxis":"MRMD:SecondExtensionAgreementMember"},"factValues":[{"value":"5000000"}]},{"name":"rpt:f-1457","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:DebtInstrumentAxis":"MRMD:PromissoryNotesMember","us-gaap:TypeOfArrangementAxis":"MRMD:SecondExtensionAgreementMember"},"factValues":[{"value":"0.25"}]},{"name":"rpt:f-1458","factDimensions":{"xbrl:concept":"us-gaap:FairValueAdjustmentOfWarrants","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:DebenturePayableMember"},"factValues":[{"value":"639000","decimals":0}]},{"name":"rpt:f-1459","factDimensions":{"xbrl:concept":"us-gaap:AdjustmentForAmortization","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:DebenturePayableMember"},"factValues":[{"value":"10000","decimals":0}]},{"name":"rpt:f-1460","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:StatementEquityComponentsAxis":"MRMD:WarrantExercisedMember"},"factValues":[{"value":"1237500"}]},{"name":"rpt:f-1461","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:StatementEquityComponentsAxis":"MRMD:WarrantExercisedMember","srt:RangeAxis":"srt:MinimumMember"},"factValues":[{"value":"0.11"}]},{"name":"rpt:f-1462","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:StatementEquityComponentsAxis":"MRMD:WarrantExercisedMember","srt:RangeAxis":"srt:MaximumMember"},"factValues":[{"value":"0.55"}]},{"name":"rpt:f-1463","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:StatementEquityComponentsAxis":"MRMD:WarrantExercisedMember"},"factValues":[{"value":"437500"}]},{"name":"rpt:f-1464","factDimensions":{"xbrl:concept":"MRMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsSurrender","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:StatementEquityComponentsAxis":"MRMD:WarrantExercisedMember"},"factValues":[{"value":"257438"}]},{"name":"rpt:f-1465","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:StatementEquityComponentsAxis":"MRMD:WarrantForfeitedMember"},"factValues":[{"value":"6968637"}]},{"name":"rpt:f-1466","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:StatementEquityComponentsAxis":"MRMD:WarrantForfeitedMember","srt:RangeAxis":"srt:MinimumMember"},"factValues":[{"value":"0.90"}]},{"name":"rpt:f-1467","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:StatementEquityComponentsAxis":"MRMD:WarrantForfeitedMember","srt:RangeAxis":"srt:MaximumMember"},"factValues":[{"value":"5.50"}]},{"name":"rpt:f-1468","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:StatementEquityComponentsAxis":"MRMD:WarrantForfeitedMember"},"factValues":[{"value":"817939"}]},{"name":"rpt:f-1469","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:StatementEquityComponentsAxis":"MRMD:WarrantForfeitedMember","srt:RangeAxis":"srt:MinimumMember"},"factValues":[{"value":"0.40"}]},{"name":"rpt:f-1470","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:StatementEquityComponentsAxis":"MRMD:WarrantForfeitedMember","srt:RangeAxis":"srt:MaximumMember"},"factValues":[{"value":"2.25"}]},{"name":"rpt:f-1471","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:StatementEquityComponentsAxis":"us-gaap:CommonStockMember"},"factValues":[{"value":"26351571"}]},{"name":"rpt:f-1472","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:StatementEquityComponentsAxis":"us-gaap:CommonStockMember"},"factValues":[{"value":"16917168"}]},{"name":"rpt:f-1473","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","srt:RangeAxis":"srt:MinimumMember","us-gaap:StatementEquityComponentsAxis":"us-gaap:CommonStockMember"},"factValues":[{"value":"0.11"}]},{"name":"rpt:f-1474","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","srt:RangeAxis":"srt:MinimumMember","us-gaap:StatementEquityComponentsAxis":"us-gaap:CommonStockMember"},"factValues":[{"value":"0.11"}]},{"name":"rpt:f-1475","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","srt:RangeAxis":"srt:MaximumMember","us-gaap:StatementEquityComponentsAxis":"us-gaap:CommonStockMember"},"factValues":[{"value":"5.50"}]},{"name":"rpt:f-1476","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","srt:RangeAxis":"srt:MaximumMember","us-gaap:StatementEquityComponentsAxis":"us-gaap:CommonStockMember"},"factValues":[{"value":"5.50"}]},{"name":"rpt:f-1477","factDimensions":{"xbrl:concept":"us-gaap:RevenueFromContractWithCustomerTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"NOTE\n17 \u2013 REVENUES
\n\n\u00a0
\n\nFor\nthe years ended December 31, 2021 and 2020, the Company\u2019s revenues were comprised of the following major categories:
\n\n\u00a0SCHEDULE OF REVENUES COMPRISED OF MAJOR CATEGORIES
\n\n| \u00a0 | \u00a0 | \n2021 | \u00a0 | \u00a0 | \n2020 | \u00a0 | ||
| Product sales - retail | \u00a0 | \n$ | 82,127,513 | \u00a0 | \u00a0 | \n$ | 28,980,763 | \u00a0 |
| Product sales - wholesale | \u00a0 | \n\u00a0 | 26,118,751 | \u00a0 | \u00a0 | \n\u00a0 | 10,419,963 | \u00a0 |
| Real estate rentals | \u00a0 | \n\u00a0 | 6,548,047 | \u00a0 | \u00a0 | \n\u00a0 | 6,776,697 | \u00a0 |
| Management fees | \u00a0 | \n\u00a0 | 3,078,925 | \u00a0 | \u00a0 | \n\u00a0 | 1,481,897 | \u00a0 |
| Supply procurement | \u00a0 | \n\u00a0 | 2,107,969 | \u00a0 | \u00a0 | \n\u00a0 | 1,549,856 | \u00a0 |
| Licensing fees | \u00a0 | \n\u00a0 | 1,482,648 | \u00a0 | \u00a0 | \n\u00a0 | 1,684,792 | \u00a0 |
| Other | \u00a0 | \n\u00a0 | 305 | \u00a0 | \u00a0 | \n\u00a0 | 1,183 | \u00a0 |
| Total revenues | \u00a0 | \n$ | 121,464,158 | \u00a0 | \u00a0 | \n$ | 50,895,151 | \u00a0 |
\u00a0
\n\nFor\nthe years ended December 31, 2021 and 2020, revenues from two clients represented 11%\nand 20%,\nrespectively, of total revenues.
\n\n\u00a0
\n\n\n\n\n\u00a0
\n\n"}]},{"name":"rpt:f-1478","factDimensions":{"xbrl:concept":"us-gaap:DisaggregationOfRevenueTableTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"For\nthe years ended December 31, 2021 and 2020, the Company\u2019s revenues were comprised of the following major categories:
\n\n\u00a0SCHEDULE OF REVENUES COMPRISED OF MAJOR CATEGORIES
\n\n| \u00a0 | \u00a0 | \n2021 | \u00a0 | \u00a0 | \n2020 | \u00a0 | ||
| Product sales - retail | \u00a0 | \n$ | 82,127,513 | \u00a0 | \u00a0 | \n$ | 28,980,763 | \u00a0 |
| Product sales - wholesale | \u00a0 | \n\u00a0 | 26,118,751 | \u00a0 | \u00a0 | \n\u00a0 | 10,419,963 | \u00a0 |
| Real estate rentals | \u00a0 | \n\u00a0 | 6,548,047 | \u00a0 | \u00a0 | \n\u00a0 | 6,776,697 | \u00a0 |
| Management fees | \u00a0 | \n\u00a0 | 3,078,925 | \u00a0 | \u00a0 | \n\u00a0 | 1,481,897 | \u00a0 |
| Supply procurement | \u00a0 | \n\u00a0 | 2,107,969 | \u00a0 | \u00a0 | \n\u00a0 | 1,549,856 | \u00a0 |
| Licensing fees | \u00a0 | \n\u00a0 | 1,482,648 | \u00a0 | \u00a0 | \n\u00a0 | 1,684,792 | \u00a0 |
| Other | \u00a0 | \n\u00a0 | 305 | \u00a0 | \u00a0 | \n\u00a0 | 1,183 | \u00a0 |
| Total revenues | \u00a0 | \n$ | 121,464,158 | \u00a0 | \u00a0 | \n$ | 50,895,151 | \u00a0 |
NOTE\n18 \u2013 BAD DEBTS
\n\n\u00a0
\n\nThe\nCompany maintains two types of reserves to address uncertain collections of amounts due\u2014an allowance against trade accounts receivable\n(the \u201cAR Allowance\u201d), and a reserve against cash advanced by the Company to its cannabis-licensed clients for working capital\npurposes (the WC Reserve\u201d).
\n\n\u00a0
\n\nDuring\n2021, the Company increased (i) the AR Allowance by $1,400,000,\nas a general reserves against aging receivable balances, and (ii) the WC Reserve by approximately $462,000,\nto reserve the working capital balance of Harvest. During 2020, the Company increased (i) the AR Allowance by $500,000,\nwhich was comprised of increases to the specific allowances against Kind and Harvest receivables of approximately $790,000\nand $76,000,\nrespectively, offset by a reduction to the general allowance of approximately $366,000,\nand (ii) the WC Reserve by approximately $482,000,\nto reserve the working capital balance of Harvest. The increases to the AR Allowance and WC Reserve were charged to Bad Debts\non the statement of operations for the year ended December 31, 2020
\n\n\u00a0
\n\n"}]},{"name":"rpt:f-1498","factDimensions":{"xbrl:concept":"us-gaap:AllowanceForDoubtfulAccountsReceivable","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:AwardTypeAxis":"MRMD:ARAllowanceMember"},"factValues":[{"value":"1400000","decimals":0}]},{"name":"rpt:f-1499","factDimensions":{"xbrl:concept":"MRMD:IncreaseInReserveWorkingCapital","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:AwardTypeAxis":"MRMD:ARAllowanceMember"},"factValues":[{"value":"462000","decimals":0}]},{"name":"rpt:f-1500","factDimensions":{"xbrl:concept":"us-gaap:AllowanceForDoubtfulAccountsReceivable","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:AwardTypeAxis":"MRMD:ARAllowanceMember"},"factValues":[{"value":"500000","decimals":0}]},{"name":"rpt:f-1501","factDimensions":{"xbrl:concept":"us-gaap:AllowanceForDoubtfulAccountsReceivable","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:AwardTypeAxis":"MRMD:ARAllowanceMember","us-gaap:RelatedPartyTransactionsByRelatedPartyAxis":"MRMD:KindReceivablesMember"},"factValues":[{"value":"790000","decimals":0}]},{"name":"rpt:f-1502","factDimensions":{"xbrl:concept":"us-gaap:AllowanceForDoubtfulAccountsReceivable","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:AwardTypeAxis":"MRMD:ARAllowanceMember","us-gaap:RelatedPartyTransactionsByRelatedPartyAxis":"MRMD:HarvestReceivablesMember"},"factValues":[{"value":"76000","decimals":0}]},{"name":"rpt:f-1503","factDimensions":{"xbrl:concept":"us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"366000","decimals":0}]},{"name":"rpt:f-1504","factDimensions":{"xbrl:concept":"MRMD:IncreaseInReserveWorkingCapital","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:AwardTypeAxis":"MRMD:ARAllowanceMember"},"factValues":[{"value":"482000","decimals":0}]},{"name":"rpt:f-1505","factDimensions":{"xbrl:concept":"us-gaap:IncomeTaxDisclosureTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"NOTE\n19 \u2013 INCOME TAXES
\n\n\u00a0
\n\nAt\nDecember 31, 2021 and 2020, the Company\u2019s cumulative federal net operating losses were approximately $24.0\nmillion and $10.6 million,\nrespectively. At December 31, 2021, the Company recorded a provision for income taxes of approximately $16.2\nmillion, due in part to the aforementioned impact of Section 280E of the Internal Revenue Code, which prohibits the deduction\ncertain ordinary business expenses. At December 31, 2020, no income tax provision was recorded.
\n\n\u00a0
\n\nThe\nreconciliations between the Company\u2019s effective tax rates and the statutory tax rate for the years ended December 31, 2021 and\n2020 were as follows:
\n\n\u00a0SCHEDULE OF RECONCILIATION OF INCOME TAXES
\n\n| \u00a0 | \u00a0 | \n2021 | \u00a0 | \u00a0 | \n2020 | \u00a0 | \n||
| U.S federal taxes at the statutory rate | \u00a0 | \n\u00a0 | 21.0 | % | \u00a0 | \n\u00a0 | 21.0 | % | \n
| State taxes net of federal benefit | \u00a0 | \n\u00a0 | 16.5 | % | \u00a0 | \n\u00a0 | 46.0 | % | \n
| Section 280E adjustment | \u00a0 | \n\u00a0 | 14.7 | % | \u00a0 | \n\u00a0 | 43.6 | % |
| Stock based compensation | \u00a0 | \n\u00a0 | 10.5 | % | \u00a0 | \n\u00a0 | 30.0 | % |
| Other | \u00a0 | \n\u00a0 | 0.9 | % | \u00a0 | \n\u00a0 | (1.0 | )% |
| Valuation allowance | \u00a0 | \n\u00a0 | 0.0 | % | \u00a0 | \n\u00a0 | (93.6 | )% | \n
| Total | \u00a0 | \n\u00a0 | 63.6 | % | \u00a0 | \n\u00a0 | 46.0 | % | \n
\u00a0
\n\nThe\napproximate income tax effect of the Company\u2019s loss carryforwards and temporary differences at December 31, 2021 and 2020 were\nas follows:
\n\n\u00a0SCHEDULE OF DEFERRED TAX ASSET
\n\n| \u00a0 | \n\u00a0 | \n2021 | \n\u00a0 | \n\u00a0 | \n2020 | \n\u00a0 | ||
| Deferred\n tax assets: | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 |
| Net operating\n loss carryforwards | \n\u00a0 | \n$ | \n6,981,492 | \n\u00a0 | \n\u00a0 | \n\n | 2,235,987 | \n\u00a0 |
| Allowance for doubtful\n accounts | \n\u00a0 | \n\u00a0 | \n11,810,425 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n11,400,555 | \n\u00a0 |
| Stock compensation | \n\u00a0 | \n\u00a0 | \n2,556,946 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n2,758,541 | \n\u00a0 |
| Loss on equity investments | \n\u00a0 | \n\u00a0 | \n8,632,902 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n8,629,490 | \n\u00a0 |
| Goodwill writeoffs | \n\u00a0 | \n\u00a0 | \n1,262,877 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n1,138,419 | \n\u00a0 |
| Change in fair value of\n investments | \n\u00a0 | \n\u00a0 | \n598,957 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n282,291 | \n\u00a0 |
| Lease payments | \n\u00a0 | \n\u00a0 | \n170,543 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n151,936 | \n\u00a0 |
| Reserves | \n\u00a0 | \n\u00a0 | \n147,982 | \n\u00a0 | \n\u00a0 | \n\n | - | \n\u00a0 |
| Deferred tax liabilities: | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 |
| Depreciation | \n\u00a0 | \n\u00a0 | \n(2,520,188 | \n) | \n\u00a0 | \n\u00a0 | \n(1,717,596 | \n ) |
| Real estate revenue | \n\u00a0 | \n\u00a0 | \n(999,739 | \n ) | \n\u00a0 | \n\u00a0 | \n(997,590 | \n ) |
| Net deferred tax asset | \n\u00a0 | \n\u00a0 | \n28,642,197 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n23,882,033 | \n\u00a0 |
| Valuation\n allowance | \n\u00a0 | \n\u00a0 | \n(28,642,197 | \n) | \n\u00a0 | \n\u00a0 | \n(23,882,033 | \n ) |
| Total | \n\u00a0 | \n$ | \n- | \n\u00a0 | \n\u00a0 | \n$ | \n\n | \u00a0 |
\u00a0
\n\n\n\n\n\u00a0
\n\nFederal\nnet operating losses carryforward indefinitely, subject to an annual limitation of 80%\nof taxable income, while state net operating losses expire\nat various dates beginning in 2031. These tax\nattributes are subject to an annual limitation from equity shifts, which constitute a change of ownership as defined under IRC Section\n382. The Company recorded a valuation allowance against its net deferred tax assets at December 31, 2021 and 2020 due to\nthe uncertainty regarding the realization of such assets. The Company\u2019s assessment of the realization of its deferred tax assets\nof future periods may differ in light of changing circumstances.
\n\n\n\n
\u00a0
\n\nThe\nCompany files income tax returns in the U.S. federal tax jurisdiction and various state jurisdictions. The Company is currently open\nto examination under the statute of limitations by the Internal Revenue Service and state jurisdictions for the tax years ended 2017\nthrough 2020.
\n\n\u00a0
\n\n\n\n\n\u00a0
\n\n"}]},{"name":"rpt:f-1506","factDimensions":{"xbrl:concept":"us-gaap:OperatingLossCarryforwards","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:IncomeTaxAuthorityAxis":"us-gaap:DomesticCountryMember"},"factValues":[{"value":"24000000.0","decimals":-5}]},{"name":"rpt:f-1507","factDimensions":{"xbrl:concept":"us-gaap:OperatingLossCarryforwards","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"10600000","decimals":-5}]},{"name":"rpt:f-1508","factDimensions":{"xbrl:concept":"us-gaap:OperatingLossCarryforwards","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:IncomeTaxAuthorityAxis":"us-gaap:DomesticCountryMember"},"factValues":[{"value":"10600000","decimals":-5}]},{"name":"rpt:f-1509","factDimensions":{"xbrl:concept":"us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:IncomeTaxAuthorityAxis":"us-gaap:DomesticCountryMember"},"factValues":[{"value":"16200000","decimals":-5}]},{"name":"rpt:f-1510","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"The\nreconciliations between the Company\u2019s effective tax rates and the statutory tax rate for the years ended December 31, 2021 and\n2020 were as follows:
\n\n\u00a0SCHEDULE OF RECONCILIATION OF INCOME TAXES
\n\n| \u00a0 | \u00a0 | \n2021 | \u00a0 | \u00a0 | \n2020 | \u00a0 | \n||
| U.S federal taxes at the statutory rate | \u00a0 | \n\u00a0 | 21.0 | % | \u00a0 | \n\u00a0 | 21.0 | % | \n
| State taxes net of federal benefit | \u00a0 | \n\u00a0 | 16.5 | % | \u00a0 | \n\u00a0 | 46.0 | % | \n
| Section 280E adjustment | \u00a0 | \n\u00a0 | 14.7 | % | \u00a0 | \n\u00a0 | 43.6 | % |
| Stock based compensation | \u00a0 | \n\u00a0 | 10.5 | % | \u00a0 | \n\u00a0 | 30.0 | % |
| Other | \u00a0 | \n\u00a0 | 0.9 | % | \u00a0 | \n\u00a0 | (1.0 | )% |
| Valuation allowance | \u00a0 | \n\u00a0 | 0.0 | % | \u00a0 | \n\u00a0 | (93.6 | )% | \n
| Total | \u00a0 | \n\u00a0 | 63.6 | % | \u00a0 | \n\u00a0 | 46.0 | % | \n
The\napproximate income tax effect of the Company\u2019s loss carryforwards and temporary differences at December 31, 2021 and 2020 were\nas follows:
\n\n\u00a0SCHEDULE OF DEFERRED TAX ASSET
\n\n| \u00a0 | \n\u00a0 | \n2021 | \n\u00a0 | \n\u00a0 | \n2020 | \n\u00a0 | ||
| Deferred\n tax assets: | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 |
| Net operating\n loss carryforwards | \n\u00a0 | \n$ | \n6,981,492 | \n\u00a0 | \n\u00a0 | \n\n | 2,235,987 | \n\u00a0 |
| Allowance for doubtful\n accounts | \n\u00a0 | \n\u00a0 | \n11,810,425 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n11,400,555 | \n\u00a0 |
| Stock compensation | \n\u00a0 | \n\u00a0 | \n2,556,946 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n2,758,541 | \n\u00a0 |
| Loss on equity investments | \n\u00a0 | \n\u00a0 | \n8,632,902 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n8,629,490 | \n\u00a0 |
| Goodwill writeoffs | \n\u00a0 | \n\u00a0 | \n1,262,877 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n1,138,419 | \n\u00a0 |
| Change in fair value of\n investments | \n\u00a0 | \n\u00a0 | \n598,957 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n282,291 | \n\u00a0 |
| Lease payments | \n\u00a0 | \n\u00a0 | \n170,543 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n151,936 | \n\u00a0 |
| Reserves | \n\u00a0 | \n\u00a0 | \n147,982 | \n\u00a0 | \n\u00a0 | \n\n | - | \n\u00a0 |
| Deferred tax liabilities: | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 |
| Depreciation | \n\u00a0 | \n\u00a0 | \n(2,520,188 | \n) | \n\u00a0 | \n\u00a0 | \n(1,717,596 | \n ) |
| Real estate revenue | \n\u00a0 | \n\u00a0 | \n(999,739 | \n ) | \n\u00a0 | \n\u00a0 | \n(997,590 | \n ) |
| Net deferred tax asset | \n\u00a0 | \n\u00a0 | \n28,642,197 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n23,882,033 | \n\u00a0 |
| Valuation\n allowance | \n\u00a0 | \n\u00a0 | \n(28,642,197 | \n) | \n\u00a0 | \n\u00a0 | \n(23,882,033 | \n ) |
| Total | \n\u00a0 | \n$ | \n- | \n\u00a0 | \n\u00a0 | \n$ | \n\n | \u00a0 |
NOTE\n20 \u2013 RELATED PARTY TRANSACTIONS
\n\n\u00a0
\n\nEffective\nJuly 1, 2021, the Company entered into employment agreements with its CEO, CFO, and COO, expiring in June 2024, that provide for an annual\nbase salary of $350,000, $325,000, and $300,000, respectively, and the ability to receive annual bonuses of up to 75% of the executive\u2019s\nannual base salary for each year during the term, based on reaching certain performance goals established by the Company.
\n\n\u00a0
\n\nPursuant\nto the agreements, the CEO, CFO, and COO were granted (i) on the effective date, options to purchase up to , , and\n shares, respectively, of the Company\u2019s common stock, at an exercise price of $ per share, that vest over \nand expire in , and (ii) in October 2021, options to purchase up to , , and shares, respectively,\nof the Company\u2019s common stock, at an exercise price of $ per share, that vest over and expire in .
\n\n\u00a0
\n\nAdditionally,\nthe agreements (i) provide these officers with additional grants on each anniversary of the effective date of the agreements in the sole\ndiscretion of the Company\u2019s Compensation Committee, and contain covenants not to compete, non-solicitation provisions, and termination\nobligations, among other terms and conditions.
\n\n\u00a0
\n\nIn\nJuly 2021, the Company granted -year options to purchase up to shares of common stock to each of the Company\u2019s three\nindependent board members at an exercise price of $ per share.
\n\n\u00a0
\n\nIn\nDecember 2021, the CEO and CFO each exercised options to purchase shares of common stock on a cashless basis. The exercise price\nof $ per share was paid via the surrender by each individual of 73,256 shares of common stock. Also in this month, an independent\nboard member allowed to expire options to purchase up to of commons stock at an exercise price of $ per share.
\n\n\u00a0
\n\nIn\nApril 2020, the Company issued options to purchase up to shares of common stock to its COO, with an exercise price of $ per\nshare and expiring three years from grant date. The fair value of these options of approximately $6,000 was charged to compensation expense\nover the annual vesting period. No options were issued to related parties in 2021.
\n\n\u00a0
\n\nIn\n2020, options to purchase an aggregate of shares of common stock were exercised by the Company\u2019s CEO, CFO, and an independent\nboard member at exercise prices of $ and $ per share.
\n\n\u00a0
\n\nThe\nCompany\u2019s corporate offices are leased from an entity in which the Company\u2019s CFO has an investment interest. This lease expires\nin October 2028 and contains a five-year extension option. In 2021 and 2020, expenses incurred under this lease approximated $156,000\nin both years.
\n\n\u00a0
\n\nThe\nCompany procures nutrients, lab equipment, cultivation supplies, furniture, and tools from an entity owned by the family of the Company\u2019s\nCOO. The aggregate purchases from this entity in 2021 and 2020 approximated $4.9 million and $2.5\nmillion, respectively.
\n\n\u00a0
\n\nThe\nCompany pays royalties on the revenue generated from its Betty\u2019s Eddies product line to an entity owned by the Company\u2019s\nCOO and its SVP of Sales under a royalty agreement. This agreement was amended effective January 1, 2021 whereby, among other modifications,\nthe royalty percentage changed from 2.5% on all sales of Betty\u2019s Eddies products to (i)\n3.0% and 10.0% of wholesale sales of existing products within the product line if sold directly by the Company, or licensed by the Company\nfor sale by third-parties, respectively, and (ii) 0.5% and 1.0% of wholesale sales of future developed products within the product line\nif sold directly by the Company, or licensed by the Company for sale by third-parties, respectively. The\naggregate royalties due to this entity in 2021 and 2020 approximated $266,000 and $615,000,\nrespectively.
\n\n\u00a0
\n\nIn\n2021 and 2020, one of the Company\u2019s majority owned subsidiaries paid aggregate distributions of approximately $44,000 and $30,000,\nrespectively, to the Company\u2019s CEO and CFO, who own minority equity interests in such subsidiary. In 2021, another of the Company\u2019s\nmajority owned subsidiaries paid distributions of approximately $7,000 to a current employee who owns a minority equity interest in such\nsubsidiary.
\n\n\u00a0
\n\nIn\n2021 and 2020, the Company purchased fixed assets and consulting services of approximately $836,000 and $938,000,\nrespectively, in the aggregate from two entities owned by two of the Company\u2019s general managers.
\n\n\u00a0
\n\nIn\n2021 and 2020, the Company purchased fixed assets of approximately $642,000 and $182,000 from an entity owned by an employee.
\n\n\u00a0
\n\nThe\nbalance of Due To Related Parties at December 31, 2020 of approximately $1.2 million was comprised of amounts owed of approximately\n(i) $460,000 to the Company\u2019s CEO, (ii) $653,000 to entities owned by the Company\u2019s CEO and CFO, and (iii) $45,000 to a stockholder\nof the Company. All amounts owed were repaid in March 2021.
\n\n\u00a0
\n\nThe\nCompany\u2019s mortgages with Bank of New England, DuQuoin State Bank, and South Porte Bank are personally guaranteed by the Company\u2019s\nCEO and CFO.
\n\n\u00a0
\n\n\n\n\n\u00a0
\n\n"}]},{"name":"rpt:f-1540","factDimensions":{"xbrl:concept":"us-gaap:OfficersCompensation","xbrl:period":"2021-06-29T00:00:00/2021-07-03T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","srt:TitleOfIndividualAxis":"srt:ChiefExecutiveOfficerMember","us-gaap:TypeOfArrangementAxis":"MRMD:EmploymentAgreementMember"},"factValues":[{"value":"350000","decimals":0}]},{"name":"rpt:f-1541","factDimensions":{"xbrl:concept":"us-gaap:OfficersCompensation","xbrl:period":"2021-06-29T00:00:00/2021-07-03T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","srt:TitleOfIndividualAxis":"srt:ChiefFinancialOfficerMember","us-gaap:TypeOfArrangementAxis":"MRMD:EmploymentAgreementMember"},"factValues":[{"value":"325000","decimals":0}]},{"name":"rpt:f-1542","factDimensions":{"xbrl:concept":"us-gaap:OfficersCompensation","xbrl:period":"2021-06-29T00:00:00/2021-07-03T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","srt:TitleOfIndividualAxis":"srt:ChiefOperatingOfficerMember","us-gaap:TypeOfArrangementAxis":"MRMD:EmploymentAgreementMember"},"factValues":[{"value":"300000","decimals":0}]},{"name":"rpt:f-1543","factDimensions":{"xbrl:concept":"MRMD:PercentageOfAnnualBonuses","xbrl:period":"2021-06-29T00:00:00/2021-07-03T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:TypeOfArrangementAxis":"MRMD:EmploymentAgreementMember"},"factValues":[{"value":"0.75"}]},{"name":"rpt:f-1544","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber","xbrl:period":"2021-07-03T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","srt:TitleOfIndividualAxis":"srt:ChiefExecutiveOfficerMember","us-gaap:AwardTypeAxis":"MRMD:NonQualifiedStockOptionsMember","us-gaap:TypeOfArrangementAxis":"MRMD:EmploymentAgreementMember"},"factValues":[{"value":"5000000"}]},{"name":"rpt:f-1545","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber","xbrl:period":"2021-07-03T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","srt:TitleOfIndividualAxis":"srt:ChiefFinancialOfficerMember","us-gaap:AwardTypeAxis":"MRMD:NonQualifiedStockOptionsMember","us-gaap:TypeOfArrangementAxis":"MRMD:EmploymentAgreementMember"},"factValues":[{"value":"5000000"}]},{"name":"rpt:f-1546","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber","xbrl:period":"2021-07-03T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","srt:TitleOfIndividualAxis":"srt:ChiefOperatingOfficerMember","us-gaap:AwardTypeAxis":"MRMD:NonQualifiedStockOptionsMember","us-gaap:TypeOfArrangementAxis":"MRMD:EmploymentAgreementMember"},"factValues":[{"value":"1250000"}]},{"name":"rpt:f-1547","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice","xbrl:period":"2021-07-01T00:00:00/2021-08-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:TypeOfArrangementAxis":"MRMD:EmploymentAgreementMember","us-gaap:AwardTypeAxis":"MRMD:NonQualifiedStockOptionsMember"},"factValues":[{"value":"0.88"}]},{"name":"rpt:f-1548","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1","xbrl:period":"2021-06-29T00:00:00/2021-07-03T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:TypeOfArrangementAxis":"MRMD:EmploymentAgreementMember","us-gaap:AwardTypeAxis":"MRMD:NonQualifiedStockOptionsMember"},"factValues":[{"value":"P1Y"}]},{"name":"rpt:f-1549","factDimensions":{"xbrl:concept":"MRMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationMonthAndYear","xbrl:period":"2021-06-29T00:00:00/2021-07-03T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:TypeOfArrangementAxis":"MRMD:EmploymentAgreementMember","us-gaap:AwardTypeAxis":"MRMD:NonQualifiedStockOptionsMember"},"factValues":[{"value":"2026-07"}]},{"name":"rpt:f-1550","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber","xbrl:period":"2021-11-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","srt:TitleOfIndividualAxis":"srt:ChiefExecutiveOfficerMember","us-gaap:AwardTypeAxis":"MRMD:NonQualifiedStockOptionsMember","us-gaap:TypeOfArrangementAxis":"MRMD:EmploymentAgreementMember"},"factValues":[{"value":"5000000"}]},{"name":"rpt:f-1551","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber","xbrl:period":"2021-11-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","srt:TitleOfIndividualAxis":"srt:ChiefFinancialOfficerMember","us-gaap:AwardTypeAxis":"MRMD:NonQualifiedStockOptionsMember","us-gaap:TypeOfArrangementAxis":"MRMD:EmploymentAgreementMember"},"factValues":[{"value":"5000000"}]},{"name":"rpt:f-1552","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber","xbrl:period":"2021-11-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","srt:TitleOfIndividualAxis":"srt:ChiefOperatingOfficerMember","us-gaap:AwardTypeAxis":"MRMD:NonQualifiedStockOptionsMember","us-gaap:TypeOfArrangementAxis":"MRMD:EmploymentAgreementMember"},"factValues":[{"value":"1250000"}]},{"name":"rpt:f-1553","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice","xbrl:period":"2021-10-29T00:00:00/2021-11-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:TypeOfArrangementAxis":"MRMD:EmploymentAgreementMember","us-gaap:AwardTypeAxis":"MRMD:NonQualifiedStockOptionsMember"},"factValues":[{"value":"0.90"}]},{"name":"rpt:f-1554","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1","xbrl:period":"2021-10-29T00:00:00/2021-11-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:TypeOfArrangementAxis":"MRMD:EmploymentAgreementMember","us-gaap:AwardTypeAxis":"MRMD:NonQualifiedStockOptionsMember"},"factValues":[{"value":"P1Y"}]},{"name":"rpt:f-1555","factDimensions":{"xbrl:concept":"MRMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationMonthAndYear","xbrl:period":"2021-10-29T00:00:00/2021-11-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:TypeOfArrangementAxis":"MRMD:EmploymentAgreementMember","us-gaap:AwardTypeAxis":"MRMD:NonQualifiedStockOptionsMember"},"factValues":[{"value":"2026-09"}]},{"name":"rpt:f-1556","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward","xbrl:period":"2021-07-01T00:00:00/2021-08-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","srt:TitleOfIndividualAxis":"MRMD:ThreeIndependentBoardMembersMember"},"factValues":[{"value":"100000"}]},{"name":"rpt:f-1557","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice","xbrl:period":"2021-07-01T00:00:00/2021-08-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","srt:TitleOfIndividualAxis":"MRMD:ThreeIndependentBoardMembersMember"},"factValues":[{"value":"0.88"}]},{"name":"rpt:f-1558","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","srt:TitleOfIndividualAxis":"srt:ChiefExecutiveOfficerMember","us-gaap:TypeOfArrangementAxis":"MRMD:CashlessMember"},"factValues":[{"value":"100000"}]},{"name":"rpt:f-1559","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","srt:TitleOfIndividualAxis":"srt:ChiefFinancialOfficerMember","us-gaap:TypeOfArrangementAxis":"MRMD:CashlessMember"},"factValues":[{"value":"100000"}]},{"name":"rpt:f-1560","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice","xbrl:period":"2021-12-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","srt:TitleOfIndividualAxis":"srt:ChiefExecutiveOfficerMember"},"factValues":[{"value":"0.63"}]},{"name":"rpt:f-1561","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice","xbrl:period":"2021-12-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","srt:TitleOfIndividualAxis":"srt:ChiefFinancialOfficerMember"},"factValues":[{"value":"0.63"}]},{"name":"rpt:f-1562","factDimensions":{"xbrl:concept":"MRMD:SurrenderOfCommonStock","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","srt:TitleOfIndividualAxis":"srt:ChiefFinancialOfficerMember"},"factValues":[{"value":"73256"}]},{"name":"rpt:f-1563","factDimensions":{"xbrl:concept":"MRMD:SurrenderOfCommonStock","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","srt:TitleOfIndividualAxis":"srt:ChiefExecutiveOfficerMember"},"factValues":[{"value":"73256"}]},{"name":"rpt:f-1564","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","srt:TitleOfIndividualAxis":"MRMD:IndependentBoardMembersMember"},"factValues":[{"value":"100000"}]},{"name":"rpt:f-1565","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice","xbrl:period":"2021-12-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","srt:TitleOfIndividualAxis":"MRMD:IndependentBoardMembersMember"},"factValues":[{"value":"0.63"}]},{"name":"rpt:f-1566","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised","xbrl:period":"2020-04-01T00:00:00/2020-05-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","srt:TitleOfIndividualAxis":"srt:ChiefOperatingOfficerMember","us-gaap:StatementEquityComponentsAxis":"us-gaap:CommonStockMember"},"factValues":[{"value":"50000"}]},{"name":"rpt:f-1567","factDimensions":{"xbrl:concept":"us-gaap:SharesIssuedPricePerShare","xbrl:period":"2020-05-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","srt:TitleOfIndividualAxis":"srt:ChiefOperatingOfficerMember","us-gaap:StatementEquityComponentsAxis":"us-gaap:CommonStockMember"},"factValues":[{"value":"0.30"}]},{"name":"rpt:f-1568","factDimensions":{"xbrl:concept":"MRMD:FairValueOfOption","xbrl:period":"2020-04-01T00:00:00/2020-05-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","srt:TitleOfIndividualAxis":"srt:ChiefOperatingOfficerMember","us-gaap:StatementEquityComponentsAxis":"us-gaap:CommonStockMember"},"factValues":[{"value":"6000","decimals":0}]},{"name":"rpt:f-1569","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised","xbrl:period":"2020-12-03T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","srt:TitleOfIndividualAxis":"MRMD:CEOAndCFOAndIndependentBoardMemberMember","us-gaap:StatementEquityComponentsAxis":"us-gaap:CommonStockMember"},"factValues":[{"value":"550000"}]},{"name":"rpt:f-1570","factDimensions":{"xbrl:concept":"us-gaap:SharesIssuedPricePerShare","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","srt:RangeAxis":"srt:MinimumMember","srt:TitleOfIndividualAxis":"MRMD:CEOAndCFOAndIndependentBoardMemberMember","us-gaap:StatementEquityComponentsAxis":"MRMD:OptionsMember"},"factValues":[{"value":"0.13"}]},{"name":"rpt:f-1571","factDimensions":{"xbrl:concept":"us-gaap:SharesIssuedPricePerShare","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","srt:RangeAxis":"srt:MaximumMember","srt:TitleOfIndividualAxis":"MRMD:CEOAndCFOAndIndependentBoardMemberMember","us-gaap:StatementEquityComponentsAxis":"MRMD:OptionsMember"},"factValues":[{"value":"0.14"}]},{"name":"rpt:f-1572","factDimensions":{"xbrl:concept":"us-gaap:OperatingLeaseExpense","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"156000","decimals":0}]},{"name":"rpt:f-1573","factDimensions":{"xbrl:concept":"us-gaap:OperatingLeaseExpense","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"156000","decimals":0}]},{"name":"rpt:f-1574","factDimensions":{"xbrl:concept":"us-gaap:PaymentsToAcquirePropertyPlantAndEquipment","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","srt:TitleOfIndividualAxis":"srt:ChiefOperatingOfficerMember"},"factValues":[{"value":"4900000","decimals":-5}]},{"name":"rpt:f-1575","factDimensions":{"xbrl:concept":"us-gaap:PaymentsToAcquirePropertyPlantAndEquipment","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","srt:TitleOfIndividualAxis":"srt:ChiefOperatingOfficerMember"},"factValues":[{"value":"2500000","decimals":-5}]},{"name":"rpt:f-1576","factDimensions":{"xbrl:concept":"MRMD:RoyaltyPercentageDescription","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","srt:ProductOrServiceAxis":"MRMD:BettysEddiesProductsMember","us-gaap:TypeOfArrangementAxis":"MRMD:RoyaltyAgreementMember"},"factValues":[{"value":"(i)\n3.0% and 10.0% of wholesale sales of existing products within the product line if sold directly by the Company, or licensed by the Company\nfor sale by third-parties, respectively, and (ii) 0.5% and 1.0% of wholesale sales of future developed products within the product line\nif sold directly by the Company, or licensed by the Company for sale by third-parties, respectively."}]},{"name":"rpt:f-1577","factDimensions":{"xbrl:concept":"us-gaap:AccruedRoyaltiesCurrentAndNoncurrent","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","srt:ProductOrServiceAxis":"MRMD:BettysEddiesProductsMember","us-gaap:TypeOfArrangementAxis":"MRMD:RoyaltyAgreementMember"},"factValues":[{"value":"266000","decimals":0}]},{"name":"rpt:f-1578","factDimensions":{"xbrl:concept":"us-gaap:AccruedRoyaltiesCurrentAndNoncurrent","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","srt:ProductOrServiceAxis":"MRMD:BettysEddiesProductsMember","us-gaap:TypeOfArrangementAxis":"MRMD:RoyaltyAgreementMember"},"factValues":[{"value":"615000","decimals":0}]},{"name":"rpt:f-1579","factDimensions":{"xbrl:concept":"us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","srt:TitleOfIndividualAxis":"MRMD:CEOandCFOMember"},"factValues":[{"value":"44000","decimals":0}]},{"name":"rpt:f-1580","factDimensions":{"xbrl:concept":"us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","srt:TitleOfIndividualAxis":"MRMD:CEOandCFOMember"},"factValues":[{"value":"30000","decimals":0}]},{"name":"rpt:f-1581","factDimensions":{"xbrl:concept":"us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","srt:TitleOfIndividualAxis":"MRMD:CurrentEmployeeMember"},"factValues":[{"value":"7000","decimals":0}]},{"name":"rpt:f-1582","factDimensions":{"xbrl:concept":"MRMD:PaymentsToAcquireFixedAssetsAndConsultingServices","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"836000","decimals":0}]},{"name":"rpt:f-1583","factDimensions":{"xbrl:concept":"MRMD:PaymentsToAcquireFixedAssetsAndConsultingServices","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"938000","decimals":0}]},{"name":"rpt:f-1584","factDimensions":{"xbrl:concept":"us-gaap:PaymentsToAcquirePropertyPlantAndEquipment","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","srt:TitleOfIndividualAxis":"MRMD:EmployeeMember"},"factValues":[{"value":"642000000000","decimals":-5}]},{"name":"rpt:f-1585","factDimensions":{"xbrl:concept":"us-gaap:PaymentsToAcquirePropertyPlantAndEquipment","xbrl:period":"2020-01-01T00:00:00/2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","srt:TitleOfIndividualAxis":"MRMD:EmployeeMember"},"factValues":[{"value":"182000000000","decimals":-5}]},{"name":"rpt:f-1586","factDimensions":{"xbrl:concept":"us-gaap:DueToRelatedPartiesCurrentAndNoncurrent","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1200000","decimals":-5}]},{"name":"rpt:f-1587","factDimensions":{"xbrl:concept":"us-gaap:DueToRelatedPartiesCurrentAndNoncurrent","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","srt:TitleOfIndividualAxis":"srt:ChiefExecutiveOfficerMember"},"factValues":[{"value":"460000","decimals":0}]},{"name":"rpt:f-1588","factDimensions":{"xbrl:concept":"us-gaap:DueToRelatedPartiesCurrentAndNoncurrent","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","srt:TitleOfIndividualAxis":"MRMD:CEOandCFOMember"},"factValues":[{"value":"653000","decimals":0}]},{"name":"rpt:f-1589","factDimensions":{"xbrl:concept":"us-gaap:DueToRelatedPartiesCurrentAndNoncurrent","xbrl:period":"2021-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","srt:TitleOfIndividualAxis":"MRMD:StockholdersMember"},"factValues":[{"value":"45000","decimals":0}]},{"name":"rpt:f-1590","factDimensions":{"xbrl:concept":"us-gaap:CommitmentsAndContingenciesDisclosureTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"NOTE\n21 \u2013 COMMITMENTS AND CONTINGENCIES
\n\n\u00a0
\n\nLease\nCommitments
\n\n\u00a0
\n\nThe\nCompany is the lessee under six operating leases and four finance leases. These leases contain rent holidays and customary escalations\nof lease payments for the type of facilities being leased. The Company recognizes rent expense on a straight-line basis over the expected\nlease term, including cancelable option periods which the Company fully expects to exercise. Certain leases require the payment of property\ntaxes, insurance and/or maintenance costs in addition to the rent payments.
\n\n\u00a0
\n\nThe\ndetails of the Company\u2019s operating lease agreements are as follows:
\n\n\u00a0
\n\n| \u00a0 | \n\u25cf | \nDelaware\n \u2013 4,000\n square feet of retail space in a multi-use\n building under a five-year\n lease that expires in April 2027 that the Company has developed into a cannabis dispensary which is subleased\n to its cannabis-licensed client. |
| \u00a0 | \n\u00a0 | \n\u00a0 |
| \u00a0 | \n\u25cf | \nDelaware\n \u2013 a 100,000\n square foot warehouse, of which the\n Company developed 60,000\n square feet\n into a cultivation facility, and is developing the remaining space into processing facility, subleased to its\n cannabis-licensed client. The\n lease expires in March 2030, with an option to extend the term for three additional five-year periods. |
| \u00a0 | \n\u00a0 | \n\u00a0 |
| \u00a0 | \n\u25cf | \nDelaware\n \u2013 a 12,000\n square foot premises which the Company developed into a cannabis production facility with offices, and is subleases to its\n cannabis-licensed client. The lease expires\n in January 2026 and contains an option to negotiate an extension at the end of the lease term. |
| \u00a0 | \n\u00a0 | \n\u00a0 |
| \u00a0 | \n\u25cf | \nNevada \u2013 10,000 square\n feet of an industrial building that the Company has built-out into a cannabis cultivation facility and plans to rent to its cannabis-licensed\n client under a sublease which will be coterminous with this lease expiring in 2024. |
| \u00a0 | \n\u00a0 | \n\u00a0 |
| \u00a0 | \n\u25cf | \nMassachusetts \u2013 10,000\n square feet of office space which the Company utilizes as its corporate offices under a lease with a related party expiring in 2028,\n with an option to extend the term for an additional five-year period. |
| \u00a0 | \n\u00a0 | \n\u00a0 |
| \u00a0 | \n\u25cf | \nMaryland \u2013 a 2,700\n square foot two-unit apartment under a lease that expires in July 2022. |
\u00a0
\n\nThe\nCompany leases machinery and office equipment under finance leases that expire in February 2022 through June 2024 with such terms being\na major part of the economic useful life of the leased property.
\n\n\u00a0
\n\nThe\ncomponents of lease expense for the year ended December 31, 2021 were as follows:
\n\n\u00a0SCHEDULE OF COMPONENTS OF LEASE EXPENSE
\n\n| \u00a0 | \u00a0 | \n\u00a0 | 2021 | \u00a0 |
| Operating lease cost | \u00a0 | \n$ | 1,097,620 | \u00a0 |
| \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 |
| Finance lease cost: | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 |
| Amortization of right-of-use assets | \u00a0 | \n$ | 32,683 | \u00a0 |
| Interest on lease liabilities | \u00a0 | \n\u00a0 | 5,088 | \u00a0 |
| Total finance lease cost | \u00a0 | \n$ | 37,771 | \u00a0 |
\u00a0
\n\nThe\nweighted average remaining lease term for operating leases is 7.4\nyears, and for the finance leases is 2.0\nyears. The weighted average discount rate used\nto determine the right-of-use assets and lease liabilities was between 7.5%\nto 12.0%\nfor all leases.
\n\n\u00a0
\n\nFuture\nminimum lease payments as of December 31, 2021 under all non-cancelable leases having an initial or remaining term of more than one year\nwere:
\n\n\u00a0SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER ALL NON-CANCELABLE OPERATING LEASES
\n\n| \u00a0 | \u00a0 | \nOperating \nLeases | \u00a0 | \u00a0 | \nFinance \nLeases | \u00a0 | ||
| 2021 | \u00a0 | \n$ | 1,132,909 | \u00a0 | \u00a0 | \n$ | 27,123 | \u00a0 |
| 2022 | \u00a0 | \n\u00a0 | 1,119,003 | \u00a0 | \u00a0 | \n\u00a0 | 23,201 | \u00a0 |
| 2023 | \u00a0 | \n\u00a0 | 1,049,635 | \u00a0 | \u00a0 | \n\u00a0 | 3,229 | \u00a0 |
| 2024 | \u00a0 | \n\u00a0 | 1,025,054 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| 2025 | \u00a0 | \n\u00a0 | 969,584 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| Thereafter | \u00a0 | \n\u00a0 | 2,611,297 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| Total lease payments | \u00a0 | \n\u00a0 | 7,907,482 | \u00a0 | \u00a0 | \n$ | 53,553 | \u00a0 |
| Less: imputed interest | \u00a0 | \n\u00a0 | (2,262,546 | ) | \u00a0 | \n\u00a0 | (3,975 | ) |
| \u00a0 | \u00a0 | \n$ | 5,644,936 | \u00a0 | \u00a0 | \n$ | 49,578 | \u00a0 |
\u00a0
\n\n\u00a0
\n\nIn\nNovember 2021, the Company entered into lease agreements for six retail properties, each with square footage between 4,000\nand 6,000\nsquare feet, in the state of Ohio (each an \u201cOhio Lease\u201d and collectively the \u201cOhio Leases\u201d). Each Ohio Lease\nhas an initial lease period of eleven months, with a minimum rent of $31.00\nper square foot which increases 3.0% annually.
\n\n\n\u00a0
\n\n\n\nShould the Company be awarded one or more cannabis\nlicenses by the state of Ohio prior to the end of the initial lease period, it can extend the term of one or more of the Ohio Leases\nto ten years (with two additional five-year options to extend) upon the payment of $50,000 for each extended Ohio Lease, and develop\nthe premises of such extended lease(s) into a cannabis dispensary. As of December 31, 2021, the lease terms of the Ohio Leases were all\nless than one year, and accordingly the Company was not required to record a right-of-use asset and corresponding lease liability on\nits balance sheet. The future lease payments of the Ohio Leases are excluded from the table of future minimum lease payments shown above.
\n\n\n
\u00a0
\n\n\n\n\n\u00a0
\n\nTerminated\nEmployment Agreement
\n\n\u00a0
\n\nAn\nemployment agreement which commenced in 2012 with Thomas Kidrin, the former CEO of the Company, was terminated by the Company in 2017.\nSince the termination date, the Company had maintained an accrual of approximately $1,043,000 for any amounts that may be owed under\nthis agreement.
\n\n\u00a0
\n\nIn\nJuly 2019, Mr. Kidrin, also a former director of the Company, filed a complaint in the Massachusetts Superior Court, which alleged the\nCompany failed to pay all wages owed to him and breached the employment agreement, and requested multiple damages, attorney fees, costs,\nand interest. The Company moved to dismiss certain counts of the complaint and asserted counterclaims against Mr. Kidrin alleging breach\nof contract, breach of fiduciary duty, money had and received, and unjust enrichment.
\n\n\u00a0
\n\nWhile\nthe Company\u2019s motion to dismiss was pending, the parties entered into a settlement agreement and general release in August 2021\nwhereby, among other conditions, (i) Mr. Kidrin\u2019s complaint was dismissed with prejudice, (ii) the Company issued to Mr. Kidrin\nfive-year warrants to purchase up to 1,000,000 shares of the Company\u2019s common stock at an exercise price of $0.50 per share, (iii)\nthe Company irrevocably transferred intangible assets relating to the online virtual worlds business the Company had conducted in early\n2014, prior to its pivot into the legal cannabis industry (such assets had zero carrying value on the Company\u2019s balance sheet),\nand (iv) each party released and discharged the other from all claims, losses, and liabilities.
\n\n\u00a0
\n\nIn\nAugust 2021, the fair value of the warrants of approximately $776,000 was charged to compensation expense, and the Company reversed its\naccrual of approximately $1,043,000
\n\n\u00a0
\n\nMaryland\nLitigation
\n\n\n
\u00a0
\n\nAs\npreviously disclosed in Note 3 \u2013 Acquisitions, the members of Kind had sought to renege on the parties\u2019\noriginal agreement to a partnership/joint venture made in 2016 and subsequent MOU. The Company engaged with the members of Kind in good\nfaith in an attempt to reach updated terms acceptable to both parties, however the members of Kind failed to reciprocate in good faith,\nresulting in an impasse. Incrementally, both parties through counsel further sought to resolve the impasse, however such initiative resulted\nin both parties commencing legal proceedings.
\n\n\n\n
\u00a0
\n\nIn\nNovember 2019, Kind commenced an action by filing a complaint against the Company in the Circuit Court for Washington County, MD captioned\nKind Therapeutics USA, Inc. vs. MariMed, Inc., et al. (Case No. C-21-CV-19-000670) (the \u201cComplaint\u201d). The Complaint, as amended,\nalleges breach of contract, breach of fiduciary duty, unjust enrichment, intentional misrepresentation, rescission, civil conspiracy,\nand seeking an accounting and declaratory judgment and damages in excess of $75,000\n(the Court has subsequently dismissed\nKind\u2019s claims for declaratory judgment on the lease, rescission of the lease, and civil conspiracy). On November 15, 2019, the\nCompany filed counterclaims against Kind and a third-party complaint against the members of Kind (Jennifer DiPietro, Susan Zimmerman,\nand Sophia Leonard-Burns) and William Tham (the \u201cCounterclaims\u201d). The Counterclaims, as amended, allege breach of contract\nwith respect to each of the partnership/joint venture agreement, the MOU, the MSA, the Lease, and the Licensing and Manufacturing Agreement\n(\u201cLMA\u201d), unjust enrichment, promissory estoppel/detrimental reliance, fraud in the inducement, breach of fiduciary duty,\nand seeks reformation of the MSA, a declaratory judgment regarding enforceability of the partnership/joint venture arrangement and/or\nthe MOU, specific performance of the parties\u2019 various contracts, and the establishment of a constructive trust for the Company\u2019s\nbenefit. The Counterclaims also seek damages.
\n\n\u00a0
\n\n\n\n
At\nthe time the Complaint and Counterclaims were filed, both parties, the Company (including its subsidiaries Mari-MD and\nMariMed Advisors Inc.) and Kind, brought motions for a temporary restraining order and a preliminary injunction. By Opinion and Order\nentered on November 21, 2019, the Court denied both parties motions for a temporary restraining order. In its opinion, the Court specifically\nnoted that, contrary to Kind\u2019s allegations, the MSA and the Lease \u201cappear to be independent, valid and enforceable contracts.\u201d
\n\u00a0
\n\nA\nhearing on the parties\u2019 cross-motions for preliminary injunction was held in September 2020 and November 2020. Also in November\n2020, the Court granted the Company\u2019s motion for summary judgment as to the Lease, determining that the Lease is valid and enforceable.\nBased on this ruling, the Company is seeking judgment at trial in the amount of approximately $5.4 million for past due rent and expenses\nowed by Kind under the Lease.
\n\n\u00a0
\n\nIn\nDecember 2020, the Court entered a Preliminary Injunction Order, accompanied by a Memorandum Opinion, denying Kind\u2019s motion for\na preliminary injunction (which Kind had withdrawn at the conclusion of the hearing) and granting the Company\u2019s request for preliminary\ninjunction. The Court determined that the Company is likely to succeed with respect to the validity and enforceability of the MSA and\nthe LMA, that the Company would suffer substantial and irreparable harm without the preliminary injunction, and that the balance of convenience\nand public interest both warranted the issuance of a preliminary injunction in the Company\u2019s favor. The Court ordered, inter\nalia, that the MSA and LMA are in effect pending judgment after trial on the merits, and that Kind and its members, and their\nattorneys, agents, employees, and representatives, are prohibited from (a) interfering with the Company\u2019s duties and responsibilities\nunder the MSA and (b) withdrawing funds, making any distribution, paying any loans, returning any capital, or making any payment towards\na debt from any Kind bank or other financial account(s) without written consent of the Company or Order of the Court, thereby preserving\nthe Company\u2019s management of Kind\u2019s operations and finances at least through the jury trial currently scheduled to begin on\nMarch 28, 2022. Further, the Court ordered Kind to pay management and licensing fees to the Company beginning January 1, 2021. Kind has\nnoted an appeal of the Order to the Maryland Court of Special Appeals, which the Court denied in December 2021, leaving the preliminary\ninjunction order in effect.
\n\n\u00a0
\n\nIn\naddition to the favorable rulings on the Lease, MSA, and LMA, the Company believes that its claims for declaratory relief, specific\nperformance, and/or breach of contract with respect to the partnership/joint venture agreement claims are meritorious. Further, the\nCompany believes that Kind\u2019s claims against the Company are without merit. On March 18, 2021, the Court issued an opinion and order\non Kind\u2019s motion for summary judgment finding that the MOU was not enforceable by the Company against Kind as a final binding agreement.\nThe Company is evaluating an appeal of this ruling which under Maryland rules can only be pursued upon final judgment.
\n\n\u00a0
\n\nIn\nMarch 2021, the Kind parties filed motions to modify the preliminary injunction order or, alternatively, for direction from the Court\nbased on Kind\u2019s claim to have terminated the MSA. In September 2021, the court denied the motion to modify the preliminary injunction\nand granted, in part, the motion for direction, but only with respect to Kind\u2019s request to pay litigation costs. The preliminary\ninjunction remains in full effect, and the Company filed a petition for civil contempt against the Kind parties for interfering with\nthe Company\u2019s management of Kind. The contempt petition is currently pending.
\n\n\u00a0
\n\nOn\nDecember 31, 2021, the parties to the foregoing Maryland litigation entered into a global Confidential Settlement and Release Agreement,\nalong with the parties to the DiPietro lawsuit (described below). Also on such date, as previously discussed in Note 3 -- Acquisitions\nin this report, the Company entered into (i) a membership interest purchase agreement with the members of Kind to acquire 100% of\nthe equity ownership of Kind, and (ii) a membership interest purchase agreement with one of the members of Kind to acquire such member\u2019s\nentire equity ownership interest Mari-MD and Mia.
\n\n\u00a0
\n\nOn\nJanuary 4, 2022, the Maryland court entered an order staying the litigation and rescheduling the jury trial to October 24, 2022, to November\n4, 2022, in the event the transactions contemplated by the Confidential Settlement and Release Agreement are not consummated. Otherwise,\nsimultaneous with the closing of the transactions contemplated by the Confidential Settlement and Release Agreement, the foregoing Maryland\nlitigation will be dismissed with prejudice, along with the DiPietro lawsuit.
\n\n\u00a0
\n\nIn\nthe event the transactions contemplated by the Confidential Settlement and Release Agreement are not consummated, the Company intends\nto aggressively prosecute and defend the action.
\n\n\u00a0
\n\nDiPietro\nLawsuit
\n\n\n
\u00a0
\n\n\n\n
In\nAugust 2020, Jennifer DiPietro, directly and derivatively on behalf of Mari-MD and Mia, commenced a suit against the Company\u2019s\nCEO, CFO, and wholly-owned subsidiary MariMed Advisors Inc. (\u201cMMA\u201d), in Suffolk Superior Court, Massachusetts.
\n\u00a0
\n\n\n\n\n\u00a0
\n\nIn\nthis action, DiPietro, a party to prior ongoing litigation in Maryland involving the Company and Kind as discussed above, brings claims\nfor breach of fiduciary duty, breach of contract, fraud in the inducement, aiding and abetting the alleged breach of fiduciary duty,\nand also seeks access to books and records and an accounting related to her investments in Mari-MD and Mia. DiPietro seeks unspecified\nmoney damages and rescission of her interest in Mari-MD, but not of her investment in Mia, which has provided substantial returns to\nher as a member.
\n\n\u00a0
\n\nThe\nCompany has answered the complaint and MMA filed counterclaims against DiPietro on its own behalf and derivatively on behalf of Mari-MD\nfor breach of her fiduciary duties to each of those entities, and for tortious interference with Mari-MD\u2019s lease and MMA\u2019s\nmanagement services agreement with Kind.
\n\n\u00a0
\n\nOn\nDecember 31, 2021, the parties to the foregoing Massachusetts litigation entered into a global Confidential Settlement and Release Agreement,\nalong with the parties to the Maryland lawsuit described above. Because the Massachusetts litigation involves derivative claims, the\nMassachusetts Superior Court must approve the parties\u2019 proposed dismissal of those claims. The parties to the Massachusetts litigation\nhave filed a joint motion seeking to dismiss the derivative claims. Simultaneous with the closing of the transactions contemplated by\nthe Confidential Settlement and Release Agreement, all direct claims in the foregoing Massachusetts litigation will be dismissed with\nprejudice, along with the Maryland lawsuit.
\n\n\u00a0
\n\nIn\nthe event the transactions contemplated by the Confidential Settlement and Release Agreement are not consummated, the Company believes\nthat the allegations of the complaint in the foregoing Massachusetts litigation are without merit and intends to defend the case vigorously.\nThe Company\u2019s counterclaim seeks monetary damages from DiPietro, including the Company\u2019s legal fees in the Maryland lawsuit.
\n\n\u00a0
\n\nBankruptcy\nClaim
\n\n\u00a0
\n\nDuring\n2019, the Company\u2019s MMH subsidiary sold and delivered hemp seed inventory to GenCanna Global Inc., a Kentucky-based cultivator,\nproducer, and distributor of hemp (\u201cGenCanna\u201d). At the time of sale, the Company owned a 33.5% ownership interest in GenCanna.\nThe Company recorded a related party receivable of approximately $29.0 million from the sale, which was fully reserved on December 31,\n2019.
\n\n\u00a0
\n\nIn\nFebruary 2020, GenCanna USA, GenCanna\u2019s wholly-owned operating subsidiary, under pressure from certain of its creditors including\nMGG Investment Group LP, GenCanna\u2019s senior lender (\u201cMGG\u201d), agreed to convert a previously-filed involuntary bankruptcy\nproceeding with the U.S. Bankruptcy Court in the Eastern District of Kentucky (the \u201cBankruptcy Court\u201d) into a voluntary Chapter\n11 proceeding. In addition, GenCanna and GenCanna USA\u2019s subsidiary, Hemp Kentucky LLC (collectively with GenCanna and GenCanna\nUSA, the \u201cGenCanna Debtors\u201d), filed voluntary petitions under Chapter 11 in the Bankruptcy Court.
\n\n\u00a0
\n\nIn\nMay 2020, after an abbreviated solicitation/bid/sale process, the Bankruptcy Court, over numerous objections by creditors and shareholders\nof the GenCanna Debtors which included the Company, entered an order authorizing the sale of all or substantially all of the assets of\nthe GenCanna Debtors to MGG. After the consummation of the sale of all or substantially all of their assets and business, the GenCanna\nDebtors n/k/a OGGUSA, Inc. and OGG, Inc. (the \u201cOGGUSA Debtors\u201d) filed their liquidating plan of reorganization (the \u201cLiquidating\nPlan\u201d) to collect various prepetition payments and commercial claims against third parties, liquidate the remaining assets of the\nODDUSA Debtors, and make payments to creditors. The Company and the unsecured creditors committee filed objections to such Liquidating\nPlan, including opposition to the release of litigation against the OGGUSA Debtors\u2019 senior lender, MGG, for lender liability, equitable\nsubordination, and return of preference. As a part of such plan confirmation process, the OGGUSA Debtors filed various objections to\nproofs of claims filed by various creditors, including the proof of claim in the amount of approximately $33.6 million filed by the Company.\nThrough intense and lengthy negotiations with the OGGUSA Debtors and the unsecured creditors committee regarding the objections to the\nLiquidating Plan, the Company reached an agreement with the OGGUSA Debtors to withdraw the objections to the Company\u2019s claim and\nto have it approved by the Bankruptcy Court as a general unsecured claim in the amount of $31.0 million.
\n\n\u00a0
\n\nSince\nthe approval of the Liquidating Plan, the OGGUSA Debtors have been in the process of liquidating the remaining assets, negotiating and\nprosecuting objections to other creditors\u2019 claims, and pursuing the collection of accounts receivable and Chapter 5 bankruptcy\navoidance claims.
\n\n\n\n
\u00a0
\n\nIn January 2022, the\nCompany, at the request of the Liquidating Plan administrator for the OGGUSA Debtors, executed a written release of claims, if any, of\nthe Company against Huron Consulting Group (\u201cHuron\u201d), a financial consulting and management company retained by the senior\nlender of the OGGUSA Debtors to perform loan management services for the lender and OGGUSA Debtors prior to and during their Chapter\n11 bankruptcy cases. Such release was executed in connection with a comprehensive settlement agreement between the OGGUSA Debtors and\nHuron. In consideration for the Company\u2019s execution of the release, Huron paid an additional $40,000 to the bankruptcy estates\nof the OGGUSA Debtors to be included in the funds to be distributed to creditors, including the Company.
\n\u00a0
\n\n\n\n
As\nof the date of this filing, there is still insufficient information as to what portion, if any, of the Company\u2019s allowed\nclaim will be paid upon the completion of the liquidation of the remaining assets of the OGGUSA Debtors.
\n\n\n\n\n\n
\u00a0
\n\n\n\n\n\u00a0
\n\n"}]},{"name":"rpt:f-1591","factDimensions":{"xbrl:concept":"MRMD:NumberOfOperatingLeasesDescription","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"six"}]},{"name":"rpt:f-1592","factDimensions":{"xbrl:concept":"MRMD:NumberOfFinanceLeasesDescription","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"four finance leases"}]},{"name":"rpt:f-1593","factDimensions":{"xbrl:concept":"us-gaap:AreaOfLand","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"utr:sqft","srt:StatementGeographicalAxis":"stpr:DE","us-gaap:LeaseContractualTermAxis":"MRMD:RetailSpaceMember"},"factValues":[{"value":"4000"}]},{"name":"rpt:f-1594","factDimensions":{"xbrl:concept":"MRMD:LeaseExpirationDescription","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","srt:StatementGeographicalAxis":"stpr:DE","us-gaap:LeaseContractualTermAxis":"MRMD:RetailSpaceMember"},"factValues":[{"value":"five-year\n lease that expires in April 2027 that the Company has developed into a cannabis dispensary which is subleased\n to its cannabis-licensed client."}]},{"name":"rpt:f-1595","factDimensions":{"xbrl:concept":"us-gaap:AreaOfLand","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"utr:sqft","srt:StatementGeographicalAxis":"stpr:DE","us-gaap:LeaseContractualTermAxis":"srt:WarehouseMember"},"factValues":[{"value":"100000"}]},{"name":"rpt:f-1596","factDimensions":{"xbrl:concept":"us-gaap:AreaOfLand","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"utr:sqft","srt:StatementGeographicalAxis":"stpr:DE","us-gaap:LeaseContractualTermAxis":"MRMD:CultivationAndProcessingFacilityMember"},"factValues":[{"value":"60000"}]},{"name":"rpt:f-1597","factDimensions":{"xbrl:concept":"MRMD:LeaseExpirationDescription","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","srt:StatementGeographicalAxis":"stpr:DE","us-gaap:LeaseContractualTermAxis":"srt:WarehouseMember"},"factValues":[{"value":"The\n lease expires in March 2030, with an option to extend the term for three additional five-year periods"}]},{"name":"rpt:f-1598","factDimensions":{"xbrl:concept":"us-gaap:AreaOfLand","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"utr:sqft","srt:StatementGeographicalAxis":"stpr:DE","us-gaap:LeaseContractualTermAxis":"MRMD:PremisesMember"},"factValues":[{"value":"12000"}]},{"name":"rpt:f-1599","factDimensions":{"xbrl:concept":"MRMD:LeaseExpirationDescription","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","srt:StatementGeographicalAxis":"stpr:DE","us-gaap:MajorPropertyClassAxis":"MRMD:PremisesMember"},"factValues":[{"value":"expires\n in January 2026"}]},{"name":"rpt:f-1600","factDimensions":{"xbrl:concept":"us-gaap:AreaOfLand","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"utr:sqft","srt:StatementGeographicalAxis":"stpr:NV","us-gaap:LeaseContractualTermAxis":"MRMD:IndustrialBuildingMember"},"factValues":[{"value":"10000"}]},{"name":"rpt:f-1601","factDimensions":{"xbrl:concept":"MRMD:LeaseExpirationDescription","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","srt:StatementGeographicalAxis":"stpr:NV","us-gaap:LeaseContractualTermAxis":"MRMD:IndustrialBuildingMember"},"factValues":[{"value":"expiring in 2024"}]},{"name":"rpt:f-1602","factDimensions":{"xbrl:concept":"us-gaap:AreaOfLand","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"utr:sqft","srt:StatementGeographicalAxis":"country:MA","us-gaap:LeaseContractualTermAxis":"MRMD:OfficeSpaceMember"},"factValues":[{"value":"10000"}]},{"name":"rpt:f-1603","factDimensions":{"xbrl:concept":"MRMD:LeaseExpirationDescription","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","srt:StatementGeographicalAxis":"country:MA","us-gaap:LeaseContractualTermAxis":"MRMD:OfficeSpaceMember"},"factValues":[{"value":"expiring in 2028"}]},{"name":"rpt:f-1604","factDimensions":{"xbrl:concept":"us-gaap:LesseeOperatingLeaseOptionToExtend","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","srt:StatementGeographicalAxis":"country:MA","us-gaap:LeaseContractualTermAxis":"MRMD:OfficeSpaceMember"},"factValues":[{"value":"option to extend the term for an additional five-year period."}]},{"name":"rpt:f-1605","factDimensions":{"xbrl:concept":"us-gaap:AreaOfLand","xbrl:period":"2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"utr:sqft","srt:StatementGeographicalAxis":"stpr:MD","us-gaap:LeaseContractualTermAxis":"MRMD:TwoUnitApartmentMember"},"factValues":[{"value":"2700"}]},{"name":"rpt:f-1606","factDimensions":{"xbrl:concept":"MRMD:LeaseExpirationDescription","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","srt:StatementGeographicalAxis":"stpr:MD","us-gaap:LeaseContractualTermAxis":"MRMD:TwoUnitApartmentMember"},"factValues":[{"value":"expires in July 2022"}]},{"name":"rpt:f-1607","factDimensions":{"xbrl:concept":"MRMD:LeaseExpirationDescription","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis":"MRMD:MachineryAndOfficeEquipmentMember","us-gaap:LeaseContractualTermAxis":"MRMD:FinanceLeaseCommitmentsMember"},"factValues":[{"value":"expire in February 2022 through June 2024"}]},{"name":"rpt:f-1608","factDimensions":{"xbrl:concept":"us-gaap:LeaseCostTableTextBlock","xbrl:period":"2021-01-01T00:00:00/2022-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"The\ncomponents of lease expense for the year ended December 31, 2021 were as follows:
\n\n\u00a0SCHEDULE OF COMPONENTS OF LEASE EXPENSE
\n\n| \u00a0 | \u00a0 | \n\u00a0 | 2021 | \u00a0 |
| Operating lease cost | \u00a0 | \n$ | 1,097,620 | \u00a0 |
| \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 |
| Finance lease cost: | \u00a0 | \n\u00a0 | \u00a0 | \u00a0 |
| Amortization of right-of-use assets | \u00a0 | \n$ | 32,683 | \u00a0 |
| Interest on lease liabilities | \u00a0 | \n\u00a0 | 5,088 | \u00a0 |
| Total finance lease cost | \u00a0 | \n$ | 37,771 | \u00a0 |
Future\nminimum lease payments as of December 31, 2021 under all non-cancelable leases having an initial or remaining term of more than one year\nwere:
\n\n\u00a0SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER ALL NON-CANCELABLE OPERATING LEASES
\n\n| \u00a0 | \u00a0 | \nOperating \nLeases | \u00a0 | \u00a0 | \nFinance \nLeases | \u00a0 | ||
| 2021 | \u00a0 | \n$ | 1,132,909 | \u00a0 | \u00a0 | \n$ | 27,123 | \u00a0 |
| 2022 | \u00a0 | \n\u00a0 | 1,119,003 | \u00a0 | \u00a0 | \n\u00a0 | 23,201 | \u00a0 |
| 2023 | \u00a0 | \n\u00a0 | 1,049,635 | \u00a0 | \u00a0 | \n\u00a0 | 3,229 | \u00a0 |
| 2024 | \u00a0 | \n\u00a0 | 1,025,054 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| 2025 | \u00a0 | \n\u00a0 | 969,584 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| Thereafter | \u00a0 | \n\u00a0 | 2,611,297 | \u00a0 | \u00a0 | \n\u00a0 | \u00a0 | |
| Total lease payments | \u00a0 | \n\u00a0 | 7,907,482 | \u00a0 | \u00a0 | \n$ | 53,553 | \u00a0 |
| Less: imputed interest | \u00a0 | \n\u00a0 | (2,262,546 | ) | \u00a0 | \n\u00a0 | (3,975 | ) |
| \u00a0 | \u00a0 | \n$ | 5,644,936 | \u00a0 | \u00a0 | \n$ | 49,578 | \u00a0 |
NOTE\n22 \u2013 SUBSEQUENT EVENTS
\n\n\u00a0
\n\n\n\nAcquisition
\n\n\n
\u00a0
\n\n\n\nIn\nJanuary 2022, the Company entered into a stock purchase agreement to acquire 100%\nof\nthe ownership interests of Green Growth Group Inc., an entity that has been awarded a craft grow cannabis license issued by the Illinois\nDepartment of Agriculture (\u201cIDA\u201d) for cultivation, production, and transporting of cannabis and cannabis-infused products\nin Illinois. The purchase price of $3,400,000\nshall\nbe comprised of $1,900,000\nin\ncash and shares of the Company\u2019s common stock valued at $1,500,000.\nThe acquisition is conditioned upon the approval by the IDA, among other closing conditions, which is expected to occur by July 2022.
\n\n\u00a0
\n\n\n\nProperty Purchase
\n\n\u00a0
\n\nIn January 2022, the\nCompany entered into an agreement to purchase a 30-acre parcel of land located in Mt. Vernon, IL containing a 33,000 square\nfoot manufacturing facility and a 13,000 square\nfoot storage warehouse, in exchange for $1,495,000 in\ncash. Upon execution of the agreement, the Company provided a deposit of $100,000 to\nthe seller. The transaction is expected to close in the second quarter of 2022, after the Company has performed a complete\ninspection and feasibility review. If such review determines that the premises will not satisfy the Company\u2019s requirements,\nthe Company shall have the right to terminate the agreement with no other obligation other than the loss of the deposit.
\n\n\u00a0
\n\nReturn on Investment
\n\n\u00a0
\n\nIn February 2022, the Company received \nshares of common stock of WM Technology, Inc. (Nasdaq: MAPS), a technology and software infrastructure provider to the cannabis industry.\nThe shares were received for no consideration, and represent the Company\u2019s pro rata share of additional consideration received\nby MRSVP pursuant to the asset purchase agreement previously discussed in Note 4 \u2013 Investments.
\n\n\u00a0
\n\nPromissory\nNote Conversion
\n\n\u00a0
\n\nIn\nFebruary 2022, the noteholder of the $3.2M Note converted $400,000 of\nprincipal into shares\nof the Company\u2019s common stock. Such conversion was effected in accordance with the terms of the note agreement, and therefore\nthe Company was not required to record a gain or loss upon conversion. Upon this conversion, the $3.2M Note no longer had an\noutstanding balance and was fully retired.
\n\n\u00a0
\n\nCannabis\nLicense
\n\n\u00a0
\n\nIn\nFebruary 2022, the Company was notified that it was awarded a cannabis dispensary license from the state of Ohio, and is awaiting the final verification process to be completed by the state.
\n\u00a0
\n\nEquity\nTransactions
\n\n\u00a0
\n\nSubsequent\nto December 31, 2021, (i) options to purchase shares of common stock were exercised at an exercise price of $\nper share.
\n\n"}]},{"name":"rpt:f-1655","factDimensions":{"xbrl:concept":"us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity","xbrl:period":"2022-01-29T00:00:00/2022-02-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember","us-gaap:BusinessAcquisitionAxis":"MRMD:GreenGrowthGroupIncMember","us-gaap:TypeOfArrangementAxis":"MRMD:StockPurchaseAgreementMember"},"factValues":[{"value":"In\nJanuary 2022, the Company entered into a stock purchase agreement to acquire"}]},{"name":"rpt:f-1656","factDimensions":{"xbrl:concept":"us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired","xbrl:period":"2022-02-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember","us-gaap:BusinessAcquisitionAxis":"MRMD:GreenGroupIncMember"},"factValues":[{"value":"1"}]},{"name":"rpt:f-1657","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets","xbrl:period":"2022-01-29T00:00:00/2022-02-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember","us-gaap:BusinessAcquisitionAxis":"MRMD:GreenGrowthGroupIncMember","us-gaap:TypeOfArrangementAxis":"MRMD:StockPurchaseAgreementMember"},"factValues":[{"value":"3400000","decimals":0}]},{"name":"rpt:f-1658","factDimensions":{"xbrl:concept":"us-gaap:PrepaidExpenseCurrent","xbrl:period":"2022-02-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember","us-gaap:TypeOfArrangementAxis":"MRMD:StockPurchaseAgreementMember","us-gaap:BusinessAcquisitionAxis":"MRMD:GreenGrowthGroupIncMember"},"factValues":[{"value":"1900000","decimals":0}]},{"name":"rpt:f-1659","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodValueNewIssues","xbrl:period":"2022-01-29T00:00:00/2022-02-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember","us-gaap:BusinessAcquisitionAxis":"MRMD:GreenGrowthGroupIncMember","us-gaap:TypeOfArrangementAxis":"MRMD:StockPurchaseAgreementMember"},"factValues":[{"value":"1500000","decimals":0}]},{"name":"rpt:f-1660","factDimensions":{"xbrl:concept":"us-gaap:AreaOfLand","xbrl:period":"2022-02-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"utr:sqft","srt:StatementGeographicalAxis":"stpr:IL","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember","us-gaap:LeaseContractualTermAxis":"us-gaap:ManufacturingFacilityMember"},"factValues":[{"value":"33000"}]},{"name":"rpt:f-1661","factDimensions":{"xbrl:concept":"us-gaap:AreaOfLand","xbrl:period":"2022-02-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"utr:sqft","srt:StatementGeographicalAxis":"stpr:IL","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember","us-gaap:LeaseContractualTermAxis":"srt:WarehouseMember"},"factValues":[{"value":"13000"}]},{"name":"rpt:f-1662","factDimensions":{"xbrl:concept":"us-gaap:SaleOfStockConsiderationReceivedOnTransaction","xbrl:period":"2022-01-01T00:00:00/2022-02-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","srt:StatementGeographicalAxis":"stpr:IL","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember","us-gaap:LeaseContractualTermAxis":"MRMD:ManufacturingFacilityAndWarehouseMember"},"factValues":[{"value":"1495000","decimals":0}]},{"name":"rpt:f-1663","factDimensions":{"xbrl:concept":"us-gaap:RetailLandSalesDepositMethodDepositReceived","xbrl:period":"2022-02-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember"},"factValues":[{"value":"100000","decimals":0}]},{"name":"rpt:f-1664","factDimensions":{"xbrl:concept":"us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction","xbrl:period":"2022-02-01T00:00:00/2022-03-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","dei:LegalEntityAxis":"MRMD:WMTechnologyIncMember","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember"},"factValues":[{"value":"121968"}]},{"name":"rpt:f-1665","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentFaceAmount","xbrl:period":"2022-03-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember","srt:TitleOfIndividualAxis":"MRMD:NoteHolderMember","us-gaap:AwardTypeAxis":"MRMD:ThreePointTwoMillionNoteMember"},"factValues":[{"value":"400000","decimals":0}]},{"name":"rpt:f-1666","factDimensions":{"xbrl:concept":"us-gaap:DebtConversionConvertedInstrumentSharesIssued1","xbrl:period":"2022-02-01T00:00:00/2022-03-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","srt:TitleOfIndividualAxis":"MRMD:NoteHolderMember","us-gaap:AwardTypeAxis":"MRMD:ThreePointTwoMillionNoteMember","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember"},"factValues":[{"value":"1142858"}]},{"name":"rpt:f-1667","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward","xbrl:period":"2022-03-15T00:00:00/2022-03-17T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember"},"factValues":[{"value":"10000"}]},{"name":"rpt:f-1668","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice","xbrl:period":"2022-03-15T00:00:00/2022-03-17T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember"},"factValues":[{"value":"0.30","decimals":2}]}]}}